

(19) **DANMARK**



Patent- og
Varemærkestyrelsen

(12)

Oversættelse af europæisk patentskrift

(10) **DK/EP 2563813 T3**

-
- (51) Int.Cl.: **C 07 K 16/18 (2006.01)** **A 61 K 39/395 (2006.01)** **A 61 P 37/06 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2015-11-30**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2015-08-26**
- (86) Europæisk ansøgning nr.: **11775670.0**
- (86) Europæisk indleveringsdag: **2011-04-29**
- (87) Den europæiske ansøgnings publiceringsdag: **2013-03-06**
- (86) International ansøgning nr.: **US2011034672**
- (87) Internationalt publikationsnr.: **WO2011137395**
- (30) Prioritet: **2010-04-30 US 330260 P** **2011-04-04 US 471465 P**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **Alexion Pharmaceuticals, Inc., 352 Knotter Drive, Cheshire, CT 06410, USA**
- (72) Opfinder: **Rother, Russell P., 10325 Forest Meadow Drive, Oklahoma City, OK 73151, USA**
Tamburini, Paul P., 80 Devonshire Way, Kensington, CT 06037, USA
SHERIDAN, Douglas L., 33 Fenway Road, Branford, CT 06405, USA
ZHANG, Yuchun, 15 Kensington Court, Cheshire, CT 06410, USA
- (74) Fuldmægtig i Danmark: **RWS Group, Europa House, Chiltern Park, Chiltern Hill, Chalfont St Peter, Bucks SL9 9FG, Storbritannien**
- (54) Benævnelse: **ANTI-C5A-ANTISTOFFER OG FREMGANGSMÅDER TIL ANVENDELSE AF ANTISTOFFERNE**
- (56) Fremdragne publikationer:
EP-A1- 2 130 552
EP-A2- 0 245 993
EP-A2- 1 878 441
EP-A2- 2 153 848
EP-B1- 2 055 777
WO-A1-2009/072598
WO-A1-2010/006059
WO-A2-2004/103294
US-A1- 2009 186 036
LARRICK J W ET AL: "CHARACTERIZATION OF MURINE MONOCLONAL ANTIBODIES THAT RECOGNIZE NEUTRALIZING EPITOPES ON HUMAN C5A", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MACROBIOLOGY, USA, vol. 55, no. 8, 1 January 1987 (1987-01-01), pages 1867-1872, XP002570405, ISSN: 0019-9567
KOLA A ET AL: "Epitope mapping of a C5a neutralizing mAb using a combined approach of phage display, synthetic peptides and site-directed mutagenesis", IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS

Fortsættes ...

BV, NL, vol. 2, no. 2, 1 June 1996 (1996-06-01), pages 115-126, XP004052676, ISSN: 1380-2933, DOI: 10.1016/1380-2933(96)00425-3

HARTMANN H ET AL: "Rapid quantification of C3a and C5a using a combination of chromatographic and immunoassay procedures", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 166, no. 1, 5 November 1993 (1993-11-05), pages 35-44, XP023656782, ISSN: 0022-1759, DOI: 10.1016/0022-1759(93)90326-3 [retrieved on 1993-11-05]

AMES R S ET AL: "Isolation of neutralizing anti-C5a monoclonal antibodies from a filamentous phage monovalent Fab display library", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 152, no. 9, 1 January 1994 (1994-01-01), pages 4572-4581, XP002088283, ISSN: 0022-1767

BERGH K ET AL: "Production of monoclonal antibodies against the human anaphylatoxin C5a des Arg and their application in the neopeptide-specific sandwich-ELISA for the quantification of C5a des Arg in plasma", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 152, no. 1, 31 July 1992 (1992-07-31) , pages 79-87, XP023657542, ISSN: 0022-1759, DOI: 10.1016/0022-1759(92)90091-7 [retrieved on 1992-07-31]

MONTZ H ET AL: "Regulation of the human autologous T cell proliferation by endogenously generated C5a", CELLULAR IMMUNOLOGY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 127, no. 2, 1 May 1990 (1990-05-01), pages 337-351, XP024005225, ISSN: 0008-8749, DOI: 10.1016/0008-8749(90)90137-G [retrieved on 1990-05-01]

MOLLNES T E ET AL: "Complement activation in septic baboons detected by neopeptide-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC).", CLINICAL AND EXPERIMENTAL IMMUNOLOGY FEB 1993, vol. 91, no. 2, February 1993 (1993-02), pages 295-300, XP002711689, ISSN: 0009-9104

DESCRIPTION

Cross-Reference to Related Applications

[0001] This application claims priority to and the benefit of U.S. provisional patent application serial nos.: 61/330,260, filed on April 30, 2010, and 61/471,465, filed on April 4, 2011.

Technical Field

[0002] The field of the invention is medicine, immunology, molecular biology, and protein chemistry.

Background

[0003] The complement system acts in conjunction with other immunological systems of the body to defend against intrusion of cellular and viral pathogens. There are at least 25 complement proteins, which are found as a complex collection of plasma proteins and membrane cofactors. The plasma proteins make up about 10% of the globulins in vertebrate serum. Complement components achieve their immune defensive functions by interacting in a series of intricate but precise enzymatic cleavage and membrane binding events. The resulting complement cascade leads to the production of products with opsonic, immunoregulatory, and lytic functions. A concise summary of the biologic activities associated with complement activation is provided, for example, in The Merck Manual, 16th Edition.

[0004] The complement cascade progresses via the classical pathway, the alternative pathway, or the lectin pathway. These pathways share many components, and while they differ in their initial steps, they converge and share the same "terminal complement" components (C5 through C9) responsible for the activation and destruction of target cells.

[0005] The classical pathway (CP) is typically initiated by antibody recognition of, and binding to, an antigenic site on a target cell. The alternative pathway (AP) can be antibody independent, and can be initiated by certain molecules on pathogen surfaces. Additionally, the lectin pathway is typically initiated with binding of mannose-binding lectin (MBL) to high mannose substrates. These pathways converge at the point where complement component C3 is cleaved by an active protease to yield C3a and C3b. Other pathways activating complement attack can act later in the sequence of events leading to various aspects of complement function.

[0006] C3a is an anaphylatoxin. C3b binds to bacterial and other cells; as well as to certain viruses and immune complexes, and tags them for removal from the circulation. (C3b in this role is known as opsonin.) The opsonic function of C3b is generally considered to be the most important anti-infective action of the complement system. Patients with genetic lesions that block C3b function are prone to infection by a broad variety of pathogenic organisms, while patients with lesions later in the complement cascade sequence, i.e., patients with lesions that block C5 functions, are found to be more prone only to *Neisseria* infection, and then only somewhat more prone.

[0007] C3b also forms a complex with other components unique to each pathway to form classical or alternative C5 convertase, which cleaves C5 into C5a and C5b. C3 is thus regarded as the central protein in the complement reaction sequence since it is essential to both the alternative and classical pathways. This property of C3b is regulated by the serum protease Factor I, which acts on C3b to produce iC3b. While still functional as opsonin, iC3b cannot form an active C5 convertase.

[0008] C5 is a 190 kDa beta globulin found in normal serum at a concentration of approximately 75 µg/mL (0.4 µM). C5 is glycosylated, with about 1.5 to 3 percent of its mass attributed to carbohydrate. Mature C5 is a heterodimer of a 999 amino acid 115 kDa alpha chain that is disulfide linked to a 655 amino acid 75 kDa beta chain. C5 is synthesized as a single chain precursor protein product of a single copy gene (Haviland et al. (1991) J Immunol 146:362-368). The cDNA sequence of the transcript of this gene predicts a secreted pro-C5 precursor of 1658 amino acids along with an 18 amino acid leader sequence (see, e.g., U.S. Patent No. 6,355,245).

[0009] The pro-C5 precursor is cleaved after amino acids 655 and 659, to yield the beta chain as an amino terminal fragment (amino acid residues +1 to 655 of the above sequence) and the alpha chain as a carboxyl terminal fragment (amino acid residues

660 to 1658 of the above sequence), with four amino acids (amino acid residues 656-659 of the above sequence) deleted between the two.

[0010] C5a is cleaved from the alpha chain of C5 by either alternative or classical C5 convertase as an amino terminal fragment comprising the first 74 amino acids of the alpha chain (i.e., amino acid residues 660-733 of the above sequence). Approximately 20 percent of the 11 kDa mass of C5a is attributed to carbohydrate. The cleavage site for convertase action is at, or immediately adjacent to, amino acid residue 733 of the above sequence. A compound that would bind at, or adjacent, to this cleavage site would have the potential to block access of the C5 convertase enzymes to the cleavage site and thereby act as a complement inhibitor.

[0011] C5 can also be activated by means other than C5 convertase activity. Limited trypsin digestion (see, e.g., Minta and Man (1997) J Immunol 119:1597-1602 and Wetsel and Kolb (1982) J Immunol 128:2209-2216), thrombin, and acid treatment (Yamamoto and Gewurz (1978) J Immunol 120:2008 and Damerau et al. (1989) Molec Immunol 26:1133-1142) can also cleave C5 and produce active C5b.

[0012] Cleavage of C5 releases C5a, a potent anaphylatoxin and chemotactic factor, and C5b which through a series of protein interactions leads to the formation of the lytic terminal complement complex, C5b-9. C5a and C5b-9 also have pleiotropic cell activating properties, by amplifying the release of downstream inflammatory factors, such as hydrolytic enzymes, reactive oxygen species, arachidonic acid metabolites and various cytokines.

[0013] C5b combines with C6, C7, and C8 to form the C5b-8 complex at the surface of the target cell. Upon binding of several C9 molecules, the membrane attack complex (MAC, C5b-9, terminal complement complex-TCC) is formed. When sufficient numbers of MACs insert into target cell membranes the openings they create (MAC pores) mediate rapid osmotic lysis of the target cells. Lower, non-lytic concentrations of MACs can produce other effects. In particular, membrane insertion of small numbers of the C5b-9 complexes into endothelial cells and platelets can cause deleterious cell activation. In some cases activation may precede cell lysis.

[0014] As mentioned above, C3a and C5a are anaphylatoxins. These activated complement components can trigger mast cell degranulation, which releases histamine from basophils and mast cells, and other mediators of inflammation, resulting in smooth muscle contraction, increased vascular permeability, leukocyte activation, and other inflammatory phenomena including cellular proliferation resulting in hypercellularity. C5a also functions as a chemotactic peptide that serves to attract pro-inflammatory granulocytes to the site of complement activation.

[0015] C5a receptors are found on the surfaces of bronchial and alveolar epithelial cells and bronchial smooth muscle cells. C5a receptors have also been found on eosinophils, mast cells, monocytes, neutrophils, and activated lymphocytes.

[0016] EP 0245 993 A2 discloses monoclonal antibodies which bind to C5a. Larric: et al (Infection and Immunity, American Society for Microbiology, USA, Vol. 55, No.8, 1987, pages 1867-1872) discloses the characterization of murine monoclonal antibodies that recognise neutralizing epitopes on human C5a.

Summary

[0017] The present disclosure relates to, *inter alia*, the generation by the inventors of a series of humanized monoclonal antibodies that specifically bind to free C5a protein (that is, C5a that has been proteolytically cleaved from C5 protein), but not to paralog protein fragments free C4a or free C3a [the antibodies are, often, referred to herein as anti-C5a antibodies or anti-C5a neoepitope antibodies]. As described herein and exemplified in the working examples, the generated anti-C5a antibodies exhibit a high affinity for free C5a. For example, all of the humanized anti-C5a antibodies described herein bind to free C5a with a K_D that is less than 1.25 nanomolar. Many of the antibodies bind to free C5a (e.g., free human C5a) with a K_D that is less than 300 picomolar; several of the antibodies bind to free C5a with a K_D that is less than 100 picomolar. In addition, the humanized anti-C5a antibodies described herein also inhibit C5a-mediated signaling. Further structural and functional properties of the antibodies described herein are elaborated on below and exemplified in the working examples.

[0018] The inventors have also demonstrated, using an animal model of rheumatoid arthritis (RA) and a surrogate anti-mouse C5a antibody with properties similar to the humanized antibody counterparts, efficacy of anti-C5a antibodies in treating RA. Also shown in the working examples are experiments demonstrating the positive therapeutic effects of a humanized anti-C5a antibody in an animal model of human C5a-induced neutropenia.

[0019] Accordingly, the inventors believe that the anti-C5a antibodies, or antigen-binding fragments thereof, described herein are useful in a host of diagnostic and therapeutic methods related to disorders in which C5a-mediated signaling contributes to pathogenesis. For example, the inventors assert that the humanized anti-C5a antibodies described herein are useful for treating or preventing RA and other complement-associated disorders including, but not limited to: atypical hemolytic uremic syndrome (aHUS), age-related macular degeneration (AMD), sepsis, burn (e.g., severe burn), antiphospholipid syndrome (APS), acute respiratory distress syndrome (ARDS), inflammation-related pain, asthma, lupus nephritis, intrauterine growth restriction (IUGR), HELLP syndrome (*Hemolytic anemia, Elevated Liver enzymes and Low Platelet count*), Goodpasture's syndrome, and chronic obstructive pulmonary disease (COPD). Additional disorders that are particularly amenable to treatment with a humanized anti-C5a antibody, or antigen-binding fragment thereof, are known in the art and recited herein.

[0020] The humanized anti-C5a antibodies described herein feature a number of advantages, e.g., over agents that bind to, and inhibit cleavage of, full-length of mature C5. Like such agents, the anti-C5a antibodies (and antigen-binding fragments thereof) described herein are capable of inhibiting the anaphylatoxic downstream effects of C5 activation as mediated through C5 fragment C5a. That is, the anti-C5a antibodies described herein can inhibit the C5a-mediated inflammatory response, which is known to play an integral part in the pathogenesis of complement-associated disorders such as, but not limited to, sepsis, RA, and asthma. However, as the concentration of C5 in human serum is approximately 0.37 μM (Rawal and Pangburn (2001) *J Immunol* 166(4):2635-2642), the use of high concentrations and/or frequent administration of anti-C5 antibodies is often necessary to effectively inhibit C5, and thereby inhibit the C5a-mediated inflammatory response, in a human. Unlike C5, C5a is present in blood at much lower concentrations and is often restricted to specific areas of local complement activation such as, e.g., the lungs in asthma patients, the joints of RA patients, or the drusen in the eyes of patients with AMD. Thus, the anti-C5a antibodies described herein can be administered (e.g., locally administered to sites of complement activation) to a human at a much lower dose and/or less frequently than, e.g., an anti-C5 antibody, and effectively provide the same or greater inhibition of C5a in a human. The ability to administer a lower dose of the anti-C5a antibody, as compared to the required dose of an anti-C5 antibody, also allows for additional delivery routes such as, e.g., subcutaneous administration, intramuscular administration, intrapulmonary delivery, and administration via the use of biologically degradable microspheres. A lower concentration of antigen C5a versus C5 also favors a longer half-life of the anti-C5a antibody, as compared to, e.g., the half-life of a therapeutic antibody that targets terminal complement, due to a reduced contribution of antigen-mediated antibody clearance.

[0021] In addition, the anti-C5a antibodies described herein can also be distinguished from therapeutic agents that inhibit terminal complement (such as C5 inhibitors) by their safety profile. A notable consequence of inhibiting terminal complement components such as C5, C5b, C6, C7, C8, or C9 is decreased protection by the host immune system against the encapsulated bacteria that terminal complement ordinarily lyses - for example, *Neisseria meningitides* and *Neisseria gonorrhoeae*. See, e.g., Haeney et al. (1980) *Clin Exp Immunol* 40:16-24 and Brodsky (2009) *Blood* 113(26):6522-6527. As the anti-C5a antibodies inhibit the C5a-mediated inflammatory response, but do not prevent the formation of the terminal complement complex that lyses those encapsulated bacteria, patients receiving a therapeutic anti-C5a antibody described herein would not require a protective vaccination, e.g., a vaccination against *Neisseria meningitides* and *Neisseria gonorrhoeae*.

[0022] Accordingly, there is provided an isolated antibody or antigen-binding fragment thereof that binds to a free C5a polypeptide, wherein the free C5a is a human polypeptide (hC5a) having the amino acid sequence depicted in SEQ ID NO:1, and wherein the antibody or antigen-binding fragment thereof binds to the free hC5a polypeptide *in vitro* with a K_D that is less than 1.25×10^{-9} M as measured by surface plasmonresonance (SPR) in the presence of a molar excess of uncleaved, native human C5, and wherein the antibody or antigen-binding fragment thereof comprises:

1. I.
 1. (a) a light chain polypeptide comprising:
 1. (i) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:20; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:21; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:22; or
 2. (ii) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:20; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:38; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:22; and
 2. (b) a heavy chain polypeptide comprising:
 1. (i) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:28; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:29; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:30; or
 2. (ii) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:28; a heavy chain CDR2

in SEQ ID NO:28; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:29; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:30.

[0026] In another embodiment, the isolated antibody or antigen-binding fragment thereof comprises: (a) a light chain polypeptide comprising: (i) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:20; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:38; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:22; and a heavy chain polypeptide comprising: a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:28; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:46; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:47.

[0027] Thus, there is described an isolated antibody, or antigen-binding fragments thereof, that binds to free C5a. The antibody or antigen-binding fragment thereof may bind to free human C5a (hC5a; e.g., a human C5a protein comprising, or consisting of, the amino acid sequence depicted in SEQ ID NO:1). In some aspects of the disclosure, the antibody may bind to a desarginated form of free C5a, e.g., the desarginated form of human C5a comprising, or consisting of, the amino acid sequence depicted in SEQ ID NO:2. The antibody can bind to a neoepitope of free C5a, which epitope is not present on uncleaved C5 or is present on only a minor fraction of total uncleaved C5.

[0028] While the disclosure is in no way limited to any particular theory or mechanism of action, in some aspects of the disclosure, the anti-C5a antibody or antigen-binding fragment thereof binds to free C5a (e.g., free hC5a) and may also bind to a subpopulation of uncleaved, processed C5 (e.g., plasma C5) constituting less than 10 (e.g., less than 9.5, 9, 8.5, 8, 7.5, 7, 6.5, 6, 5.5, 5, 4.5, 4, 3.5, 3, 2.5, 2, 1.5, 1, 0.5, 0.4, 0.3, 0.2, or less than 0.1) % of the total population of full length C5 in a sample (e.g., a blood or plasma sample or a sample comprising recombinant full length C5), which subpopulation is, in whole or in part, denatured such that an otherwise occluded C5a neoepitope, to which the anti-C5a antibody or fragment binds, is exposed. Thus, an anti-C5a antibody or antigen-binding fragment thereof described herein can, in some aspects of the disclosure, bind to free C5a, but not to the uncleaved C5 protein of the 90% or greater uncleaved, native C5 population. In some aspects of the disclosure, the above-described partially or fully denatured subpopulation of C5 is inactive or has reduced activity (e.g., less than 90, 85, 80, 75, 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15, 10, 5% of the activity of fully-functional, full-length C5 protein) in any number of suitable assays useful for testing C5 activity, e.g., a hemolytic assay or a CH50eq assay (see below). Suitable methods for testing the activity of the minor subpopulation to which an anti-C5a antibody described herein may bind are known in the art and described herein.

[0029] In some aspects of the disclosure, any of the anti-C5a antibodies or antigen-binding fragments thereof described herein do not inhibit C5 activity in an *in vitro* hemolysis assay or an *in vitro* CH50eq assay even in the presence of at least, equal to, or greater than a 5 (e.g., 5.6, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, or 200) -fold excess of the anti-C5a antibody or antigen-binding fragment thereof to uncleaved C5 (e.g., uncleaved, native C5). In some aspects of the disclosure, any of the anti-C5a antibodies or antigen-binding fragments thereof described herein do not inhibit C5 activity in an *in vitro* hemolysis assay or an *in vitro* CH50eq assay even in the presence of between about a 5-fold to 200-fold (e.g., between about 5-fold and 100-fold, between about 10-fold and 100-fold, between about 20-fold and 100-fold, or between about 10-fold and 150-fold) excess of the anti-C5a antibody or antigen-binding fragment thereof to uncleaved, native C5. Inhibition, e.g., as it pertains to C5 activity, includes at least a 5 (e.g., at least a 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 60) % decrease in the activity of uncleaved, native C5 in, e.g., a hemolytic assay or CH50eq assay as compared to the effect of a control antibody (or antigen-binding fragment thereof) under similar conditions and at an equimolar concentration. Substantial inhibition, as used herein, refers to inhibition of a given activity (e.g., of C5 activity) of at least 40 (e.g., at least 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, or 95 or greater) %. In some embodiments, the C5 is obtained from plasma (e.g., purified from or present in plasma, e.g., human plasma).

[0030] In some aspects of the disclosure, the antibody or antigen-binding fragment thereof binds to a C5a protein (e.g., a human C5a protein) with a K_D that is less than 2 nM. In some aspects, the antibody or antigen-binding fragment thereof binds to a C5a protein with a K_D that is less than 1 nM [also referred to herein as "subnanomolar affinity"].

[0031] In some aspects of the disclosure, the anti-C5a antibody or antigen-binding fragment thereof binds to free C5a with a subnanomolar affinity [e.g., a K_D of less than or equal to 9.9×10^{-10} (e.g., less than or equal to 9×10^{-10} , 8×10^{-10} , 7×10^{-10} , 6×10^{-10} , 5×10^{-10} , 4×10^{-10} , 3×10^{-10} , 2.5×10^{-10} , 2×10^{-10} , 1×10^{-10} , 8.0×10^{-11} , 7.0×10^{-11} , 6.0×10^{-11} , 5.0×10^{-11} , 4.0×10^{-11} , or 3.0×10^{-11}) M] in the presence of a molar excess of uncleaved, native C5 (e.g., purified and/or recombinant C5). In some aspect of the disclosure, any of the anti-C5a antibodies or antigen-binding fragments thereof described herein have at least a 100 (e.g., at least 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 225, 250, 275, 300, 400, 500, 600, 700, 800, 900, 1000,

2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, or 10000) -fold greater affinity (e.g., represented by its K_D) for free C5a than for uncleaved, native C5 protein.

[0032] Thus, in another aspect, the disclosure features an antibody or antigen-binding fragment thereof that (a) binds to free C5a (e.g., hC5a) with a subnanomolar affinity and (b) binds to free C5a with an affinity that is at least 100 (e.g., at least 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 225, 250, 275, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, or 10000) -fold greater than its corresponding affinity for uncleaved, native C5 protein. For example, an anti-C5a antibody or antigen-binding fragment thereof described herein can, in some embodiments, bind to free hC5a with a K_D of 100 nM and to at least a subpopulation of uncleaved human C5 protein with a K_D that is at least 100-fold higher (e.g., at least 10 nM).

[0033] In another aspect, the disclosure features an isolated antibody or antigen-binding fragment thereof that binds to a free human C5a polypeptide having the amino acid sequence depicted in SEQ ID NO:1, wherein the antibody or antigen-binding fragment thereof binds to the human C5a polypeptide with a K_D that is less than 1.25×10^{-9} M in the presence of a molar excess (e.g., a 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, or 500-fold molar excess) of uncleaved, native human C5 over human C5a (hC5a). In some aspects of the disclosure, the antibody or antigen-binding fragment thereof binds to a free hC5a polypeptide with a subnanomolar affinity (e.g., any of the subnanomolar K_D 's recited herein) in the presence of at least, or greater than, a 2-fold molar excess, but no greater or less than a 500 (e.g., 500, 450, 400, 350, 300, 250, 200, 150, 100, 90, 80, 70, 60, 50, 40, 30, 25, 20, or 15) -fold molar excess of uncleaved, native C5 over free hC5a. In some aspects of the disclosure, the antibody or antigen-binding fragment thereof binds to a free hC5a polypeptide with a subnanomolar affinity (e.g., any of the subnanomolar K_D 's recited herein) in the presence of between 2-fold and 20-fold molar excess of uncleaved, native C5 over free hC5a. In some aspect of the disclosure, an antibody or antigen-binding fragment thereof binds to a free hC5a polypeptide with a subnanomolar affinity (e.g., any of the subnanomolar K_D 's recited herein) in the presence of between 10-fold and 20-fold molar excess of uncleaved, native C5 over free hC5a. In some aspects of the disclosure, an antibody or antigen-binding fragment thereof binds to a free hC5a polypeptide with a subnanomolar affinity (e.g., any of the subnanomolar K_D 's recited herein) in the presence of between 5-fold and 15-fold molar excess of uncleaved, native C5 over free hC5a. In some aspects of the disclosure, an antibody or antigen-binding fragment thereof binds to a free hC5a polypeptide with a subnanomolar affinity (e.g., any of the subnanomolar K_D 's recited herein) in the presence of at least 2-fold, but no greater than a 20-fold molar excess of uncleaved, native C5 over free hC5a. Such measurements can be *in vitro* measurements using, e.g., standard affinity determination techniques, many of which are recited and/or described herein.

[0034] In another aspect, the disclosure features an isolated antibody or antigen-binding fragment thereof that binds to a human C5a polypeptide having the amino acid sequence depicted in SEQ ID NO:1, wherein the antibody or antigen-binding fragment thereof binds to the human C5a polypeptide with a K_D that is less than 1.25×10^{-9} M and wherein the antibody or antigen-binding fragment thereof does not substantially inhibit, as compared to an equimolar amount of a control antibody or antigen-binding fragment thereof, C5 activity even in the presence of less than, or equal to, a 10-fold molar excess of the anti-C5a antibody or antigen-binding fragment thereof to uncleaved, native C5.

[0035] In some aspects of the disclosure of any of the anti-C5a antibodies or antigen-binding fragments thereof described herein, the antibody or antigen-binding fragment thereof binds to free human C5a and is cross-reactive with free C5a from at least one non-human mammalian species. For example, in some aspects of the disclosure, an anti-C5a antibody (or antigen-binding fragment thereof) binds to free C5a from human (e.g., with subnanomolar affinity) and also binds to free C5a from a non-human primate (e.g., cynomolgus macaque, rhesus macaque, ape, baboon, chimpanzee, orangutan, or gorilla), a rodent (e.g., mouse, rat, hamster, Guinea pig, or rabbit), cow, goat, donkey, pig, dog, cat or horse. In some aspects of the disclosure, an anti-C5a antibody or antigen-binding fragment thereof described herein binds to free hC5a with a K_D of less than or equal to 9.9×10^{-10} (e.g., less than or equal to 9×10^{-10} , 8×10^{-10} , 7×10^{-10} , 6×10^{-10} , 5×10^{-10} , 4×10^{-10} , 3×10^{-10} , 2.5×10^{-10} , 2×10^{-10} , 1×10^{-10} , 8.0×10^{-11} , 7.0×10^{-11} , 6.0×10^{-11} , 5.0×10^{-11} , 4.0×10^{-11} , or 3.0×10^{-11}) M and also binds to free C5a from cynomolgus macaque (or another non-human primate species), wherein the affinity (e.g., represented by its K_D) for human C5a is no more than 500 (e.g., no more than 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 200, 250, 300, 350, 400, 450, or 475) -fold greater than the affinity for cynomolgus macaque (or other non-human primate species) C5a. For example, in some aspects of the disclosure, the anti-C5a antibody binds to free hC5a with an affinity that is no more than 50-fold greater than the corresponding affinity of the antibody for non-human primate C5a (e.g., a K_D for free hC5a of 100 nM and a K_D for non-human primate C5a of no more than 5 nM). In some aspects of the disclosure, an anti-C5a antibody or antigen-binding fragment thereof described herein binds to free hC5a with a K_D of less than or equal to 9.9×10^{-10} (e.g., less than or equal to 9×10^{-10} , 8×10^{-10} , 7

$\times 10^{-10}$, 6×10^{-10} , 5×10^{-10} , 4×10^{-10} , 3×10^{-10} , 2.5×10^{-10} , 2×10^{-10} , 1×10^{-10} , 8.0×10^{-11} , 7.0×10^{-11} , 6.0×10^{-11} , 5.0×10^{-11} , 4.0×10^{-11} , or 3.0×10^{-11}) M and also binds to C5a from a rodent (e.g., mouse, rat, or rabbit), wherein the affinity (e.g., represented by its K_D) for human C5a is no more than 1000 (e.g., no more than 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 200, 250, 300, 350, 400, 450, 475, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, or 975) -fold greater than the affinity for rodent C5a. In some aspects of the disclosure, any of the anti-C5a antibodies or antigen-binding fragments thereof described herein bind with subnanomolar affinity to both human C5a and to C5a from a non-human mammal (e.g., a rodent or a non-human primate such as cynomolgus macaque). An antibody or antigen-binding fragment thereof can, in some aspects of the disclosure, bind to human C5a and non-human primate C5a with equal affinity (e.g., an equivalent K_D).

[0036] For example, the disclosure features an antibody or antigen-binding fragment thereof that binds to free human C5a with subnanomolar affinity [e.g., a K_D of less than or equal to 9.9×10^{-10} (e.g., less than or equal to 9×10^{-10} , 8×10^{-10} , 7×10^{-10} , 6×10^{-10} , 5×10^{-10} , 4×10^{-10} , 3×10^{-10} , 2.5×10^{-10} , 2×10^{-10} , 1×10^{-10} , 8.0×10^{-11} , 7.0×10^{-11} , 6.0×10^{-11} , 5.0×10^{-11} , 4.0×10^{-11} , or 3.0×10^{-11}) M] and is cross-reactive with free C5a from cynomolgus macaque (or other non-human primate), the antibody or antigen-binding fragment thereof binding to cynomolgus macaque (or other non-human primate) C5a with a K_D of less than 10×10^{-9} , 9×10^{-9} , 8×10^{-9} , 7×10^{-9} , 6×10^{-9} , 5×10^{-9} , 4×10^{-9} , 3×10^{-9} , 2×10^{-9} , 1×10^{-9} , 9.9×10^{-10} (e.g., less than 9×10^{-10} , 8×10^{-10} , 7×10^{-10} , 6×10^{-10} , 5×10^{-10} , 4×10^{-10} , 3×10^{-10} , 2.5×10^{-10} , 2×10^{-10} , 1×10^{-10} , or 8.0×10^{-11}) M], wherein the affinity for human C5a is no more than 500 (e.g., no more than 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 200, 250, 300, 350, 400, 450, or 475) -fold greater than the affinity for cynomolgus macaque (or non-human primate) C5a (e.g., K_D for human C5a of 100 nM and a K_D for non-human primate C5a of no more than 50 nM). Suitable methods for determining the affinity of an antibody or antigen-binding fragment thereof for a given antigen are known in the art and described and, exemplified herein.

[0037] In some aspects of the disclosure, the cross-reactive anti-C5a antibody or antigen-binding fragment thereof functionally inhibits both free hC5a and the non-human mammalian C5a to which it binds. For example, an antibody inhibits by at least 70 (e.g., at least 75, 80, 85, 90, or 95 or greater) % human C5a-dependent human neutrophil activation at a molar ratio of 1:1 (antigen-binding site:C5a) and inhibits by at least 70 (e.g., at least 75, 80, 85, 90, or 95 or greater) % non-human mammalian C5a-dependent neutrophil activation (the neutrophils being from the same species as the non-human mammalian C5a to which the antibody binds) at a molar ratio of 1:1 (antigen-binding site:C5a).

[0038] In another aspect, the disclosure features an isolated antibody or antigen-binding fragment thereof that binds to a free hC5a polypeptide having the amino acid sequence depicted in SEQ ID NO:1, wherein the antibody or antigen-binding fragment thereof binds to the human C5a polypeptide with a K_D that is less than 1.25×10^{-9} M and wherein the antibody or antigen-binding fragment thereof binds to both hC5a and to C5a from a non-human mammalian species. The non-human mammalian species can be, e.g., a non-human primates such as cynomolgus macaque, rhesus macaque, or baboon. In some aspects of the disclosure the non-human mammalian species is a rodent such as a mouse, rat, rabbit, Guinea pig, gerbil, or hamster. In some aspect of the disclosure, the antibody or antigen-binding fragment thereof binds to hC5a with an affinity no greater than 100-fold higher than the corresponding affinity for C5a from the non-human mammalian species. In some aspects of the disclosure, the antibody or antigen-binding fragment inhibits by at least 50% human C5a-dependent human neutrophil activation at a molar ratio of 1:1, (antigen-binding site: C5a).

[0039] In some aspects of the disclosure, the antibody or antigen-binding fragment thereof binds to free C5a from a non-human primate (e.g., a cynomolgus macaque or rhesus macaque), the free C5a protein having an amino acid sequence comprising, or consisting of, the amino acid sequence depicted in SEQ ID NO:179 or SEQ ID NO:180.

[0040] As described in the working examples, the inventors have also discovered a bivalent anti-C5a antibody, BNJ383, that binds to free C5a (in this case human C5a) with high affinity and, with a much lower affinity, uncleaved human C5 (hC5), wherein, in a composition (e.g., an aqueous solution) under physiological conditions at equilibrium, and in the presence of a molar excess of uncleaved human C5 as compared to the molar amount of the antigen-binding sites of the antibodies, at least 95% of the plurality of antibodies each bind no more than one hC5 molecule. The second antigen-binding site of the at least 95% of the plurality of antibodies remains available (e.g., substantially available) to bind to free C5a. While the disclosure is in no way bound by any particular theory or mechanism of action, the inventors believe that the bivalent anti-C5a antibody binds to uncleaved C5 in such a way (e.g., at such an epitope) that steric hindrance precludes, or at least substantially inhibits, the binding of the second antigen-binding site of the anti-C5a antibody to a second uncleaved C5 protein, although the antibody can easily accommodate the binding to two hC5a molecules. Thus, the antibody, even in a molar excess of uncleaved C5, retains the ability to bind to free C5a with high affinity and thereby retains, even in that molar excess, the ability to inhibit the pro-inflammatory activity of C5a.

[0041] One of ordinary skill in the art would easily and readily appreciate the myriad therapeutic benefits of such an anti-C5a antibody. For example, as noted above, the concentration of circulating C5 in human serum is very high. Thus, when introduced into a mammal, an anti-C5a antibody that is capable of simultaneously binding to two uncleaved C5 molecules would be rapidly inactivated in the molar excess of C5 and would then no longer be capable of binding to free C5a in the event of complement activation. And, as with anti-C5 antibodies, use of high concentrations and/or frequent administration of this type of anti-C5a antibody would be necessary to effectively inhibit C5a, in the event that it is produced. In contrast, the anti-C5a antibody described herein that retains the ability to bind to free C5a, even in a molar excess of uncleaved C5, can thus be administered to a human at a much lower dose and/or less frequently than, e.g., an anti-C5 antibody and effectively provide the same or greater inhibition of C5a in the human.

[0042] Accordingly, there is also described herein an isolated antibody comprising two antigen-binding sites, wherein each antigen-binding site independently can bind to free human C5a (hC5a) or uncleaved human C5 (hC5), wherein, in an aqueous solution comprising: (i) a plurality of said antibodies and (ii) a molar excess of hC5 as compared to the molar amount of the antigen-binding sites, at equilibrium and under physiological conditions, at least 95 (e.g., at least 95.5, 96, 96.5, 97, 97.5, or 97.7) % of said plurality of antibodies bind no more than one hC5 molecule, i.e., no more than 5% of the antibodies are binding two molecules of hC5 at equilibrium.

[0043] In another aspect, the disclosure features an isolated antibody comprising two antigen-binding sites, wherein each antigen-binding site independently can bind to free human C5a (hC5a) or uncleaved human C5 (hC5), wherein, at equilibrium and under physiological conditions, in an aqueous solution comprising: (i) a plurality of said antibodies and (ii) a molar excess of hC5 as compared to the molar amount of the antigen-binding sites (or antibodies), at least 95% of said plurality of antibodies retain at least one antigen-binding site available to bind free hC5a.

[0044] In another aspect, the disclosure features an isolated antibody comprising two antigen-binding sites, wherein each antigen-binding site independently can bind to free human C5a (hC5a) or uncleaved human C5 (hC5), wherein, at equilibrium and under physiological conditions, in an aqueous solution comprising: (i) a plurality of said antibodies and (ii) a molar excess of hC5 as compared to the molar amount of the antigen-binding sites (or antibodies), each antigen-binding site of no more than 5% of said plurality of antibodies is bound to a hC5 molecule.

[0045] In some aspects of the disclosure of any of the isolated antibodies described herein, the molar excess is at least a two-fold (e.g., at least a 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or even 10-fold) molar excess.

[0046] In some aspects of the disclosure of any of the isolated antibodies described herein, the physiological condition is 3.9 mM NaH_2PO_4 , 6.1 mM Na_2HPO_4 , and 150 mM NaCl, at pH7.0.

[0047] In some aspects of the disclosure of any of the isolated antibodies described herein, each antigen-binding site independently can bind to free hC5a with a K_D that is less than 1.25×10^{-9} M. In some embodiments, each antigen-binding site can independently bind to free hC5a with a subnanomolar affinity (see above).

[0048] In some embodiments of any of the isolated antibodies described herein, the isolated antibody comprises a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:42 and a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:45.

[0049] In some embodiments of any of the isolated antibodies described herein, the isolated antibody comprises: (i) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:20; (ii) a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:21; (iii) a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:22; (iv) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:28; (v) a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:46; and (vi) a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:47.

[0050] In some aspects of the disclosure, the isolated antibody can comprises any of the light chain CDR sets described herein, any of the light chain variable regions described herein (e.g., any of the humanized light chain variable regions), any of the heavy chain CDR sets described herein, any of the heavy chain variable regions described herein (e.g., any of the humanized heavy chain variable regions), or any suitable combinations thereof See, e.g., Tables 1 or 2.

[0051] In another aspect, the disclosure features a method for treating a human afflicted with a complement-associated disorder (e.g., a C5a-associated complement disorder), wherein the method includes administering to the human any of the isolated

antibodies described herein in an amount sufficient to treat the complement-associated disorder.

[0052] In another aspect, the disclosure features a method for treating a human afflicted with a C5a-associated complement disorders, wherein the method comprises administering to the human at least 0.6 (e.g., at least 0.7, 0.8, 0.9, or 1) mg of any of the isolated antibodies described herein per kg body weight of the human to thereby partially or completely bind and sequester nanogram levels of free C5a for greater than, equal to, or at least 12 (e.g., 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25) days.

[0053] In another aspect, the disclosure features a method for treating a human afflicted with a C5a-associated complement disorder, wherein the method comprises administering to the human at least 10 mg of any of the isolated antibodies described herein per kg body weight of the human to thereby partially or completely bind and sequester nanogram levels of free C5a for at least 24 days.

[0054] In another aspect, the disclosure features a method for treating a human afflicted with a C5a-associated complement disorder, wherein the method comprises administering to the human any of the isolated antibodies described herein (or for example a pharmaceutical composition comprising any of the isolated antibodies described herein) in an amount sufficient to (a) achieve molar C_{max} values equal to or less than the physiologic molar concentration of uncleaved hC5 and (b) partially or completely bind and sequester pathophysiologic levels of free C5a.

[0055] In some aspects of any of the methods described herein, an antibody is administered to a subject (e.g., a human) in an amount sufficient to achieve a molar C_{max} value that is substantially lower than the physiologic molar concentration of uncleaved C5 (e.g., hC5).

[0056] In some aspects of any of the methods described herein, the C_{max} value is, e.g., no greater than 80 nM (or approximately 0.6 mg/kg). In some aspects, C_{max} levels are no greater than 70 (e.g., 60, 50, 40, 30, or 20) nM. In some aspects, the C_{max} value is no greater than approximately 100 nM. In some aspects,

[0057] the C_{max} value is no greater than 200 nM. In some aspects of any of the methods described herein, the C_{max} value is, e.g., no greater than 400 nM (or approximately 3 mg/kg). In some aspects, the C_{max} value is no greater than 400 (e.g. 350, 300, 250, 200, 150, 100, 90, 80, 70, 60, 50, 40, 30, 20 or 10) nM.

[0058] In another aspect, the disclosure features a method for treating a human afflicted with a C5a-associated complement disorder, wherein the method comprises administering to the human any of the isolated antibodies described herein (or for example a pharmaceutical composition comprising any of the isolated antibodies described herein) in an amount sufficient to (a) achieve molar C_{max} values equal to, less than, or substantially lower than the molar physiologic concentration of uncleaved hC5 and (b) partially or completely bind and sequester nanogram levels of free C5a for at least 12 days (e.g., at least 24 days). Suitable C_{max} values are described above.

[0059] In some aspects of any of the methods described herein, the C5a-associated complement disorder can be, e.g., one selected from the group consisting of sepsis, acute respiratory distress syndrome (ARDS), septic shock, anti-phospholipid syndrome, catastrophic anti-phospholipid syndrome, disseminated intravascular coagulation, lupus nephritis, Goodpasture's Syndrome, burn or severe burn, asthma, HELLP syndrome (*H*emolytic anemia, *E*levated *L*iver enzymes and *L*ow Platelet count), inflammation-induced pain, C5a-mediated neutropenia, age-related macular degeneration (AMD), chronic obstructive pulmonary disease, and rheumatoid arthritis.

[0060] In yet another aspect, the disclosure features a composition comprising a plurality of isolated antibodies, each antibody of the plurality comprising two antigen-binding sites, wherein each antigen-binding site independently can bind to free human C5a (hC5a) or uncleaved human C5 (hC5), and wherein, in the presence of human C5 (hC5) and under physiological conditions, no more than 5% of the antibodies of the plurality at equilibrium comprise two antigen-binding sites simultaneously bound to uncleaved hC5.

[0061] In some aspects of any of the compositions described herein, the percentage of the plurality in any particular binding configuration can be evaluated using high performance liquid chromatography (HPLC). In some aspects of the disclosure, the physiological conditions in which the antibodies are evaluated comprises the following conditions: incubation of hC5 (e.g., a molar excess (e.g., a 2-fold molar excess) of hC5) with the plurality of antibodies at 4 °C for 84 hours in an aqueous solution comprising 3.9 mM NaH₂PO₄, 6.1 mM Na₂HPO₄, and 150 mM NaCl, at pH7.0. For the purposes of this disclosure, the solution obtained at 84 hours at 4°C is considered to be at equilibrium.

[0062] In some aspects of any the compositions described herein, no more than 5% of the antibodies of the plurality comprise two antigen-binding sites simultaneously bound to uncleaved hC5 under physiological conditions and in the presence of at least a 2-fold molar excess of hC5 to antibody.

[0063] In some aspects of any of the compositions described herein, no more than 5% of the antibodies of the plurality comprise two antigen-binding sites simultaneously bound to uncleaved hC5 molecules as evaluated using HPLC following incubation of the plurality of antibodies with hC5 at 4 °C for 84 hours in an aqueous solution comprising 3.9 mM NaH₂PO₄, 6.1 mM Na₂BPO₄, and 150 mM NaCl, at pH7.0.

[0064] In another aspect, the disclosure features a composition comprising a plurality of isolated antibodies, each antibody of the plurality comprising two antigen-binding sites, wherein each antigen-binding site independently can bind to free human C5a (hC5a) or uncleaved human C5 (hC5), and wherein no more than 5% of the antibodies of the plurality comprise two antigen-binding sites simultaneously bound to uncleaved hC5 as evaluated (e.g., using HPLC) following incubation of the plurality of antibodies with hC5 at 4 °C for 84 hours in an aqueous solution comprising 3.9 mM NaH₂PO₄, 6.1 mM Na₂HPO₄, and 150 mM NaCl, at pH7.0.

[0065] In yet another aspect, the disclosure features a composition comprising a plurality of isolated antibodies, each antibody of the plurality comprising a first antigen-binding site and a second antigen-binding site, wherein each antigen-binding site independently can bind to free human C5a (hC5a) or uncleaved human C5 (hC5), wherein each antigen-binding site independently can bind to the free hC5a polypeptide with a K_D that is less than 1.25×10^{-9} M, and wherein, in the presence of human C5 (hC5) and as evaluated (e.g., using high performance liquid chromatography (HPLC)) under physiological conditions, the two antigen-binding sites of at least 95% of the plurality of antibodies are occupied by uncleaved hC5 in the following configurations: (i) the first antigen-binding site binds uncleaved hC5 and the second antigen-binding site is unbound; or (ii) the first antigen-binding site is unbound and the second antigen-binding site binds uncleaved hC5.

[0066] In yet another aspect, the disclosure features a composition comprising a plurality of isolated antibodies, each antibody of the plurality comprising two antigen-binding sites, wherein each antigen-binding site independently can bind to free human C5a (hC5a) or uncleaved human C5 (hC5), and wherein, in the presence of human C5 (hC5) and as evaluated (e.g., using high performance liquid chromatography (HPLC)) under physiological conditions, at least 95% of the antibodies of the plurality comprise at least one antigen-binding site capable of binding to free hC5a.

[0067] In some aspects of any of the compositions described herein, the plurality of antibodies is evaluated in the presence of at least a 2-fold molar excess of hC5:antibody. In some aspects of any of the compositions described herein, the plurality of antibodies is evaluated in the presence of at least a 2-fold molar excess of hC5:antigen-binding sites.

[0068] In yet another aspect, the disclosure features an isolated antibody comprising two antigen binding sites, wherein the antibody binds to free C5a or uncleaved C5, and wherein one of the antigen-binding sites of the antibody remains available to bind free C5a in the presence of a molar excess (e.g., at least or greater than a 2-fold, 5-fold, 10-fold, 15-fold, or even a 20-fold molar excess) of uncleaved C5.

[0069] In some aspects of the disclosure, the antigen-binding sites have the same specificity (e.g., the CDRs of each of the two antigen-binding sites share identical amino acid, sequences). In some embodiments, free C5a is human C5a. In some aspects of the disclosure the antibody is cross-reactive between human C5a and C5a from a non-human mammalian species. The antibody can, in some aspects bind to free C5a with a subnanomolar affinity. In some aspects of the disclosure, the antibody has an affinity for C5a that is at least 100- fold greater than its corresponding affinity for uncleaved C5.

[0070] In another aspect, the disclosure features an isolated antibody comprising two antigen-binding sites, wherein each antigen-binding site independently binds to free human C5a (hC5a) or uncleaved human C5 (hC5), and wherein, at any concentration of uncleaved hC5 (e.g., in a molar excess of uncleaved hC5 over hC5a), at least one of the antigen-binding sites of the antibody remains available to bind to free hC5a (e.g., under human physiological conditions, e.g., in human blood or serum).

[0071] In another aspect, the disclosure features a composition comprising a plurality of isolated antibodies, wherein each antibody of the plurality comprises two antigen-binding sites, wherein each of the antigen-binding sites independently can bind to free human C5a (hC5a) or uncleaved human C5 (hC5), and wherein, at a molar ratio of 1:1 (antibody:hC5), no more than, or less than, 5 (e.g., no more than, or less than 4.9, 4.8, 4.7, 4.6, 4.5, 4.4, 4.3, 4.2, 4.1, 4.0, 3.9, 3.8, 3.7, 3.6, 3.5, 3.4, 3.3, 3.2, 3.1, 3.0,

2.9, 2.8, 2.7, 2.6, 2.5, 2.4, 2.3, 2.2, 2.1, 2.0, 1.9, 1.8, 1.7, 1.6, 1.5, 1.4, 1.3, 1.2, 1.1, or 1) % of the antibodies of the plurality comprise two antigen-binding sites simultaneously bound to uncleaved hC5. In some aspects of the disclosure, each antigen-binding site independently can bind to free hC5a with a K_D that is less than 1.25×10^{-9} M (or, for example, with subnanomolar affinity).

[0072] In another aspect, the disclosure features a composition comprising a plurality of isolated antibodies, wherein each antibody of the plurality comprises two antigen-binding sites, wherein each of the antigen-binding sites independently can bind to free human C5a (hC5a) or uncleaved human C5 (hC5), and wherein, in the presence of physiologic levels of uncleaved hC5, the antibodies of the plurality partially or completely bind and sequester nanogram levels of free C5a for greater than, equal to, or at least 12 (e.g., 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25) days when administered to a human at doses of 1 mg/kg or higher.

[0073] In another aspect, the disclosure features a composition comprising a plurality of isolated antibodies, wherein each antibody of the plurality comprises two antigen-binding sites, wherein each of the antigen-binding sites independently can bind to free human C5a (hC5a) or uncleaved human C5 (hC5), and wherein, in the presence of physiologic levels of uncleaved hC5, the antibodies of the plurality partially or completely bind and sequester nanogram levels of free C5a for greater than, equal to, or at least 12 (e.g., 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25) days when administered to a human at doses of 10 mg/kg or higher.

[0074] In another aspect, the disclosure features a composition comprising a plurality of isolated antibodies, wherein each antibody of the plurality comprises two antigen-binding sites, wherein each of the antigen-binding sites independently can bind to free human C5a (hC5a) or uncleaved human C5 (hC5), and wherein, in the presence of physiologic levels of uncleaved hC5, the antibodies of the plurality partially or completely binds and sequesters nanogram levels of free C5a for greater than, equal to, or at least 12 (e.g., 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25) days when administered at doses achieving molar C_{max} values substantially lower than the molar physiologic concentration of uncleaved hC5.

[0075] In another aspect, the disclosure features a composition comprising a plurality of isolated antibodies, wherein each antibody of the plurality comprises two antigen-binding sites, wherein each of the antigen-binding sites independently can bind to free human C5a (hC5a) or uncleaved human C5 (hC5), and wherein, in the presence of physiologic levels of uncleaved hC5, the antibodies of the plurality partially or completely bind and sequester pathophysiologic levels of free C5a when administered at doses achieving molar C_{max} values substantially lower than the molar physiologic concentration of un-cleaved hC5.

[0076] In another aspect, the disclosure features an isolated antibody comprising a first antigen-binding site and a second antigen-binding site, wherein each antigen-binding site independently can bind to free human C5a (hC5a) or uncleaved human C5 (hC5), and wherein, when both antigen-binding sites are fully-occupied (and, e.g., under human physiological conditions, e.g., in human blood or serum), the following binding configurations are possible: (i) the first antigen-binding site binds free hC5a and the second antigen-binding site binds uncleaved hC5; (ii) the first antigen-binding site binds free hC5a and the second antigen-binding site binds free hC5a; or (iii) the first antigen-binding site binds uncleaved hC5 and the second antigen-binding site binds free hC5a.

[0077] In yet another aspect, the disclosure features an isolated antibody comprising a first antigen-binding site and a second antigen-binding site, wherein each antigen-binding site independently can bind to free human C5a (hC5a) or uncleaved human C5 (hC5), wherein each antigen-binding site independently can bind to free hC5a with a K_D that is less than 1.25×10^{-9} M (or, for example, with subnanomolar affinity), and wherein, in a physiological solution containing a plurality of the antibodies, at least 95% of the antibodies are in the following configurations: (i) the first antigen-binding site binds free hC5a and the second antigen-binding site binds uncleaved hC5; (ii) the first antigen-binding site binds free hC5a and the second antigen-binding site binds free hC5a; (iii) the first antigen-binding site binds uncleaved hC5 and the second antigen-binding site binds free hC5a; (iv) the first antigen-binding site binds uncleaved hC5 and the second antigen-binding site is unbound; (v) the first antigen-binding site binds hC5a and the second antigen-binding site is unbound; (vi) the first antigen-binding site is unbound and the second antigen-binding site binds uncleaved hC5; (vii) the first antigen-binding site is unbound and the second antigen-binding site binds hC5a; and (viii) the first antigen-binding site is unbound and the second antigen-binding site is unbound.

[0078] In another aspect, the disclosure features an isolated antibody comprising two antigen-binding sites, wherein each antigen-binding site independently can bind to free human C5a (hC5a) or uncleaved human C5 (hC5), and wherein, in a molar excess of uncleaved hC5 over hC5a, the antibody inhibits by at least 50% hC5a-dependent human neutrophil activation at a molar ratio of 1:1 (antigen-binding site: hC5a).

[0079] In some aspects of any of the antibodies described herein, the configurations are possible under human physiological conditions with fully-folded, native, human C5a and C5 proteins.

[0080] In some aspects of any of the antibodies described herein, the antibody binds to free hC5a with a K_D that is less than 1.25×10^{-9} M (or, for example, with subnanomolar affinity).

[0081] In yet another aspect, the disclosure features an antibody that (a) binds to free C5a (e.g., hC5a) with a subnanomolar affinity and (b) binds to free C5a with an affinity that is at least 100 (e.g., at least 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 225, 250, 275, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, or 10000) -fold greater than its corresponding affinity for uncleaved C5 protein. In a physiologic composition comprising a plurality of the antibodies, for at least 95% of the antibodies, only one antigen-binding site of the antibody binds to uncleaved C5 protein, whereas the second antigen-binding site remains available to bind to free C5a. (The hC5a can have the amino acid sequence depicted in SEQ ID NO:1.)

[0082] In another aspect, the disclosure features a method for treating a human afflicted with a C5a-associated complement disorder, the method comprising administering to the human a composition comprising a plurality of isolated antibodies, wherein each antibody of the plurality comprises two antigen-binding sites, wherein each of the antigen-binding sites independently can bind to free human C5a (hC5a) or uncleaved human C5 (hC5), wherein at least 1 mg of the antibodies per kg body weight of the human is administered to the human, and wherein administration of the antibodies is effective to partially or completely bind and sequester nanogram levels of free C5a for at least 12 days.

[0083] In another aspect, the disclosure features a method for treating a human afflicted with a complement-associated disorder (e.g., a C5a-associated complement disorder), the method comprising administering to the human a composition comprising a plurality of isolated antibodies, wherein each antibody of the plurality comprises two antigen-binding sites, wherein each of the antigen-binding sites independently can bind to free human C5a (hC5a) or uncleaved human C5 (hC5), wherein at least 10 mg of the antibodies per kg body weight of the human is administered to the human, and wherein administration of the antibodies is effective to partially or completely bind and sequester nanogram levels of free C5a for at least 24 days.

[0084] In another aspect, the disclosure features a method for treating a human afflicted with a complement-associated disorder (e.g., a C5a-associated complement disorder), the method comprising administering to the human a composition comprising a plurality of isolated antibodies, wherein each antibody of the plurality comprises two antigen-binding sites, wherein each of the antigen-binding sites independently can bind to free human C5a (hC5a) or uncleaved human C5 (hC5), wherein the antibodies are administered at a dose sufficient to: (a) achieve molar C_{max} values substantially lower than the molar physiologic concentration of uncleaved hC5 and (b) partially or completely bind and sequester nanogram levels of free C5a for at least 12 days.

[0085] In another aspect, the disclosure features a method for treating a human afflicted with a complement-associated disorder (e.g., a C5a-associated complement disorder), the method comprising administering to the human a composition comprising a plurality of isolated antibodies, wherein each antibody of the plurality comprises two antigen-binding sites, wherein each of the antigen-binding sites independently can bind to free human C5a (hC5a) or uncleaved human C5 (hC5), wherein the antibodies are administered at a dose sufficient to: (a) achieve molar C_{max} values substantially lower than the molar physiologic concentration of uncleaved hC5 and (b) partially or completely bind and sequester nanogram levels of free C5a for at least 24 days.

[0086] In another aspect, the disclosure features a method for treating a human afflicted with a complement-associated disorder (e.g., a C5a-associated complement disorder), the method comprising administering to the human a composition comprising a plurality of isolated antibodies, wherein each antibody of the plurality comprises two antigen-binding sites, wherein each of the antigen-binding sites independently can bind to free human C5a (hC5a) or uncleaved human C5 (hC5), wherein the antibodies are administered at a dose sufficient to: (a) achieve molar C_{max} values substantially lower than the molar physiologic concentration of uncleaved hC5 and (b) partially or completely bind and sequester pathophysiologic levels of free C5a.

[0087] It is understood that any of the compositions (e.g., comprising a plurality of antibodies) or isolated antibodies (e.g., that retain, in the presence of C5 or molar excess of C5, a free Fab arm capable of binding to free C5a) described herein can be: (a) formulated as pharmaceutical compositions in accordance with the disclosure, (b) included in therapeutic kits (described herein), or (c) included in the pre-filled syringes described herein.

[0088] As described in the working examples provided herein, the inventors have also discovered an antibody, BNJ383 (see

below), that not only binds with high affinity (subnanomolar affinity) to free hC5a, but at concentrations in excess of uncleaved C5 also inhibits terminal complement complex (TCC) formation in a dose dependent manner. Even at concentrations of the anti-C5a antibody in greater than 6.5-fold excess of C5, however, inhibition of TCC is not complete. While the disclosure is by no means limited by any particular theory or mechanism of action, the antibody may inhibit TCC formation by binding to at least a fraction of uncleaved C5 and preventing its cleavage and/or otherwise preventing the successful association of C5 with additional TCC components. The inventors appreciated that such an antibody is useful for treating complement-associated disorders, e.g., in which C5a plays a significant role and the C5b-containing TCC may play a less substantial role. Such disorders can include, e.g., sepsis, acute respiratory distress syndrome (ARDS), septic shock, anti-phospholipid syndrome, catastrophic anti-phospholipid syndrome, disseminated intravascular coagulation, lupus nephritis, Goodpasture's Syndrome, burn or severe burn, asthma, HELLP syndrome (*Hemolytic anemia, Elevated Liver enzymes and Low Platelet count*), inflammation-induced pain, C5a-mediated neutropenia, age-related macular degeneration (AMD), chronic obstructive pulmonary disease, and rheumatoid arthritis.

[0089] The inventors also appreciated that use of such an anti-C5a antibody to treat these conditions, among others, may provide an even more beneficial safety profile as compared to use of terminal complement inhibitory drugs. As noted above, one notable consequence of inhibiting terminal complement components such as C5, C5b, C6, C7, C8, or C9 is decreased protection by the host immune system against the encapsulated bacteria that terminal complement ordinarily lyses - for example, *Neisseria meningitides* and *Neisseria gonorrhoeae*. As the anti-C5a antibodies described in this section inhibit the C5a-mediated inflammatory response, but do not completely inhibit the formation of the terminal complement complex that lyses those encapsulated bacteria, patients receiving a therapeutic anti-C5a antibody described herein may not require a protective vaccination, e.g., a vaccination against *Neisseria meningitides* and *Neisseria gonorrhoeae*. Partial inhibition of the TCC, while not wholly abrogating terminal complement's anti-microbial response, may in fact reduce TCC-induced inflammation as tissue injury. The partial TCC inhibition, in combination with inhibition of C5a, is believed to make the anti-C5a antibody an even more potent anti-inflammatory compound.

[0090] Accordingly, in another aspect, the disclosure features an antibody or antigen-binding fragment thereof that binds to free C5a, wherein the free C5a is human C5a having the amino acid sequence depicted in SEQ ID NO:1, wherein the antibody inhibits the binding of C5a to C5a receptor, and wherein the antibody partially inhibits formation of the terminal complement complex (TCC). Partial inhibition by an anti-C5a antibody or antigen-binding fragment thereof described herein can be, e.g., a complement activity that is, in the presence of the antibody, up to, or no greater than, 80 (e.g., 75, 70, 65, 60, 55, 50, 45, 40, 35, 30, or 25) % of the complement activity in the absence of the antibody or antigen-binding fragment thereof. In some embodiments, the antibody or antigen-binding fragment thereof binds to free C5a (e.g. free hC5a) with a subnanomolar affinity. In some aspects of the disclosure, the antibody or antigen-binding fragment thereof has an affinity for free C5a that is at least 100-fold greater than the corresponding affinity of the antibody or antigen-binding fragment for uncleaved C5. In some embodiments, the antibody or antigen-binding fragment thereof inhibits by at least 50% formation of TCC at concentrations exceeding 200 (e.g., 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 320, 340, 360, 380, or 400 or more) $\mu\text{g/mL}$ as measured using a CH50eq assay. In some aspects of the disclosure, the antibody or antigen-binding fragment thereof inhibits by at least 50% classical complement pathway activation at concentrations exceeding 200 (e.g., 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 320, 340, 360, 380, or 400 or more) $\mu\text{g/mL}$ as measured using the Wieslab® Classical Pathway Complement Kit as described in the working examples.

[0091] In another aspect, the disclosure features a method for treating a human afflicted with a complement-associated disorder (e.g., a C5a-associated complement disorder or a complement-associated inflammatory disorder). The method includes administering to the human an effective amount of an antibody or antigen-binding fragment thereof that inhibits the binding of C5a to C5a receptor, and wherein the antibody partially inhibits formation of the terminal complement complex (TCC). See above. The disorder can be any of those known in the art or described herein.

[0092] In another aspect, the disclosure features an isolated antibody or antigen-binding fragment thereof that binds to a human C5a polypeptide having the amino acid sequence depicted in SEQ ID NO:1, but does not bind to the alpha chain of uncleaved, native C5, wherein the antibody or antigen-binding fragment thereof binds to the human C5a polypeptide with a K_D that is less than 1.25×10^{-9} M.

[0093] In another aspect, the disclosure features an isolated antibody or antigen-binding fragment thereof that binds to a human C5a polypeptide having the amino acid sequence depicted in SEQ ID NO:1, but does not bind to the alpha chain of uncleaved, native C5, wherein the antibody inhibits by at least 50% human C5a-dependent human neutrophil activation at a molar ratio of 1:1 (antigen-binding site:C5a). In some aspects of the disclosure, the antibody inhibits by at least 50% human C5a-dependent human neutrophil migration in an assay in which 0.4 nM of antibody is used to inhibit the neutrophil-activation activity of 2 nM human C5a as described in Example 5. In some aspects of the disclosure, the antibody does not comprise exemplary CDR pairing 3 depicted in Table 1. In some aspects of the disclosure, the antibody is not BNJ371.

[0094] In some aspects of the disclosure, an isolated antibody or antigen-binding fragment thereof described herein binds to a human C5a polypeptide having the amino acid sequence depicted in SEQ ID NO:2.

[0095] In some embodiments, an isolated antibody or antigen-binding fragment thereof described herein comprises a light chain polypeptide comprising: a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:20; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:21; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:22.

[0096] In some embodiments, an isolated antibody or antigen-binding fragment thereof described herein comprises a light chain polypeptide comprising: a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:20; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:38; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:22.

[0097] In some embodiments, an isolated antibody or antigen-binding fragment thereof described herein comprises a heavy chain polypeptide comprising: a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:28; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:29; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:30.

[0098] In some aspects of the disclosure, an isolated antibody or antigen-binding fragment thereof described herein comprises a heavy chain polypeptide comprising: a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:28; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:67; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:30.

[0099] In some embodiments, an isolated antibody or antigen-binding fragment thereof described herein comprises a heavy chain polypeptide comprising: a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:28; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:46; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:47.

[0100] In some embodiments, an isolated antibody or antigen-binding fragment thereof described herein comprises a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:37 or SEQ ID NO:36.

[0101] In some embodiments, an isolated antibody or antigen-binding fragment thereof described herein comprises a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:27 or SEQ ID NO:33.

[0102] In some embodiments, an isolated antibody or antigen-binding fragment thereof described herein comprises a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:37 and a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:27.

[0103] In some embodiments, an isolated antibody or antigen-binding fragment thereof described herein comprises a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:36 and a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:33.

[0104] In some embodiments, an isolated antibody or antigen-binding fragment thereof described herein comprises a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO: 19 or SEQ ID NO:17.

[0105] In some embodiments, an isolated antibody or antigen-binding fragment thereof described herein comprises a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:27 or SEQ ID NO:25.

[0106] In some embodiments, an isolated antibody or antigen-binding fragment thereof described herein comprises a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:19 and a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:27.

[0107] In some embodiments, an isolated antibody or antigen-binding fragment thereof described herein comprises a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:17 and a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:25.

[0108] In some embodiments, an isolated antibody or antigen-binding fragment thereof described herein comprises a light chain

polypeptide comprising the amino acid sequence depicted in SEQ ID NO:40 and a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:49.

[0125] In some aspects of the disclosure, an isolated antibody or antigen-binding fragment thereof described herein binds to hC5a with a K_D that is less than 7×10^{-10} M.

[0126] In some aspects of the disclosure, an isolated antibody or antigen-binding fragment thereof described herein, binds to hC5a with a K_D that is less than 5×10^{-10} M.

[0127] In some aspects of the disclosure, an isolated antibody or antigen-binding fragment thereof described herein binds to hC5a with a K_D that is less than 3×10^{-10} M.

[0128] In some aspects of the disclosure, an isolated antibody or antigen-binding fragment thereof described herein binds to hC5a with a K_D that is less than 2.5×10^{-10} M.

[0129] In some aspects of the disclosure, an isolated antibody or antigen-binding fragment thereof described herein binds to hC5a with a K_D that is less than 1.5×10^{-10} M.

[0130] In some aspects of the disclosure, an isolated antibody or antigen-binding fragment thereof described herein binds to hC5a with a K_D that is less than 1.0×10^{-10} M.

[0131] In some aspects of the disclosure, an isolated anti-body or antigen-binding fragment thereof described herein binds to hC5a with a K_D that is less than 8.0×10^{-11} M.

[0132] In some aspects of the disclosure, an antibody inhibits by at least 70 (e.g., at least 75, 80, 85, 90, or 95 or greater) % human C5a-dependent human neutrophil activation at a molar ratio of 1:1 (antigen-binding site:C5a). In some aspects, the antibody does not comprise exemplary CDR pairing 3 depicted in Table 1. In some aspects, the antibody is not BNJ371.

[0133] In yet another aspect, the disclosure features an isolated antibody or antigen-binding fragment thereof that comprises a light chain CDR set as set forth in Table 3 or Table 7. For example, the isolated antibody or antigen-binding fragment thereof of the disclosure can comprise a light chain polypeptide comprising: (i) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:140; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:96; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:142; (ii) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:156; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:157; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:158; (iii) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:164; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:165; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:166; (iv) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:172; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:173; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:174; (v) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:84; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:85; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:86; (vi) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:92; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:89; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:93; (vii) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:88; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:89; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:90; (viii) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:95; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:96; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:97; (ix) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:99; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:100; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:101; (x) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:84; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:85; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:103; (xi) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:105; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:106; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:107; (xii) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:92; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:89; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID

NO:108; (xiii) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:20; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:110; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:111; or (xiv) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:20; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:21; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:113. In some aspects of the disclosure, the antibody or antigen-binding fragment thereof comprising the light chain CDR set also comprises a heavy chain polypeptide comprising any one of the heavy chain CDR sets as set forth in Table 8.

[0134] In another aspect, the disclosure features an isolated antibody or antigen-binding fragment thereof that comprises a heavy chain CDR set as set forth in Table 3 or Table 8. For example, in some aspects of the disclosure an isolated antibody or antigen-binding fragment thereof described herein comprises a heavy chain polypeptide comprising: (i) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:115; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:144; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:117; (ii) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:28; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:67; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:30; (iii) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:160; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:161; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:162; (iv) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:168; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:169; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:170; (v) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:176; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:177; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:178; (vi) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:115; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:116; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:117; (vii) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:119; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:120; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:121; (viii) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:115; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:123; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:117; (ix) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:115; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:124; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:117; (x) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:119; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:126; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:127; (xi) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:115; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:129; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:117; (xii) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:131; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:132; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:133; (xiii) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:28; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:46; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:47; or (xiv) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:136; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:137; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO: 138. In some aspects of the disclosure, the antibody or antigen-binding fragment thereof comprising the heavy chain CDR set also comprises a light chain polypeptide comprising any one of the light chain CDR sets as set forth in Table 7.

[0135] In another aspect, the disclosure features an isolated antibody or antigen-binding fragment thereof comprising a light chain CDR set from Table 7 and its cognate heavy chain CDR set as set forth in Table 8. In another aspect, the disclosure features an isolated antibody or antigen-binding fragment thereof comprising a paired light chain and heavy chain CDR set as set forth in Table 3 or Table 9. For example, in some aspects of the disclosure an isolated antibody, or antigen-binding fragment thereof, described herein comprises: (i) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:140; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:96; a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:142; a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:115; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:144; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:117; (ii) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:20; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:21; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:22; a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:28; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:67; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:30; (iii) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:156; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:157; a light chain

[illegible]

depicted in SEQ ID NO:92; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:89; a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:93; a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:115; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:144; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:117; (xviii) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:84; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:85; a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:103; a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:115; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:129; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:117; (xix) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:95; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:96; a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:97; a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:115; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:123; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:117; (xx) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:84; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:85; a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:103; a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:115; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:144; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:117; or (xi) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:20; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:21; a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:113; a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:131; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:132; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:133.

[0136] In some aspects of the disclosure, an antibody or antigen-binding fragment thereof comprises a paired light chain CDR set and heavy chain CDR set as set forth in Table 3. In some aspects of the disclosure, an antibody or antigen-binding fragment thereof comprises a paired light chain CDR set and heavy chain CDR set as set forth in Table 2. For example, the disclosure features an antibody comprising: (i) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:20; (ii) a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:21; and (iii) a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:22; (iv) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:28; (v) a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:46; and (vi) a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:47.

[0137] In some aspects of the disclosure, the antibody or antigen-binding fragment thereof comprises a light chain variable region set forth in Table 2, which light chain is paired with any one of the heavy chain variable regions set forth in Table 2. For example, the disclosure features an antibody (or an antigen-binding fragment thereof) comprising: (a) a light chain variable region having an amino acid sequence comprising the amino acid sequence depicted in SEQ ID NO:42 and (b) a heavy chain variable region having an amino acid sequence comprising the amino acid sequence depicted in SEQ ID NO:45.

[0138] In some aspects of the disclosure, an antibody or antigen-binding fragment thereof described herein comprises: (i) a heavy chain variable region framework region 1 comprising the amino acid sequence depicted in SEQ ID NO:68 or SEQ ID NO:69; (ii) a heavy chain variable region framework region 2 comprising the amino acid sequence depicted in SEQ ID NO:70 or SEQ ID NO:71; and a heavy chain variable region framework region 3 comprising the amino acid sequence depicted in any one of SEQ ID Nos:72 to 74. In some aspects of the disclosure, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region framework region 4 comprising the amino acid sequence depicted in SEQ ID NO:75. In some aspects of the disclosure, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the amino acid sequence depicted in any one of SEQ ID NOs:76 to 80. The antibody heavy chain can comprise any of the heavy chain CDR sets described herein. The heavy chain variable region can be, in some embodiments, paired with the variable region polypeptide comprising the amino acid sequence depicted in SEQ ID NO:16.

[0139] In some aspects of the disclosure, an antibody or antigen-binding fragment thereof binds to a non-human C5a protein. For example, the antibody or antigen-binding fragment thereof can bind to mouse C5a and/or desarginated mouse C5a protein. In some aspects of the disclosure, an isolated antibody or antigen-binding fragment thereof can bind to mouse C5a (and/or desarginated mouse C5a) and comprise: (i) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:54; (ii) a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:55; (iii) a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:56; (iv) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:62; (v) a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:63; and (vi) a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:64. In some aspects of the disclosure, the anti-mouse C5a antibody can comprise a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:59; and a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:66.

[0140] In some aspects of the disclosure, an isolated antibody or antigen-binding fragment thereof described herein inhibits the interaction between C5a and a C5a receptor. The C5a receptor can be, e.g., C5aR1 or C5L2

[0141] In some aspects of the disclosure, an isolated antibody or antigen-binding fragment thereof described herein does not Substantially inhibit complement-mediated hemolysis of red blood cells *in vitro* and/or *in vivo*.

[0142] In some aspects of the disclosure, an isolated antibody (and accordingly any antigen-binding fragment thereof) is a monoclonal antibody, a humanized antibody, or a fully-human antibody.

[0143] In some aspects of the disclosure, an isolated antibody or antigen-binding fragment thereof described herein is selected from the group consisting of a recombinant antibody, a single chain antibody, a diabody, an intrabody, a chimerized or chimeric antibody, a deimmunized human antibody, an Fv fragment, an Fd fragment, an Fab fragment, an Fab' fragments, and an F(ab')₂ fragment.

[0144] In some aspects of the disclosure, an isolated antibody or antigen-binding fragment thereof described herein is multispecific (e.g., bispecific) in that the antibody or fragment binds to at least two different epitopes. The two different epitopes can be, e.g., two different epitopes from the same protein (e.g., C5a) or the antibody can bind to a first epitope from a first protein (e.g., C5a) and a second epitope from a second protein.

[0145] In some aspects of the disclosure, an isolated antibody or antigen-binding fragment thereof described herein comprises a heterologous moiety. The heterologous moiety can be, e.g., a sugar. For example, the antibody or antigen-binding fragment thereof can be glycosylated. The heterologous moiety can be, e.g., a detectable label such as, but not limited to, a fluorescent label, a luminescent label, a heavy metal label, a radioactive label, or an enzymatic label.

[0146] In some aspects of the disclosure, an isolated anti-C5a antibody or antigen-binding fragment thereof described herein is modified with a moiety that improves the stabilization and/or retention of the antibody in circulation. For example, the modification can be PEGylation or hesylation. In another embodiment, the anti-C5a antibody can contain an altered constant region that has reduced (or no) effector function, as compared to the effector function of its corresponding unaltered constant region. In some embodiments, the anti-C5a antibody contains an altered constant region that has between about 0 to about 20% of the effector function of the unaltered constant region. Exemplary embodiments of such decreased-effector function antibodies are described herein.

[0147] In another aspect, the disclosure features an isolated antibody or antigen-binding fragment thereof that crossblocks the binding of any one of the foregoing antibodies.

[0148] In yet another aspect, the disclosure features a pharmaceutical composition comprising one or more of any of the isolated antibodies or antigen-binding fragments thereof described herein and a pharmaceutically-acceptable carrier, diluent, and/or excipient

[0149] In another aspect, the disclosure features: (i) a nucleic acid encoding one or more of any of the antibodies or antigen-binding fragments thereof described herein; (ii) a vector comprising the nucleic acid; (iii) an expression vector comprising the nucleic acid; and/or (iv) a cell comprising the vector or the expression vector. In another aspect, the disclosure features a method for producing a polypeptide (such as any of the antibodies or antigen-binding fragments thereof described herein). The method comprises culturing the aforementioned cell (comprising the expression vector) under conditions and for a time sufficient to allow expression by the cell of the antibody or antigen-binding fragment encoded by the nucleic acid in the vector. The method can also include isolated the antibody or antigen-binding fragment from the cell or from the medium in which the cell is cultured.

[0150] In another aspect, the disclosure features an isolated nucleic acid encoding any of the amino acid sequences described herein or a polypeptide having an amino acid sequence comprising, or consisting of, any of the amino acid sequences set forth herein. The nucleic acid can be included in a vector, e.g., an expression vector, and/or can be present in a cell.

[0151] In yet another aspect, the disclosure features a therapeutic kit comprising: (i) one or more of the isolated antibodies or antigen-binding fragments described herein (e.g., one or more of any of the humanized antibodies or antigen-binding fragments thereof described herein); and (ii) means for delivery of the antibody or antigen-binding fragment to a subject. The means can be suitable for, e.g., subcutaneous delivery, intraocular delivery, or intraarticular delivery of the antibody or antigen-binding fragment thereof to the subject. The means can be, e.g., a syringe, a double-barreled syringe, or two separate syringes incorporated for

use in administering a therapeutic antibody or antigen-binding fragment thereof, while drawing off knee fluid (e.g., for analysis) in a push-pull fashion. In some aspects of the disclosure, the means is for ocular delivery and comprises a trans-scleral patch or a contact lens, each of which comprises the antibody-binding fragment thereof. In some aspects of the disclosure, the means is suitable for intrapulmonary delivery. For example, the means can be an inhaler or a nebulizer. In some aspects of the disclosure, the means is a pre-filled syringe such as a pen device. The pre-filled syringe can contain, e.g., at least one pharmaceutical unit dosage form of one or more of the antibodies or antigen-binding fragments thereof provided herein.

[0152] In some aspects of the disclosure, the therapeutic kits described herein can contain at least one additional active agent for use in treating a complement-associated disorder in a subject. The additional active agent can be, e.g., any of the additional agents described herein.

[0153] In yet another aspect, the disclosure features a method for treating or preventing a complement-associated disorder. The method includes administering to a human in need thereof a therapeutic antibody or antigen-binding fragment thereof described herein in an amount sufficient to treat a complement-associated disorder afflicting the human. The method can also include identifying the subject as having a complement-associated disorder. The complement-associated disorder can be, e.g., a complement-associated inflammatory disorder, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, or antiphospholipid syndrome. In some embodiments, the complement-associated disorder is a complement-associated pulmonary disorder. For example, the complement-associated pulmonary disorder can be, e.g., asthma or chronic obstructive pulmonary disease. Other complement-associated disorders amenable to treatment or prevention as set forth in the method are described herein. The mode of administration, which can vary depending on the type of complement-associated disorder to be treated, can be, e.g., intravenous administration, intrapulmonary administration, intraocular administration, subcutaneous administration; or intraarticular administration.

[0154] In some aspects of the disclosure, the antibody or antigen-binding fragment thereof is administered to the human in an amount and with a frequency sufficient to maintain a reduced level of systemic C5a activity for the duration of the treatment. In some aspects of the disclosure, the methods can include after the administering, monitoring the human for an improvement in one or more symptoms of the complement-associated disorder.

[0155] In some aspects of the disclosure, the methods can include administering to the human one or more additional therapeutic agents.

[0156] In yet another aspect, the disclosure features an article of manufacture, which comprises: (i) a container with a label and (ii) a composition comprising an antibody or antigen-binding fragment thereof described herein. The label can indicate that the composition is to be administered to a human having, suspected of having, or at risk for developing, a complement-associated disorder. The article of manufacture can also include one or more additional active agents.

[0157] As used throughout the present disclosure, the term "antibody" refers to a whole or intact antibody (e.g., IgM, IgG, IgA, IgD, or IgE) molecule that is generated by any one of a variety of methods that are known in the art and described herein. The term "antibody" includes a polyclonal antibody, a monoclonal antibody, a chimerized or chimeric antibody, a humanized antibody, a deimmunized human antibody, and a fully human antibody. The antibody can be made in or derived from any of a variety of species, e.g., mammals such as humans, non-human primates (e.g., monkeys, baboons, or chimpanzees), horses, cattle, pigs, sheep, goats, dogs, cats, rabbits, guinea pigs, gerbils, hamsters, rats, and mice. The antibody can be a purified or a recombinant antibody.

[0158] As used herein, the term "antibody fragment," "antigen-binding fragment," or similar terms refer to a fragment of an antibody that retains the ability to bind to an antigen (e.g., an epitope present in C5a, but not in the alpha chain of uncleaved, native C5 protein), e.g., a single chain antibody (scFv), an Fd fragment, an Fab fragment, an Fab' fragment, or an F(ab')₂ fragment. An scFv is a single polypeptide chain that includes both the heavy and light chain variable regions of the antibody from which the scFv is derived. In addition, diabodies (Poljak (1994) *Structure* 2(12):1121-1123; Hudson et al. (1999) *J Immunol Methods* 23(1-2):177-189), minibodies, triabodies (Schoonooghe et al. (2009) *BMC Biotechnol* 9:70), domain antibodies (also known as "heavy chain immunoglobulins" or camelids; Holt et al. (2003) *Trends Biotechnol* 21(11):484-490); and intrabodies (Huston et al. (2001) *Hum Antibodies* 10(3-4):127-142; Wheeler et al. (2003) *Mol Ther* 8(3):355-366; Stocks (2004) *Drug Discov Today* 9(22): 960-966) are included in the definition of antibody fragments and can be incorporated into the compositions, and used in the methods, described herein.

[0159] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. In case of conflict, the present document, including definitions,

will control. Preferred methods and materials are described below, although methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the presently disclosed methods and compositions. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety.

[0160] Other features and advantages of the present disclosure, e.g., methods for treating complement-associated disorders in a subject, will be apparent from the following description, the examples, and from the claims.

Brief Description of the Drawings

[0161]

Fig. 1 is a Venn diagram depicting the degree of overlap of the epitopes in human C5a bound by a select set of murine anti-human C5a antibodies: 5an101ME, 5an180ME, 5an048ME, 5an179ME, and 5an178ME.

Fig. 2 is a line graph depicting the antagonism of C5a-mediating signaling *in vitro* using a neutrophil activation assay. The Y-axis represents the optical density (OD) measurement of a chromogenic substrate as a function of myeloperoxidase release by freshly isolated human neutrophils. The X-axis represents the concentration of antibody incubated with the cells. The humanized antibodies tested - BNJ367, BNJ369, BNJ371, BNJ378, BNJ381, BNJ383, and a humanized anti-C5 antibody - are identified in the inset legend.

Fig. 3 is a line graph depicting the effect of several therapeutic antibodies on joint inflammation in a mouse model of rheumatoid arthritis. The Y-axis represents the thickness of the initially inflamed knee joint in millimeters. The X-axis represents the days after disease onset. The therapeutic antibodies tested - 5an195ME (a mouse anti-mouse C5a antibody) and a control antibody with the same Fc region as the anti-C5a antibody - are identified in the inset legend.

Fig. 4 is a line graph depicting the effect of several therapeutic antibodies on overall disease severity in a mouse model of rheumatoid arthritis. The Y-axis represents the arthritis index. The X-axis represents the days after disease onset. The therapeutic antibodies tested - 5an195ME (a mouse anti-mouse C5a antibody) and a control antibody with the same Fc region as the anti-C5a antibody - are identified in the inset legend.

Fig. 5 sets forth a series of humanized heavy chain variable region sequences. In order from uppermost to lowermost: the heavy chain variable region of the BNJ345 humanized anti-C5a antibody (SEQ ID NO:76); the heavy chain variable region of the BNJ346 humanized anti-C5a antibody (SEQ ID NO:77); the heavy chain variable region of the BNJ347 humanized anti-C5a antibody (SEQ ID NO:78); the heavy chain variable region of the BNJ354 humanized anti-C5a antibody (SEQ ID NO:79); and the heavy chain variable region of the BNJ350 humanized anti-C5a antibody (SEQ ID NO:80). The skilled artisan will appreciate the delineation between heavy chain framework regions 1, 2, 3, and 4 and the heavy chain CDRs 1, 2, and 3. Such delineations as defined by Kabat et al. (*infra*) are shown in the figure. "HC FR1" refers to heavy chain variable region framework region 1, "HC FR2" refers to heavy chain variable region framework region 2, "HC FR3" refers to heavy chain variable region framework region 3, and "HC FR4" refers to heavy chain variable region framework region 4. "HC CDR1" refers to heavy chain variable region complementarity determining region (CDR) 1, "HC CDR2" refers to heavy chain variable region CDR2, and "HC CDR3" refers to heavy chain variable region CDR3.

Fig. 6 is a line graph depicting the percentage of circulating neutrophils in the blood of mice following administration of hC5a to the mice. On the Y-axis, neutrophil counts are expressed as a percentage of "baseline," which is the neutrophil count at time 0 (or 100% neutrophils). The X-axis represents time in minutes. Mouse cohorts were intravenously administered a control antibody [anti-anthrax protective antigen 63, IgG2/G4 isotype] ("control"; five mice) or the anti-human C5a antibody BNJ383 at one of the following doses: 24 mg/kg (five mice); 12 mg/kg (five mice); 6 mg/kg (five mice); and 3 mg/kg (five mice) and then later were administered hC5a. See Example 13. Six mice, "sham," were not administered human C5a.

Fig. 7 is a bar graph depicting the myeloperoxidase (MPO) level in the plasma of mice before and following administration of human C5a to the mice. The Y-axis represents the concentration (ng/mL) of MPO in mouse plasma. The X-axis represents time in minutes. Mouse cohorts were intravenously administered a control antibody [anti-anthrax protective antigen 63, IgG2/G4 isotype] ("control"; eight mice) or the anti-human C5a antibody BNJ383 at one of the following doses: 24 mg/kg (five mice); 12 mg/kg (five mice); 6 mg/kg (five mice); and 3 mg/kg (five mice) and then later were administered hC5a. Four mice, "sham," were not administered human C5a.

Fig. 8 is a line graph depicting the change in human C5a level in plasma of mice (administered human C5a) in the presence or absence of different concentrations of an anti-hC5a antibody (BNJ383). The Y-axis represents the concentration (ng/mL) of hC5a in mouse plasma. The X-axis represents time in minutes. Mouse cohorts were intravenously administered a control antibody [anti-

anthrax protective antigen 63, IgG2/G4 isotype] ("control"; six mice) or the anti-human C5a antibody BNJ383 at one of the following doses: 24 mg/kg (three mice); 12 mg/kg (three mice); 6 mg/kg (three mice); and 3 mg/kg (three mice) and then later were administered hC5a. Four mice, "sham," were not administered human C5a.

Fig. 9 is a line graph depicting the competition for binding to human C5a *in vitro*. 250 pM of ruthenium-labeled anti-C5a antibody (BNJ383) was incubated with 1 nM biotinylated hC5a, along with various concentrations (e.g., 400, 133, 44.4, 14.8, 4.9, 1.6, and 0.5 nM) of one of the following: (a) human C5a desarg protein in phosphate-buffered saline, (b) human plasma, (c) cynomolgus macaque plasma, (d) Balb/C (mouse) plasma, or (e) DBA/2J (mouse) plasma. With respect to the plasma components (b), (c), (d), and (e), the concentration refers to the approximate final concentration of C5 antigen in the incubation mixture. The Y-axis represents arbitrary fluorescence units as a function of the amount of ruthenium-labeled anti-C5a antibody detected. The X-axis represents concentration (nM) of the antigen competitor.

Fig. 10 is a line graph depicting the effect of several complement inhibitory proteins on the alternative pathway (AP) of complement. The Y-axis represents the percentage of AP complement activity as compared to baseline (BL; the level of activity in the absence of a complement inhibitor). The X-axis represents the concentration of a given complement inhibitor (μ M). The effects of the anti-hC5a antibody, BNJ383, along with an anti-C5 antibody on AP activity were each evaluated.

Fig. 11 is a line graph depicting the effect of several complement inhibitory proteins on the classical pathway (CP) of complement. The Y-axis represents the percentage of CP complement activity as compared to baseline (BL; the level of activity in the absence of a complement inhibitor). The X-axis represents the concentration of a given complement inhibitor (μ M). The effects of the anti-hC5a antibody, BNJ383, along with an anti-C5 antibody on CP activity were each evaluated.

Figs. 12A, 12B, 12C, and 12D are a series of chromatographs depicting the retention times of the anti-C5a antibody (BNJ383) and an anti-hC5 antibody in the presence or absence of hC5 protein. For all of the panels, the X-axis represents retention time in minutes and the Y-axis represents the absorbance units at 214 nm wavelength. In each panel, the inlayed subpanel depicts an enhanced view of the featured peaks.

Fig. 12A depicts the retention time for BNJ383 in the absence of hC5 protein.

Fig. 12B depicts the retention time for the anti-C5 antibody in the absence of hC5 protein.

Fig. 12C depicts the retention time for BNJ383 in the presence of hC5 (2.1-fold molar excess of hC5 over BNJ383). From right to left, the enumerated peaks represent: (a) uncomplexed BNJ383 or hC5; (b) BNJ383 with one antigen-binding site bound to uncleaved hC5; and (c) a minor fraction consistent with dual occupancy of BNJ383 with uncleaved hC5.

Fig. 12D depicts the retention time for the anti-C5 antibody in the presence of an equimolar amount of hC5. From right to left, the enumerated peaks represent: (a) uncomplexed anti-C5 antibody or hC5; (b) the anti-C5 antibody with one antigen-binding site bound to uncleaved hC5; and (c) the anti-C5 antibody bound to two uncleaved C5 molecules.

Fig. 13 is a line graph depicting the binding of the anti-C5a antibody BNJ383 to hC5a desarg in the presence of hC5 using an ELISA. The X-axis represents the concentration (ng/mL) of the antibody. The Y-axis represents the optical density at 450 nm wavelength.

Fig. 14 is a scatter plot depicting the concentration of free C5a/C5a desarg present in the plasma of cynomolgus macaques as a function of the plasma concentration of anti-C5a antibody (BNJ383). The Y-axis depicts the concentration (pg/mL) of C5a/C5a desarg detected in plasma samples from cynomolgus macaques at time points ranging from 1 day to 30 days following a single dose intravenous administration of BNJ383 at 1 mg/kg, 10 mg/kg, 100 mg/kg, 250 mg/kg, or 400 mg/kg body weight of the animals. The X-axis represents the concentration of the BNJ383 (μ g/mL) in each of the samples.

Fig. 15A is a scatter plot depicting the percentage of hemolytic activity in serum samples relative to baseline values (Y-axis) initiated via the classical pathway as a function of the concentration of anti-C5a antibody (BNJ383) in circulation (X-axis).

Fig. 15B is a scatter plot depicting the percentage of terminal complement complex formation initiated via the classical pathway in serum samples measured by a CH50eq assay relative to baseline values (Y-axis) as a function of the concentration of anti-C5a antibody (BNJ383) in circulation (X-axis).

Fig. 15C is a scatter plot depicting the percentage of terminal complement complex formation initiated via the classical pathway in serum samples measured by a CCP assay relative to baseline values (Y-axis) as a function of the concentration of anti-C5a antibody (BNJ383) in circulation (X-axis).

Detailed Description

[0162] The present disclosure provides antibodies and antigen-binding fragments thereof that bind to free C5a (e.g., free human C5a), compositions containing the antibodies or their fragments, and methods for using any of the foregoing to treat or prevent complement-associated disorders such as, but not limited to, aHUS, macular degeneration (e.g., AMD), RA, sepsis, antiphospholipid syndrome, burn (e.g., severe burn), Goodpasture's syndrome, lupus nephritis, or a complement-associated pulmonary disorder such as asthma or chronic obstructive pulmonary disease (COPD). The disclosure also provides anti-C5a antibodies (and fragments thereof) that are cross-reactive between free C5a from human and free C5a from a non-human mammalian species such as a non-human primate (e.g., cynomolgus macaque or rhesus macaque). While in no way intended to be limiting, exemplary antibodies (and antigen-binding fragments), compositions (e.g., pharmaceutical compositions and formulations), and methods for using the compositions are elaborated on below and exemplified in the working Examples.

Anti-C5a Antibodies and Antigen-binding Fragments Thereof

[0163] The disclosure provides antibodies that bind to complement component C5a. As discussed above, the proform of C5, a 1676 amino acid residue precursor protein, is processed by a series of proteolytic cleavage events. The first 18 peptides (numbered -18 to -1) constitute a signal peptide that is cleaved from the precursor protein. The remaining 1658 amino acid protein is cleaved in two places to form the alpha and beta chains. The first cleavage event occurs between amino acid residues 655 and 656. The second cleavage occurs between amino acid residues 659 and 660. The two cleavage events result in the formation of three distinct polypeptide fragments: (i) a fragment comprising amino acids 1 to 655, which is referred to as the beta chain; (ii) a fragment comprising amino acids 660 to 1658, which is referred to as the alpha chain; and (iii) a tetrapeptide fragment consisting of amino acids 656 to 659. The alpha chain and the beta chain polypeptide fragments are connected to each other via disulfide bond and constitute the mature C5 protein. The CP or AP C5 convertase activates mature C5 by cleaving the alpha chain between residues 733 and 734, which results in the liberation of C5a fragment (amino acids 660 to 733). The remaining portion of mature C5 is fragment C5b, which contains the residues 734 to 1658 of the alpha chain disulfide bonded to the beta chain.

[0164] *In vivo*, C5a is rapidly metabolized by a serum enzyme, carboxypeptidase B, to a 73 amino acid form termed "C5a desarg," which has lost the carboxyterminal arginine residue. Accordingly, in some aspects of the disclosure, an antibody that binds to free C5a also binds to desarginated C5a. In some aspects of the disclosure, an antibody that binds to C5a does not bind to desarginated C5a.

[0165] In some aspects of the disclosure, the anti-C5a antibody binds to a neoepitope present in C5a, i.e., an epitope that becomes exposed upon the liberation of C5a from the alpha chain fragment of mature C5. That is, in some aspects, an anti-C5a antibody described herein binds to C5a and/or C5a desarg, but not to uncleaved, native (fully-folded) C5.

[0166] As described above, in some aspects of the disclosure, the anti-C5a antibody or antigen-binding fragment thereof can bind to a subpopulation of uncleaved, processed C5 (e.g., plasma C5) constituting less than 10 (e.g., less than 9.5, 9, 8.5, 8, 7.5, 7, 6.5, 6, 5.5, 5, 4.5, 4, 3.5, 3, 2.5, 2, 1.5, 1, 0.5, 0.4, 0.3, 0.2, or less than 0.1) % of the total population of full length C5 in a sample (e.g., a blood or plasma sample or a sample comprising recombinant full length C5), which subpopulation is in whole, or in part, denatured such that an otherwise occluded C5a neoepitope is exposed. Thus, an anti-C5a antibody or antigen-binding fragment thereof described herein can, in some embodiments, bind to free C5a, but not to C5 of the 90% or greater uncleaved, native C5 population. In some embodiments, the partially or fully denatured subpopulation is inactive or has reduced activity (e.g., less than 90, 85, 80, 75, 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15, 10, 5% of the activity of fully-functional, full-length C5 protein) in any number of suitable assays useful for testing C5 activity, e.g., a hemolytic assay or a CH50eq assay. Suitable methods for testing the activity of the minor subpopulation to which an anti-C5a antibody described herein may, in some embodiments, bind are known in the art and described herein.

[0167] In some aspects of the disclosure, the anti-C5a antibody binds to a mammalian (e.g., human) C5a protein. For example, the anti-C5a antibody can bind to a human C5a protein having the following amino acid sequence: TLQKKIEIAAKYKHSVVKCCYDGACVNNDETCEQRAARISLGPRIKAFTE CCVVASQLRANISHKDMQLGR (SEQ ID NO:1). In some aspects the disclosure, an anti-C5a antibody can bind to a desarginated human C5a protein having the following amino acid sequence: TLQKKIEIAAKYKHSVVKCCYDGACVNNDETCEQRAARISLGPRIKAFTE CCVVASQLRANISHKDMQLG (SEQ ID NO:2). An anti-C5a antibody described herein can bind to both full length human C5a and desarginated human C5a.

[0168] In some aspects of the disclosure, the antibody can bind to human C5a at an epitope within or overlapping with a structural fragment of the protein having the amino acid sequence: TLQKKIEEIAAKYK (SEQ ID NO:3); HSVVKKCCYDGAC (SEQ ID NO:4); VNNDE (SEQ ID NO:5); TCEQRAAR (SEQ ID NO:6); ISLG (SEQ ID NO:7); PRCIKAFTECCVVASQLRANIS (SEQ ID NO:8); HKDMLG (SEQ ID NO:9); or HKDMLGR (SEQ ID NO:10). See, e.g., Cook et al. (2010) *Acta Cryst* D66:190-197. In some aspects of the disclosure, the antibody can bind to C5a at an epitope within or overlapping with the amino acid sequence of a peptide fragment of C5a comprising at least two of the paired cysteine residues. For example, an anti-C5a antibody can bind to fragment comprising, or consisting of, the amino acid sequence: CCYDGACVNNDETC (SEQ ID NO:11); CYDGACVNNDETCEQRAARISLGPRCIKAFTEC (SEQ ID NO:12; and CEQRAARISLGPRCIKAFTECC (SEQ ID NO:13), wherein, in each of the peptide fragments, the first and final cysteine residues are paired by disulfide bonds. In some aspects of the disclosure, an anti-C5a antibody described herein can bind to a human C5a protein at an epitope within, or overlapping with, the amino acid sequence: YDGACVNNDETCEQRAAR (SEQ ID NO:14) or CYDGACVNNDETCEQRAA (SEQ ID NO:15). In some aspects of the disclosure, an antibody can bind to a human C5a protein or fragment thereof containing an amino acid sequence that contains, or consists of, at least four (e.g., at least four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, or 17 or more) consecutive amino acids depicted in any one of SEQ ID Nos:1 to 15. In some aspects of the disclosure, an anti-C5a antibody described herein binds to a ternary epitope comprising two or more (e.g., at least two, three, or four) discontinuous peptide regions of C5a protein, e.g., two or more discontinuous C5a peptide regions joined together by way of a disulfide linkage.

[0169] Methods for identifying the epitope to which a particular antibody (e.g., an anti-C5a antibody) binds are also known in the art. For example, the binding epitope within C5a (or desarginated C5a) to which an anti-C5a antibody binds can be identified by measuring the binding of the antibody to several (e.g., three, four, five, six, seven, eight, nine, 10, 15, 20, or 30 or more) overlapping peptide fragments of a complement component C5a protein (e.g., several overlapping fragments of a human C5a protein having the amino acid sequence depicted in SEQ ID NO:1 or SEQ ID NO:2). Each of the different overlapping peptides is then bound to a unique address on a solid support, e.g., separate wells of a multi-well assay plate. Next, the anti-C5a antibody is interrogated by contacting it to each of the peptides in the assay plate for an amount of time and under conditions that allow for the antibody to bind to its epitope. Unbound anti-C5a antibody is removed by washing each of the wells. Next, a detectably-labeled secondary antibody that binds to the anti-C5a antibody, if present in a well of the plate, is contacted to each of the wells, and unbound secondary antibody is removed by washing steps. The presence or amount of the detectable signal produced by the detectably-labeled secondary antibody in a well is an indication that the anti-C5a antibody binds to the particular peptide fragment associated with the well See, e.g., Harlow and Lane (*supra*), Benny K. C. Lo (*supra*), and U.S. Patent Application Publication No. 20060153836.

[0170] A particular epitope to which an antibody binds can also be identified using BIAcore chromatographic techniques (see, e.g., Pharmacia BIAtechnology Handbook, "Epitope Mapping," Section 6.3.2 (May 1994); and John et al. (1993) *J Immunol Methods* 160:20191-8).

[0171] In some aspects of the disclosure, an anti-C5a antibody described herein contains a specific set of light chain complementarity determining regions (CDRs) and/or a specific set of heavy chain CDRs. For example, in some aspects of the disclosure an anti-C5a antibody or antigen-binding fragment thereof described herein can comprise a light chain CDR set obtained from a light chain polypeptide comprising the amino acid sequence depicted in any one of SEQ ID NOs:19, 37, or 42. In some embodiments, an anti-C5a antibody or antigen-binding fragment thereof described herein can comprise a heavy chain CDR set obtained from a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:27 or 45. Exemplary light chain and heavy chain CDR sets obtained from the aforementioned light chain variable regions and heavy chain variable regions are described below in more detail (see Table 1).

[0172] The exact boundaries of CDRs, and framework regions, have been defined differently according to different methods. In some aspects of the disclosure, the positions of the CDRs or framework regions within a light or heavy chain variable domain can be as defined by Kabat et al [(1991) "Sequences of Proteins of Immunological Interest." NIH Publication No. 91-3242, U.S. Department of Health and Human Services, Bethesda, MD]. In such cases, the CDRs can be referred to as "Kabat CDRs" (e.g., "Kabat LCDR2" or "Kabat HCDR1"). In some aspects of the disclosure, the positions of the CDRs of a light or heavy chain variable region can be as defined by Chothia et al. (1989) *Nature* 342:877-883. Accordingly, these regions can be referred to as "Chothia CDRs" (e.g., "Chothia LCDR2" or "Chothia HCDR3"). In some aspects of the disclosure, the positions of the CDRs of the light and heavy chain variable regions can be as defined by a Kabat-Chothia combined definition. In such aspects of the disclosure, these regions can be referred to as "combined Kabat-Chothia CDRs." In some aspects of the disclosure, the positions of the CDRs and/or framework regions within a light or heavy chain variable domain can be as defined by Honnegger and Plückthun (2001) *J Mol Biol* 309: 657-670. Identification of the CDRs within a light chain or heavy chain variable region using the aforementioned definitions is well known in the art of antibody engineering. For example, Thomas et al. [(1996) *Mol Immunol* 33(17/18):1389-1401] exemplifies the identification of light chain and heavy chain CDR boundaries according to Kabat and Chothia definitions.

[0173] Accordingly, in some aspects of the disclosure an anti-C5a antibody or antigen-binding fragment thereof described herein can comprise a Kabat-defined, a Chothia-defined, or a combined Kabat-Chothia-defined light chain CDR set obtained from a light chain polypeptide comprising the amino acid sequence depicted in any one of SEQ ID NOs:19, 37, or 42. In some aspects of the disclosure, an anti-C5a antibody or antigen-binding fragment thereof described herein can comprise a Kabat-defined, a Chothia-defined, or a combined Kabat-Chothia-defined heavy chain CDR set obtained from a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:27 or 45.

[0174] In some embodiments, an anti-C5a antibody described herein comprises a light chain variable region containing one or more of a light chain CDR1 comprising or consisting of the following amino acid sequence: RASESVDSYGNSFMH (SEQ ID NO:20); a light chain CDR2 comprising or consisting of the following amino acid sequence: RASNLES (SEQ ID NO:21); and a light chain CDR3 comprising or consisting of the following amino acid sequence: QQSNEPPTY (SEQ ID NO:22). In some embodiments, an anti-C5a antibody described herein comprises a light chain variable region containing each of a light chain CDR1 comprising or consisting of the following amino acid sequence: RASESVDSYGNSFMH (SEQ ID NO:20); a light chain CDR2 comprising or consisting of the following amino acid sequence: RASNLES (SEQ ID NO:21); and a light chain CDR3 comprising or consisting of the following amino acid sequence: QQSNEPPTY (SEQ ID NO:22). Exemplary anti-C5a antibodies comprising such a light chain variable domain include, e.g., the BNJ364, BNJ367, BNJ378, BNJ366, BNJ369, and BNJ383 anti-C5a antibodies described herein (*vide infra*; Table 2).

[0175] In some embodiments, an anti-C5a antibody described herein comprises a light chain variable region containing one or more of: a light chain CDR1 comprising or consisting of the following amino acid sequence: RASESVDSYGNSFMH (SEQ ID NO:20); a light chain CDR2 comprising or consisting of the following amino acid sequence: WASTRES (SEQ ID NO:38); and a light chain CDR3 comprising or consisting of the following amino acid sequence: QQSNEPPTY (SEQ ID NO:22). In some embodiments, an anti-C5a antibody described herein comprises a light chain variable region containing each of a light chain CDR1 comprising or consisting of the following amino acid sequence: RASESVDSYGNSFMH (SEQ ID NO:20); a light chain CDR2 comprising or consisting of the following amino acid sequence: WASTRES (SEQ ID NO:38); and a light chain CDR3 comprising or consisting of the following amino acid sequence: QQSNEPPTY (SEQ ID NO:22). Exemplary anti-C5a antibodies comprising such a light chain variable domain include, e.g., the BNJ371 and BNJ381 anti-C5a antibodies described herein (*vide infra*; Table 2).

[0176] In some embodiments, an anti-C5a antibody described herein comprises a heavy chain variable region containing one or more of: a heavy chain CDR1 comprising or consisting of the following amino acid sequence: DYSMD (SEQ ID NO:28); a heavy chain CDR2 comprising or consisting of the following amino acid sequence: AINPNSGGTNYNQKFKD (SEQ ID NO:29); and a heavy chain CDR3 comprising or consisting of the following amino acid sequence: SGSYDGYAMDY (SEQ ID NO:30). In some embodiments, an anti-C5a antibody described herein comprises a heavy chain variable region containing each of a heavy chain CDR1 comprising or consisting of the following amino acid sequence: DYSMD (SEQ ID NO:28); a heavy chain CDR2 comprising or consisting of the following amino acid sequence: AINPNSGGTNYNQKFKD (SEQ ID NO:29); and a heavy chain CDR3 comprising or consisting of the following amino acid sequence: SGSYDGYAMDY (SEQ ID NO:30). Exemplary anti-C5a antibodies comprising such a heavy chain variable domain include, e.g., the BNJ364, BNJ367, BNJ371, and BNJ378 anti-C5a antibodies described herein (*vide infra*; Table 2).

[0177] In some embodiments, an anti-C5a antibody described herein comprises a heavy chain variable region containing one or more of: a heavy chain CDR1 comprising or consisting of the following amino acid sequence: DYSMD (SEQ ID NO:28); a heavy chain CDR2 comprising or consisting of the following amino acid sequence: AIHLNTGYTNYNQKFKG (SEQ ID NO:46); and a heavy chain CDR3 comprising or consisting of the following amino acid sequence: GFYDGYSPMDY (SEQ ID NO:47). In some embodiments, an anti-C5a antibody described herein comprises a heavy chain variable region containing each of a heavy chain CDR1 comprising or consisting of the following amino acid sequence: DYSMD (SEQ ID NO:28); a heavy chain CDR2 comprising or consisting of the following amino acid sequence: AIHLNTGYTNYNQKFKG (SEQ ID NO:46); and a heavy chain CDR3 comprising or consisting of the following amino acid sequence: GFYDGYSPMDY (SEQ ID NO:47). Exemplary anti-C5a antibodies comprising such a heavy chain variable domain include, e.g., the BNJ366, BNJ369, BNJ381, and BNJ383 anti-C5a antibodies described herein (*vide infra*; Table 2).

[0178] In some aspects of the disclosure, an anti-C5a antibody or antigen-binding fragment thereof described herein can contain a heavy chain CDR2 region comprising the amino acid sequence: AINPNSGGTNYNQKFKD (SEQ ID NO:67). For example, an anti-C5a antibody described herein can comprise a heavy chain variable region containing one or more of a heavy chain CDR1 comprising or consisting of the following amino acid sequence: DYSMD (SEQ ID NO:28); a heavy chain CDR2 comprising or consisting of the following amino acid sequence: AINPNSGGTNYNQKFKD (SEQ ID NO:67); and a heavy chain CDR3 comprising or consisting of the following amino acid sequence: SGSYDGYAMDY (SEQ ID NO:30). In some aspects of the disclosure, an

anti-C5a antibody described herein comprises a heavy chain variable region containing each of a heavy chain CDR1 comprising or consisting of the following amino acid sequence: DYSMD (SEQ ID NO:28); a heavy chain CDR2 comprising or consisting of the following amino acid sequence: AINPNSGGTNYSQKFKD (SEQ ID NO:67); and a heavy chain CDR3 comprising or consisting of the following amino acid sequence: SGSYDGYAMDY (SEQ ID NO:30). An example of an anti-C5a antibody described herein, which contains such a heavy chain polypeptide and binds to human C5a with a K_D that is less than 1 nM is the 5a101ME antibody described below.

[0179] In some embodiments, an anti-C5a antibody or antigen-binding fragment thereof described herein contains one of the exemplary light chain CDR set and heavy chain CDR set pairings 1 to 4 depicted in Table 1.

Table 1. Exemplary Heavy and Slight Chain CDR Pairings

Exemplary CDR Pairings	Light Chain			Heavy Chain			Exemplary Antibodies with such Pairings
	CDR1	CDR2	CDR3	CDR1	CDR2	CDR3	
1	SIN:20	SIN:21	SIN:22	SIN:28	SIN:29	SIN:30	BNJ364, BNJ367, BNJ378
2	SIN:20	SIN:21	SIN:22	SIN:28	SIN:46	SIN:47	BNJ366, BNJ369, BNJ383
3	SIN:20	SIN:38	SIN:22	SIN:28	SIN:29	SIN:30	BNJ371
4	SIN:20	SIN:38	SIN:22	SIN:28	SIN:46	SIN:47	BNJ381
"SIN" refers to "SEQ ID NO."							
The amino acid sequences represented by the SEQ ID NOs in Table 1 are set forth in Table 2.							

[0180] In some embodiments, the anti-C5a antibody does not comprise exemplary CDR pairing 3. In some embodiments, the anti-C5a antibody is not BNJ371.

[0181] In some embodiments, the light chain polypeptide of an anti-C5a antibody described herein can be a λ light chain polypeptide (e.g., a fully human or humanized λ light chain polypeptide). In some embodiments, the light chain polypeptide of an anti-C5a antibody described herein is a κ light chain polypeptide (e.g., a fully human or humanized κ light chain polypeptide). The amino acid sequences of numerous light chain polypeptides (e.g., numerous human light chain polypeptides) are well-known in the art and set forth in, e.g., Kabat et al. (1991), *supra*. Exemplary κ light chain polypeptide amino acid sequences are set forth in Table 2.

[0182] In some embodiments, an anti-C5a antibody described herein can comprise a light chain constant region. For example, the light chain constant region can be a light chain polypeptide constant region or a κ light chain constant region. The amino acid sequence for a number of human λ , and κ light chain constant regions are known in the art and described in, e.g., Kabat et al. (1991), *supra*. Exemplary κ light chain polypeptide amino acid sequences are set forth in Table 2.

[0183] The heavy chain polypeptide can comprise a constant region (e.g., a heavy chain constant region 1 (CH1), heavy chain constant region 2 (CH2), heavy chain constant region 3 (CH3), a heavy chain constant region 4 (CH4), or a combination of any of the foregoing). The heavy chain polypeptide can comprise an Fc portion of an immunoglobulin molecule. The Fc region can be, e.g., an Fc region from an IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, or IgD immunoglobulin molecule or a combination of portions of each of these. To be clear, the anti-C5a antibodies described herein can be, e.g., of IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, or IgD isotype. The amino acid sequences for a number of human heavy chain constant regions are known in the art and described in, e.g., Kabat et al. (1991), *supra*.

[0184] In some embodiments, the heavy chain polypeptide can comprise a hybrid constant region, or a portion thereof, such as a G2/G4 hybrid constant region (see e.g., Burton et al. (1992) Adv Immun 51:1-18; Canfield et al. (1991) JExp Med 173:1483-1491; and Mueller et al. (1997) Mol Immunol 34(6):441-452). For example (and in accordance with Kabat numbering), the IgG1 and IgG4 constant regions comprise G₂₄₉G₂₅₀ residues whereas the IgG2 constant region does not comprise residue 249, but does comprise G₂₅₀. In a G2/G4 hybrid constant region, where the 249-250 region comes from the G2 sequence, the constant region can be further modified to introduce a glycine residue at position 249 to produce a G2/G4 fusion having G₂₄₉/G₂₅₀. Other constant domain hybrids that comprise G₂₄₉/G₂₅₀ can also be part of engineered antibodies in accordance with the disclosure. Exemplary heavy chain polypeptide amino acid sequences are set forth in Table 2.

[0185] The anti-C5a antibody can be, e.g., one of the specific antibodies exemplified in the working examples: BNJ364, BNJ367, BNJ378, BNJ366, BNJ369, BNJ383, BNJ371, or BNJ381. The amino acid sequences for these exemplified anti-C5a antibodies, which can be used in conjunction with any of the methods described herein, are set forth in Table 2.

Table 2. Amino Acid Sequences for Select Humanized Anti-C5a Antibodies

SIN:	Ab	Description	Amino Acid Sequence
16	BNJ364	Full light chain sequence with signal peptide	MVLQTQVFISLLWISGAYGDIVMTQSPDSLAVSLGERATINCRASESVDSYGNSFMHWYQQKPGQPPKLLIYRASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSNEDPYTFGGGKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
17	BNJ364	Full light chain sequence without signal peptide	DIVMTQSPDSLAVSLGERATINCRASESVDSYGNSFMHWYQQKPGQPPKLLIYRASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSNEDPYTFGGGKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
18	BNJ364	Light chain variable region sequence signal peptide	MVLQTQVFISLLWISGAYG
19	BNJ364	Light chain variable region sequence	DIVMTQSPDSLAVSLGERATINCRASESVDSYGNSFMHWYQQKPGQPPKLLIYRASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSNEDPYTFGGGKVEIKR
20	BNJ364	Light chain variable region sequence Kabat LCDR1	RASESVDSYGNSFMH
21	BNJ364	Light chain variable region sequence Kabat LCDR2	RASNLES
22	BNJ364	Light chain variable region sequence Kabat LCDR3	QQSNEDPYT
23	BNJ364	Light chain constant region sequence	TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
24	BNJ364	Full heavy chain sequence with signal peptide	MDWTWRVFCLLAVAPGAHSQVQLVQSGAEVKKPGASVKVSCASGYFTFDYSMDWVRQAPGQGLEWMGAINPNSGGTNYNQKFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARSGSYDGYAMDYWGQGTITVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSNFGTQTYTCNVDPKPSNTKVDKTVERKCCVECPPCAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSIVLVHVDWLNKKEYCKKVSINKGLPAPIEKTIKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDISEVWESNGQPENNYKTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK
25	BNJ364	Full heavy chain sequence without signal peptide	QVQLVQSGAEVKKPGASVKVSCASGYFTFDYSMDWVRQAPGQGLEWMGAINPNSGGTNYNQKFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARSGSYDGYAMDYWGQGTITVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSNFGTQTYTCNVDPKPSNTKVDKTVERKCCVECPPCAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSIVLVHVDWLNKKEYCKKVSINKGLPAPIEKTIKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDISEVWESNGQPENNYKTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK
26	BNJ364	Heavy chain variable region sequence signal peptide	MDWTWRVFCLLAVAPGAHS
27	BNJ364	Heavy chain variable region sequence	QVQLVQSGAEVKKPGASVKVSCASGYFTFDYSMDWVRQAPGQGLEWMGAINPNSGGTNYNQKFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARSGSYDGYAMDYWGQGTITVTVSS

SIN:	Ab	Description	Amino Acid Sequence
28	BNJ364	Heavy chain variable region sequence Kabat HGDR1	DYSMD
29	BNJ364	Heavy chain variable region sequence Kabat HCDR2	AINPNSGGTNYNQKFKD
30	BNJ364	Heavy chain variable region sequence Kabat HCDR3	SGSYDGYAMDY
31	BNJ364	Heavy chain constant region sequence	ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERRKCCVECPPEPPAPPVAGPSVFLFPPKPKD TLMISRTPEVTCVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVSVLTVVHQD WLNKEYKCKVSNKGLPAPIEK TSKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDISEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK
16	BNJ367	Full light chain sequence with signal peptide	MVLQTQVFISLLWISGAYGDIVMTQSPDSLAVSLGERATINCRASESVDSYGNSFMHWYQQKPGQPPKLLIYRASNLESGVDPDRFSGSGGTDFLTITSLQAEDVAVYYCQQSNEDPYTFGGGKTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSYSTLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
17	BNJ367	Full light chain sequence without signal peptide	DIVMTQSPDSLAVSLGERATINCRASESVDSYGNSFMHWYQQKPGQPPKLLIYRASNLESGVDPDRFSGSGGTDFLTITSLQAEDVAVYYCQQSNEDPYTFGGGKTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSYSTLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
18	BNJ367	Light chain variable region sequence signal peptide	MVLQTQVFISLLWISGAYG
19	BNJ367	Light chain variable region sequence	DIVMTQSPDSLAVSLGERATINCRASESVDSYGNSFMHWYQQKPGQPPKLLIYRASNLESGVDPDRFSGSGGTDFLTITSLQAEDVAVYYCQQSNEDPYTFGGGKTKVEIKR
20	BNJ367	Light chain variable region sequence Kabat LCDR1	RASEVDSYGNSFMH
21	BNJ367	Light chain variable region sequence Kabat LCDR2	RASNLES
22	BNJ367	Light chain variable region sequence Kabat LCDR3	QQSNEDPYT
23	BNJ367	Light chain' constant region sequence	TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSYSTLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
32	BNJ367	Full heavy chain sequence with signal peptide	MDWTWRVFCLLAVAPGAHSQVQLVQSGAEVKKPGASVKVSKASGYTFTDYSMDWVRQAPGQGLEWMGAINPNSGGTNYNQKFKDRVTMTTRDTSTSTVYMELSSLRSEDTAVYYCARSGSYDGYAMDYWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERRKCCVECPPEPPAPPVAGPSVFLFPPKPKD TLMISRTPEVTCVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVSVLTVVHQD WLNKEYKCKVSNKGLPAPIEK TSKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDISEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK

SIN:	Ab	Description	Amino Acid Sequence
33	BNJ367	Full heavy chain sequence without signal peptide	QVQLVQSGAEVKKPGASVKVCSKASGYTFTDYSMDWVRQAPGQGLEWMGAINPNSGGTNYNQKFK DRVMTMRDSTSTVYMESSLRSEDAVYYCARSGSYDGYAMDYWGQGTITVTVSSASTKGPSVFPL APCSRSTSESTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSNFGTQT YTCNVDHKPSNTKVDKTVKCCVCEPCAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQE DPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTI SKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSF FLYSRLTVDKSRWQEGNVFSCSVMEALHNHYTQKLSLSLGK
26	BNJ367	Heavy chain variable region sequence signal peptide	MDWTWRVFCLLAVAPGAHS
27	BNJ367	Heavy chain variable region sequence	QVQLVQSGAEVKKPGASVKVCSKASGYTFTDYSMDWVRQAPGQGLEWMGAINPNSGGTNYNQKFK DRVMTMRDSTSTVYMESSLRSEDAVYYCARSGSYDGYAMDYWGQGTITVTVSS
28	BNJ367	Heavy chain variable region sequence Kabat HCDR1	DYSMD
29	BNJ367	Heavy chain variable region sequence Kabat HCDR2	AINPNSGGTNYNQKFKD
30	BNJ367	Heavy chain variable region sequence Kabat HCDR3	SGSYDGYAMDY
34	BNJ367	Heavy chain constant region sequence	ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV TVPSNFGTQTYTCNVDHKPSNTKVDKTVKCCVCEPCAPPVAGPSVFLFPPKPKDTLMISRTPEV TCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVS NKGLPSSIEKTIKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT TPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMEALHNHYTQKLSLSLGK
35	BNJ371	Full light chain sequence with signal peptide	MVLQTQVFISLLWISGAYGDIVMTQSPDSLAVSLGERATINCRASEVDSYGNSFMHWYQQKPGQPP KLLIYWASTRESGVDRFSGSGSDFTLTISSLQAEDVAVYYCQSQSNEDPYTFGGGTKVEIKRTVAAP SVFIFPPSDEQLKSGTASVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSSTYSLSSTLTLS KADYERHKVYACEVTHQGLSSPVTKSFNRGEC
36	BNJ371	Full light chain sequence without signal peptide	DIVMTQSPDSLAVSLGERATINCRASEVDSYGNSFMHWYQQKPGQPPKLLIYWASTRESGVDRFSG SGSGDFTLTISSLQAEDVAVYYCQSQSNEDPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSSTYSLSSTLTLSKADYERHKVYACEVTHQGL SSPVTKSFNRGEC
18	BNJ371	Light chain variable region sequence signal peptide	MVLQTQVFISLLWISGAYG
37	BNJ371	Light chain variable region sequence	DIVMTQSPDSLAVSLGERATINCRASEVDSYGNSFMHWYQQKPGQPPKLLIYWASTRESGVDRFSG SGSGDFTLTISSLQAEDVAVYYCQSQSNEDPYTFGGGTKVEIKR
20	BNJ371	Light chain variable region sequence Kabat LCDR1	RASEVDSYGNSFMH
38	BNJ371	Light chain variable region sequence Kabat LCDR2	WASTRES

SIN:	Ab	Description	Amino Acid Sequence
22	BNJ371	Light chain variable region sequence Kabat LCDR3	QQSNEDPYT
23	BNJ371	Light chain constant region sequence	TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKSDSTYSLS STLTLKADYEEKHKVYACEVTHQGLSSPVTKSFNRGEC
32	BNJ371	Full heavy chain sequence with signal peptide	MDWTWRVFCLLAVAPGAHSQVQLVQSGAEVKKPGASVKVSCKASGYTFTDYSMDWVRQAPGQGLE WMGAINPNSGGTNYNQKFKDRVTMTTRDTSTSTVYMESSLRSEDYAVYYCARSGSYDGYIAMDYWGQGT TTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNV DHKPSNTKVDKTVKRCCKVECPPCAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVDVVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLN GKKEYCKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLSLGK
33	BNJ371	Full heavy chain sequence without signal peptide	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYSMDWVRQAPGQGLEWMGAINPNSGGTNYNQKFK DRVTMTTRDTSTSTVYMESSLRSEDYAVYYCARSGSYDGYIAMDYWGQGT TTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNV DHKPSNTKVDKTVKRCCKVECPPCAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVDVVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLN GKKEYCKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSF FLYSRLTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLSLGK
26	BNJ371	Heavy chain variable region sequence signal peptide	MDWTWRVFCLLAVAPGAHS
27	BNJ371	Heavy chain variable region sequence	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYSMDWVRQAPGQGLEWMGAINPNSGGTNYNQKFK DRVTMTTRDTSTSTVYMESSLRSEDYAVYYCARSGSYDGYIAMDYWGQGT TTVTVSS
28	BNJ371	Heavy chain variable region sequence Kabat HCDR1	DYSMD
29	BNJ371	Heavy chain variable region sequence Kabat HCDR2	AINPNSGGTNYNQKFKD
30	BNJ371	Heavy chain variable region sequence Kabat HCDR3	SGSYDGYIAMDY
34	BNJ371	Heavy chain constant region sequence	ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV VTPSSNFGTQTYTCNV DHKPSNTKVDKTVKRCCKVECPPCAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVDVVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLN GKKEYCKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLSLGK
39	BNJ378	Full light chain sequence with signal peptide	MDMRVPAQLLGLLLWLRGARCIDIQMTQSPSSLSASVGDRTITCRASEVDSYGNFMHWYQKPKG KAPKLLIYRASNLSEGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQSNEDPYTFGGGTKEIKRTVA APSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKSDSTYSLSSTLT LSKADYEEKHKVYACEVTHQGLSSPVTKSFNRGEC

SIN:	Ab	Description	Amino Acid Sequence
40	BNJ378	Full light chain sequence without signal peptide	DIQMTQSPSSLSASVGDRTTTCRASESVDSYGNSFMHWYQQKPGKAPKLLIYRASNLESGVPSRFSGS GSGTDFLTITSLQPEDFATYYCQQSNEDPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKSTYSLSSTLTLSKADYEKHKVYACEVTHQGLS SPVTKSFNRGEC
41	BNJ378	Light chain variable region sequence signal peptide	MDMRVPAQLLGLLLLWLRGARC
42	BNJ378	Light chain variable region sequence	DIQMTQSPSSLSASVGDRTTTCRASESVDSYGNSFMHWYQQKPGKAPKLLIYRASNLESGVPSRFSGS GSGTDFLTITSLQPEDFATYYCQQSNEDPYTFGGGTKVEIKR
20	BNJ378	Light chain variable region sequence Kabat LCDR1	RASESVDSYGNSFMH
21	BNJ378	Light chain variable region sequence Kabat LCDR2	RASNLES
22	BNJ378	Light chain variable region sequence Kabat LCDR3	QQSNEDPYT
23	BNJ378	Light chain constant region sequence	TVAAPSVFIFPPSDEQLKSGTASVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKSTYSLS STLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
32	BNJ378	Full heavy chain sequence with signal peptide	MDWTWRVFCLLAVAPGAHSQVQLVQSGAEVKKPGASVKVSCKASGYTFTDYSMDWVRQAPQGGLLE WMGAINPNSGGTNYNQKFKDRVTMTTRDTSTSTVYMESSLRSEDYAVYYCARSGSYDGYAMDYWGQGT TFTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSSGLY SLSSVVTVPSSNFGTQTYTCNVDPKPSNTKVDKTVERKCCVECPPCAPPVAGPSVFLFPPKPKD TLMISRTPEVTCVVDVVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLN GKEYCKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESN GQFENNYKTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLSLGK
33	BNJ378	Full heavy chain sequence without signal peptide	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYSMDWVRQAPQGGLLEWMGAINPNSGGTNYNQKFK DRVTMTTRDTSTSTVYMESSLRSEDYAVYYCARSGSYDGYAMDYWGQGTFTVSSASTKGPSVFPL APCSRSTSESTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQ TYTCNVDPKPSNTKVDKTVERKCCVECPPCAPPVAGPSVFLFPPKPKDILMISRTPEVTCVVDVVSQ EPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYCKCKVSNKGLPSSIEKT ISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQFENNYKTPPVLDSDGS FFLYSRLTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLSLGK
26	BNJ378	Heavy chain variable region sequence signal peptide	MDWTWRVFCLLAVAPGAHS
27	BNJ378	Heavy chain variable region sequence	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYSMDWVRQAPQGGLLEWMGAINPNSGGTNYNQKFK DRVTMTTRDTSTSTVYMESSLRSEDYAVYYCARSGSYDGYAMDYWGQGTFTVSS
28	BNJ378	Heavy chain variable region sequence Kabat HCDR1	DYSMD
29	BNJ378	Heavy chain variable region sequence Kabat HCDR2	AINPNSGGTNYNQKFKD

SIN:	Ab	Description	Amino Acid Sequence
30	BNJ378	Heavy chain variable region sequence Kabat HCDR3	SGSYDGYAMDY
34	BNJ378	Heavy chain constant region sequence	ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDPKPSNTKVDKTVERKCCVECPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVDVDSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTIKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLSPGK
16	BNJ366	Full light chain sequence with signal peptide	MVLQTQVFISLLWISGAYGDIVMTQSPDSLAVSLGERATINCRASESVDSYGNFSFMHWYQQKPGQPPKLLIYRASNLESQVDPDRFSGSGSDFTLTISSLQAEDVAVYYCQQSNEPDYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDYSLSTLTLKADYEEKHKVYACEVTHQGLSSPVTKSFNRGEC
17	BNJ366	Full light chain sequence without signal peptide	DIVMTQSPDSLAVSLGERATINCRASESVDSYGNFSFMHWYQQKPGQPPKLLIYRASNLESQVDPDRFSGSGSDFTLTISSLQAEDVAVYYCQQSNEPDYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDYSLSTLTLKADYEEKHKVYACEVTHQGLSSPVTKSFNRGEC
18	BNJ366	Light chain variable region sequence signal peptide	MVLQTQVFISLLWISGAYG
19	BNJ366	Light chain variable region sequence	DIVMTQSPDSLAVSLGERATINCRASESVDSYGNFSFMHWYQQKPGQPPKLLIYRASNLESQVDPDRFSGSGSDFTLTISSLQAEDVAVYYCQQSNEPDYTFGGGTKVEIKR
20	BNJ366	Light chain variable region sequence Kabat LCDR1	RASEVDSYGNFSMH
21	BNJ366	Light chain variable region sequence Kabat LCDR2	RASNLES
22	BNJ366	Light chain variable region sequence Kabat LCDR3	QQSNEPDYT
23	BNJ366	Light chain constant region sequence	TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDYSLSTLTLKADYEEKHKVYACEVTHQGLSSPVTKSFNRGEC
43	BNJ366	Full heavy chain sequence with signal peptide	MDWTWRVFCLLAVAPGAHSQVQLVQSGAEVKKPGASVKVSCKASGYFTDYSMDWVRQAPGQGLEWMGAIHLNTGYTNYNQKFKGRVTMTRDTSTSTVYMESSLRSEDVAVYYCARGFYDGYSPMDYWGQGTITVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDPKPSNTKVDKTVERKCCVECPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDISVEWESNGQPENNYKTTPPMLDSGSFFLYSKLTVDKSRWQQGNVFSCSVMEALHNHYTQKSLSLSPGK
44	BNJ366	Full heavy chain sequence without signal peptide	QVQLVQSGAEVKKPGASVKVSCKASGYFTDYSMDWVRQAPGQGLEWMGAIHLNTGYTNYNQKFKGRVTMTRDTSTSTVYMESSLRSEDVAVYYCARGFYDGYSPMDYWGQGTITVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDPKPSNTKVDKTVERKCCVECPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDISVEWESNGQPENNYKTTPPMLDSGSFFLYSKLTVDKSRWQQGNVFSCSVMEALHNHYTQKSLSLSPGK

SIN:	Ab	Description	Amino Acid Sequence
26	BNJ366	Heavy chain variable region sequence signal peptide	MDWTWRVFCLLAVAPGAHS
45	BNJ366	Heavy chain variable region sequence	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYSMDWVRQAPGGGLEWMGAIHLNTGYTNYNQKFK GRVTMTRDTSTSTVYMELSSLRSEDAVYYCARGFYDGYSPMDYWGQGTITVTVSS
28	BNJ366	Heavy chain variable region sequence Kabat HCDR1	DYSMD
46	BNJ366	Heavy chain variable region sequence Kabat HCDR2	AIHLNTGYTNYNQKFKG
47	BNJ366	Heavy chain variable region sequence Kabat HCDR3	GFYDGYSPMDY
31	BNJ366	Heavy chain constant region sequence	ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV TVPSSNFGITQTYTCNVDHKPSNTKVDKTVERKCCVECPPCAPPVAGPSVFLFPPKPKDITLMISRTPEV TCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTERVSVLTVVHQDWLNGKEYKCKVVS NKGFLPAIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDISEWESNGQPENNYKT TPPMLDSDGSFFLYSKLTVDKSRWQQGNVFCSCVMHEALHNYTQKSLSPGK
16	BNJ369	Full light chain sequence with signal peptide	MVLQTQVFISLLWISGAYGDIVMTQSPDSLAVSLGERATINCRASESVDSYGNSFMHWYQQKPGQPP KLLIYRASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSNEDPYTFGGGKVEIKRTVAAP SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKSTYSLSTLTLS KADYEKHKVYACEVTHQGLSPVTKSFNRGEC
17	BNJ369	Full light chain sequence without signal peptide	DIVMTQSPDSLAVSLGERATINCRASESVDSYGNSFMHWYQQKPGQPPKLLIYRASNLESGVPDRFSGS GSGTDFTLTISSLQAEDVAVYYCQQSNEDPYTFGGGKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKSTYSLSTLTLSKADYEKHKVYACEVTHQGLS SPVTKSFNRGEC
18	BNJ369	Light chain variable region sequence signal peptide	MVLQTQVFISLLWISGAYG
19	BNJ369	Light chain variable region sequence	DIVMTQSPDSLAVSLGERATINCRASESVDSYGNSFMHWYQQKPGQPPKLLIYRASNLESGVPDRFSGS GSGTDFTLTISSLQAEDVAVYYCQQSNEDPYTFGGGKVEIKR
20	BNJ369	Light chain variable region sequence Kabat LCDR1	RASESVDSYGNSFMH
21	BNJ369	Light chain variable region sequence Kabat LCDR2	RASNLES
22	BNJ369	Light chain variable region sequence Kabat LCDR3	QQSNEDPYT

SIN:	Ab	Description	Amino Acid Sequence
23	BNJ369	Light chain constant region sequence	TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSSTYSLS STLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
48	BNJ369	Full heavy chain sequence with signal peptide	MDWTWRVFCLLA VAPGAHSQVQLVQSGAEVKKPGASVKVSCKASGYTFTDYSMDWVRQAPGQGLE WMGAIHLNTGYTNYNQKFKGRVTMTRDTSTSTVYMESSLRSEDTAVYYCARGFYDGYSPMDYWG QGTTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS GLYSLSSVTVPSNFGTQTYTCNVDHKPSNTKVDKTVKCCVECPPCAPPVAGPSVFLFPPKPKDT LMISRTPEVTCVVDVSDQEDPEVFQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNG KEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNG QPENNYKTTTPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHREALHNHYTQKSLSLSLGK
49	BNJ369	Full heavy chain sequence without signal peptide	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYSMDWVRQAPGQGLEWMGAIHLNTGYTNYNQKFK GRVTMTRDTSTSTVYMESSLRSEDTAVYYCARGFYDGYSPMDYWGQGTTTVTVSSASTKGPSVFPLA PCSRSTSESTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSNFGTQTY TCNVDHKPSNTKVDKTVKCCVECPPCAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVDVSDQEDP EVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISK AKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFL YSRLTVDKSRWQEGNVFSCSVMHREALHNHYTQKSLSLSLGK
26	BNJ369	Heavy chain variable region sequence signal peptide	MDWTWRVFCLLA VAPGAHS
45	BNJ369	Heavy chain variable region sequence	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYSMDWVRQAPGQGLEWMGAIHLNTGYTNYNQKFK GRVTMTRDTSTSTVYMESSLRSEDTAVYYCARGFYDGYSPMDYWGQGTTTVTVSS
28	BNJ369	Heavy chain variable region sequence Kabat HCDR1	DYSMD
46	BNJ369	Heavy chain variable region sequence Kabat HCDR2	AIHLNTGYTNYNQKFKG
47	BNJ369	Heavy chain variable region sequence Kabat HCDR3	GFYDGYSPMDY
34	BNJ369	Heavy chain constant region sequence	ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV TVPSNFGTQTYTCNVDHKPSNTKVDKTVKCCVECPPCAPPVAGPSVFLFPPKPKDTLMISRTPEV TCVVDVSDQEDPEVFQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVS NKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT TPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHREALHNHYTQKSLSLSLGK
35	BNJ381	Full light chain sequence with signal peptide	MVLQTVFISLLWISGAYGDIVMTQSPDSLAVSLGERATINCRASEVDSYGNSFMHWYQQKPGQPP KLLIYWASTRESQVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSNEDPYTFGGGTKVEIKRTVAAP SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSSTYSLSSTLTLS KADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

SIN:	Ab	Description	Amino Acid Sequence
36	BNJ381	Full light chain sequence without signal peptide	DIVMTQSPDSLAVSLGERATINCRASESVDSYGNSEFMHWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSNEDPYTFGGGKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVC LLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
18	BNJ381	Light chain variable region sequence signal peptide	MVLQTQVFISLLWISGAYG
37	BNJ381	Light chain variable region sequence	DIVMTQSPDSLAVSLGERATINCRASESVDSYGNSEFMHWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSNEDPYTFGGGKVEIKR
20	BNJ381	Light chain variable region sequence Kabat LCDR1	RASESVDSYGNSEFMH
38	BNJ381	Light chain variable region sequence Kabat LCDR2	WASTRES
22	BNJ381	Light chain variable region sequence Kabat LCDR3	QQSNEDPYT
23		Light chain constant region sequence	TVAAPSVFIFPPSDEQLKSGTASVCLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
48	BNJ381	Full heavy chain sequence with signal peptide	MDWTWRVFCLLAVAPGAHSQVQLVQSGAEVKKPGASVKVSCKASGYFTFDYSMDWVRQAPGQGLEWMGAIHLNTGYTNYNQKFKGRVTMTRDTSTSTVYMESSLRSEDYAVYYCARGFYDGYSPMDYWGQGITTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDPKPSNTKVDKTVERKCCVECPPCAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVDVVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYCKVSNKGLPSSIEKTSKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLGLK
49	BNJ381	Full heavy chain sequence without signal peptide	QVQLVQSGAEVKKPGASVKVSCKASGYFTFDYSMDWVRQAPGQGLEWMGAIHLNTGYTNYNQKFKGRVTMTRDTSTSTVYMESSLRSEDYAVYYCARGFYDGYSPMDYWGQGITTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDPKPSNTKVDKTVERKCCVECPPCAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVDVVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYCKVSNKGLPSSIEKTSKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLGLK
26	BNJ381	Heavy chain variable region sequence signal peptide	MD WTWRVFCLLAVAPGAHS
45	BNJ381	Heavy chain variable region sequence	QVQLVQSGAEVKKPGASVKVSCKASGYFTFDYSMDWVRQAPGQGLEWMGAIHLNTGYTNYNQKFKGRVTMTRDTSTSTVYMESSLRSEDYAVYYCARGFYDGYSPMDYWGQGITTVSS
28	BNJ381	Heavy chain variable region sequence Kabat HCDR1	DYSMD

SIN:	Ab	Description	Amino Acid Sequence
46	BNJ3 81	Heavy chain variable region sequence Kabat HCDR2	AIHLNTGYTNYNQKFKG
47	BNJ381	Heavy chain variable region sequence Kabat HCDR3	GFYDGYSPMDY
34	BNJ3 81	Heavy chain constant region sequence	ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVDVDSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLGLGK
39	BNJ383	Full light chain sequence with signal peptide	MDMRVPAQLLGLLLWLRGARCIDIQMTQSPSSLSASVGDRVITTCRASESDSYGNSFMHWYQQKPGKAPKLLIYRASNLESGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQSNEDPYTFGGGKTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
40	BNJ383	Full light chain sequence without signal peptide	DIQMTQSPSSLSASVGDRVITTCRASESDSYGNSFMHWYQQKPGKAPKLLIYRASNLESGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQSNEDPYTFGGGKTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
41	BNJ383	Light chain variable region sequence signal peptide	MDMRVPAQLLGLLLWLRGARC
42	BNJ383	Light chain variable region sequence	DIQMTQSPSSLSASVGDRVITTCRASESDSYGNSFMHWYQQKPGKAPKLLIYRASNLESGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQSNEDPYTFGGGKTKVEIKR
20	BNJ383	Light chain variable region sequence Kabat LCDR1	RASESDSYGNSFMH
21	BNJ383	Light chain variable region sequence Kabat LCDR2	RASNLES
22	BNJ383	Light chain variable region sequence Kabat LCDR3	QQSNEDPYT
23	BNJ383	Light chain constant region sequence	TVAAPSVFIFPPSDEQLKSGTASVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
48	BNJ383	Full heavy chain sequence with signal peptide	MDWTWRVFCLLAVAPGAHSQVQLVQSGAEVKKPGASVKVSCKASGYTFDYSMDWVRQAPGQGLEWMGAIHLNTGYTNYNQKFKGRVTMTRDTSTSTVYMESSLRSEDYAVYYCARGFYDGYSPMDYWGQGTITVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVDVDSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLGLGK
49	BNJ383	Full heavy chain sequence without signal peptide	QVQLVQSGAEVKKPGASVKVSCKASGYTFDYSMDWVRQAPGQGLEWMGAIHLNTGYTNYNQKFKGRVTMTRDTSTSTVYMESSLRSEDYAVYYCARGFYDGYSPMDYWGQGTITVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVDVDSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLGLGK

SIN:	Ab	Description	Amino Acid Sequence
26	BNJ383	Heavy chain variable region sequence signal peptide	MDWTWRVFCLLAVAPGAHS
45	BNJ383	Heavy chain variable region sequence	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYSMDWVRQAPGQGLEWMGAIHLNTGYTNYNQKFK GRVTMTRDTSTSTVYMESSLRSEDYAVYYCARGFYDGYSMPMDYWGQGTITVTVSS
28	BNJ383	Heavy chain variable region sequence Kabat HCDR1	DYSMD
46	HNJ383	Heavy chain variable region sequence Kabat HCDR2	AIHLNTGYTNYNQKFKG
47	BNJ383	Heavy chain variable region sequence Kabat HCDR3	GFYDGYSMPMDY
34	BNJ383	Heavy chain constant region sequence	ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTWNSGALTSGVHTFPAVLQSSGLYSLSSVV TVPSSNFGTQTYTCNVDHKPSNTKVDKTVRKCCVECPAPPVAGPSVFLFPPKPKDTLMISRTPEV TCVVVDVSDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVQLHQLDNLNGKEYKCKVS NKGLEPSSIEKTIKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT TPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHREALHNYTQKSLSLSLGK
"SIN" refers to SEQ ID NO. "Ab" in Table 2 refers to the alphanumeric designation assigned to a given antibody. Each of the antibodies is exemplified in the working examples.			

[0186] In some aspects of the disclosure, an anti-C5a antibody described herein comprises a Chothia-defined light chain CDR set or a combined Kabat-Chothia-defined light chain CDR set obtained from any of the light chain variable regions described in Tables 2 or 3. In some aspects of the disclosure, an anti-C5a antibody, or antigen-binding fragment thereof, described herein comprises a Chothia-defined heavy chain CDR set or a combined Kabat-Chothia-defined heavy chain CDR set obtained from any of the heavy chain variable regions described in Tables 2 or 3.

[0187] In preferred aspects of the disclosure, an anti-C5a antibody described binds to C5a, but not to native, full-length C5. In some aspects of the disclosure, an anti-C5a antibody binds to C5a, but does not bind to the alpha chain of uncleaved, native C5. As used herein, "uncleaved C5" refers to a C5 protein that has not been cleaved into fragments C5a and C5b by an AP or CP C5 convertase. An exemplary amino acid sequence for a human C5 alpha chain is set forth in Haviland et al. (1991), *supra*.

[0188] In some aspects of the disclosure, an anti-C5a antibody described herein does not bind to paralogs of human C5 such as human C3a or human C4a.

[0189] The disclosure also features antibodies that crossblock binding of an anti-C5a antibody described herein (e.g., crossblocks any one of BNJ364, BNJ367, BNJ378, BNJ366, BNJ369, BNJ371, BNJ381, or BNJ383). As used herein, the term "crossblocking antibody" refers to an antibody that lowers the amount of binding (or prevents binding) of an anti-C5a antibody to an epitope on a complement component C5a protein relative to the amount of binding of the anti-C5a antibody to the epitope in the absence of the crossblocking antibody. Suitable methods for determining whether a first antibody crossblocks binding of a second antibody to an epitope are known in the art. For example, crossblocking antibodies can be identified by comparing the binding of the BNJ364 monoclonal anti-C5a antibody in the presence and absence of a test antibody. Decreased binding of the BNJ364 antibody in the presence of the test antibody as compared to binding of the BNJ364 antibody in the absence of the test antibody indicates the test antibody is a crossblocking antibody.

[0190] In some aspects of the disclosure, the binding of an antibody to C5a can inhibit the biological activity of C5a. Methods for measuring C5a activity include, e.g., chemotaxis assays, radioimmunoassays (RIAs), or enzyme-linked immunospecific assays

(ELISA) (see, e.g., Ward and Zvaifler (1971) J Clin Invest 50(3):606-16 and Wurzner et al. (1991) Complement Inflamm 8:328-340). In some aspects of the disclosure, the binding of an antibody or antigen-binding-fragment thereof to C5a can inhibit Neutrophil activation *in vitro*. Suitable methods for determining whether an anti-C5a antibody inhibits C5a-mediated neutrophil activation *in vitro*, or the extent to which the antibody inhibits activation, are known in the art and exemplified in the working examples below. For example, human neutrophils obtained from healthy donors can be isolated and contacted with isolated human C5a in the presence or absence of a test anti-C5a antibody. C5a-dependent activation of human neutrophils can be measured as a function of myeloperoxidase (MPO) release from the cells in the presence of C5a. An inhibition of the amount of MPO released from the cells in the presence of C5a and the test antibody, as compared to the amount of MPO released from cells in the presence of C5a and a control antibody, indicates that the test antibody inhibits C5a-mediated neutrophil activation.

[0191] In some aspects of the disclosure, an anti-C5a antibody or antigen-binding fragment thereof does not inhibit (or does not substantially inhibit) the activity of complement component C5, as compared to the level of inhibition (if any) observed by a corresponding control antibody or antigen-binding fragment thereof (i.e., an antibody that does not bind to free C5a or CS). C5 activity can be measured as a function of its cell-lysing ability in a subject's body fluids. The cell-lysing ability, or a reduction thereof, of C5 can be measured by methods well known in the art such as, for example, by a conventional hemolytic assay such as the hemolysis assay described by Kabat and Mayer (eds), "Experimental Immunochemistry, 2nd Edition," 135-240, Springfield, IL, CC Thomas (1961), pages 135-139, or a conventional variation of that assay such as the chicken erythrocyte hemolysis method as described in, e.g., Hillmen et al. (2004) NEngl J Med 350(6):552.

[0192] In some aspects of the disclosure, C5 activity, or inhibition thereof, is quantified using a CH50eq assay. The CH50eq assay is a method for measuring the total classical complement activity in serum. This test is a lytic assay, which uses antibody-sensitized erythrocytes as the activator of the classical complement pathway and various dilutions of the test serum to determine the amount required to give 50% lysis (CH50). The percent hemolysis can be determined, for example, using a spectrophotometer. The CH50eq assay provides an indirect measure of terminal complement complex (TCC) formation, since the TCC themselves are directly responsible for the hemolysis that is measured.

[0193] The assay is well known and commonly practiced by those of skill in the art. Briefly, to activate the classical complement pathway, undiluted serum samples (e.g., human serum samples) are added to microassay wells containing the antibody-sensitized erythrocytes to thereby generate TCC. Next, the activated sera are diluted in microassay wells, which are coated with a capture reagent (e.g., an antibody that binds to one or more components of the TCC). The TCC present in the activated samples bind to the monoclonal antibodies coating the surface of the microassay wells. The wells are washed and, to each well, is added a detection reagent that is detectably labeled and recognizes the bound TCC. The detectable label can be, e.g., a fluorescent label or an enzymatic label. The assay results are expressed in CH50 unit equivalents per milliliter (CH50 U Eq/mL).

[0194] Additional methods for detecting and/or measuring C5 activity *in vitro* are set forth and exemplified in the working examples.

[0195] In some aspects of the disclosure, the binding of an antibody to C5a can inhibit the interaction between C5a and C5aR1. Suitable methods for detecting and/or measuring the interaction between C5a and C5aR1 (in the presence and absence of an antibody) are known in the art and described in, e.g., Mary and Boulay (1993) Eur J Haematol 51(5):282-287; Kaneko et al. (1995) Immunology 86(1):149-154; Giannini et al. (1995) J Biol Chem 270(32):19166-19172; and U.S. Patent Application Publication No. 20060160726. For example, the binding of detectably labeled (e.g., radioactively labeled) C5a to C5aR1-expressing peripheral blood mononuclear cells can be evaluated in the presence and absence of an antibody. A decrease in the amount of detectably-labeled C5a that binds to C5aR1 in the presence of the antibody, as compared to the amount of binding in the absence of the antibody, is an indication that the antibody inhibits the interaction between C5a and C5aR1.

[0196] In some aspects of the disclosure, the binding of an antibody to C5a can inhibit the interaction between C5a and C5L2. Methods for detecting and/or measuring the interaction between C5a and C5L2 are known in the art and described in, e.g., Ward (2009) J Mol Med 87(4):375-378 and Chen et al. (2007) Nature 446(7132):203-207. Additional methods for evaluating the biological effect of an anti-C5a antibody described herein are exemplified in the working examples below.

[0197] In some aspects of the disclosure, the anti-C5a antibody specifically binds to a human complement component C5a protein (e.g., the human C5a protein having the amino acid sequence depicted in SEQ ID NO:1 or SEQ ID NO:2). The terms "specific binding," "specifically binds," and like grammatical terms, as used herein, refer to two molecules forming a complex (e.g., a complex between an antibody and a complement component C5a protein) that is relatively stable under physiologic conditions. Typically, binding is considered specific when the association constant (k_a) is higher than $10^6 \text{ M}^{-1}\text{s}^{-1}$. Thus, an antibody can specifically bind to a C5a protein with a k_a of at least (or greater than) 10^6 (e.g., at least or greater than 10^7 , 10^8 , 10^9 , 10^{10} ,

10^{11} , 10^{12} , 10^{13} , 10^{14} , or 10^{15} or higher) $M^{-1}s^{-1}$. In some embodiments, an anti-C5a antibody described herein has a dissociation constant (k_d) of less than or equal to 10^{-3} (e.g., 8×10^{-4} , 5×10^{-4} , 2×10^{-4} , 10^{-4} , or 10^{-5}) s^{-1} .

[0198] In some aspects of the disclosure, an anti-C5a antibody described herein has a K_D of less than 10^{-8} , 10^{-9} , 10^{-10} , 10^{-11} , or 10^{-12} M. The equilibrium constant K_D is the ratio of the kinetic rate constants - k_d/k_a . In some aspects of the disclosure, an anti-C5a antibody described herein has a K_D of less than 1.25×10^{-9} M. Examples of anti-C5a antibodies that bind to C5a with a K_D that is less than 1.25×10^{-9} M include, e.g., the BNJ364, BNJ367, BNJ371, BNJ378, BNJ366, BNJ369, BNJ381, and BNJ383 anti-C5a antibodies.

[0199] In some aspects of the disclosure, an anti-C5a antibody described herein has a K_D of less than 1×10^{-9} M. Examples of anti-C5a antibodies that bind to C5a with a K_D that is less than 10^{-9} M include, e.g., the BNJ364, BNJ367, BNJ378, BNJ366, BNJ369, BNJ381, and BNJ383 anti-C5a antibodies.

[0200] In some aspects of the disclosure, an anti-C5a antibody described herein has a K_D of less than 5×10^{-10} M. Examples of anti-C5a antibodies that bind to C5a with a K_D that is less than 5×10^{-10} M include, e.g., the BNJ367, BNJ378, BNJ366, BNJ369, BNJ381, and BNJ383 anti-C5a antibodies.

[0201] In some aspects of the disclosure, an anti-C5a antibody described herein has a K_D of less than 2×10^{-10} M. Examples of anti-C5a antibodies that bind to C5a with a K_D that is less than 2×10^{-10} M include, e.g., the BNJ367, BNJ366, BNJ369, BNJ381, and BNJ383 anti-C5a antibodies.

[0202] In some aspects of the disclosure, an anti-C5a antibody described herein has a K_D of less than 1×10^{-10} M. Examples of anti-C5a antibodies that bind to C5a with a K_D that is less than 1×10^{-10} M include, e.g., the BNJ369, BNJ381, and BNJ383 anti-C5a antibodies.

[0203] In some aspects of the disclosure, an anti-C5a antibody described herein has a K_D of less than 7.5×10^{-11} M. Examples of anti-C5a antibodies that bind to C5a with a K_D that is less than 7.5×10^{-11} M include, e.g., the BNJ369 and BNJ383 anti-C5a antibodies.

[0204] Methods for determining the affinity of an antibody for a protein antigen are known in the art. For example, the affinity of an antibody for a protein antigen can be quantified using a variety of techniques such as, but not limited to, Western blot, dot blot, Biolayer Interferometry, Surface Plasmon Resonance (SPR) method (e.g., BIAcore system; Pharmacia Biosensor AB, Uppsala, Sweden and Piscataway, N.J.), or enzyme-linked immunospecific assays (ELISA). See, e.g., Harlow and Lane (1988) "Antibodies: A Laboratory Manual" Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.; Benny K. C. Lo (2004) "Antibody Engineering: Methods and Protocols," Humana Press (ISBN: 1588290921); Borrebaek (1992) "Antibody Engineering, A Practical Guide," W.H. Freeman, and Co., NY; Borrebaek (1995) "Antibody Engineering," 2nd Edition, Oxford University Press, NY, Oxford; Johne et al. (1993) Immunol Meth 160:191-198; Jonsson et al. (1993) Ann Biol Clin 51:19-26; and Jonsson et al. (1991) Biotechniques 11:620-627.

[0205] Any of the light chain CDR sets or light chain variable regions described herein can be paired with any of the heavy chain CDR sets or heavy chain variable regions described herein. It is well within the purview of the ordinarily skilled artisan to, e.g., confirm (test) that an anti-C5a antibody generated by such a pairing possesses the desired affinity or activity. Suitable methods for confirming the activity and/or affinity of an anti-C5a antibody are described herein.

[0206] In some aspects of the disclosure, anti-C5a antibodies described herein bind to both human C5a (hC5a) and C5a from a non-human mammal such as a non-human primate (e.g., cynomolgus macaque). In some aspects of the disclosure, an anti-C5a antibody or antigen-binding fragment thereof described herein does not bind to paralogs of human C5a such as C3a or C4a from the same non-human mammalian species.

[0207] In some aspects of the disclosure, an anti-C5a antibody or antigen-binding fragment thereof described herein binds to free hC5a and a cynomolgus macaque C5a protein comprising, or consisting of, the following amino acid sequence: MLQEKIEEJAAYKHLVVKK CCYDGVRIH DETCEQRAAR ISVGPRCVKA FTECCVVASQLRANNSHKDLQLGR (SEQ ID NO:179).

In some aspects of the disclosures, an anti-C5a antibody or antigen-binding fragment thereof described herein binds to free hC5a and a rhesus macaque C5a protein comprising, or consisting of, the amino acid sequence depicted in SEQ ID NO:179.

[0208] In some aspects of the disclosure, an antibody, or an antigen-binding fragment thereof, can bind to a desarginated form of C5a protein from a non-human mammalian species (e.g., a non-human primate species). For examples, the antibody or antigen-binding fragment thereof can bind to a free C5a-desarg protein from cynomolgus macaque or rhesus macaque, the protein comprising, or consisting of, the following amino acid sequence: MLQEKIEEIAAKYKHLVVKK CCYDGVRIH DETCEQRAAR ISVGPRCVKA FTECCVVASQLRANNSHKDLQLG (SEQ ID NO:180).

[0209] In some aspects of the disclosure, the anti-C5a antibodies described herein bind to mouse C5a (i.e., the free C5a from mouse). In some aspects of the disclosure, the anti-C5a antibodies described herein bind to mouse C5a, but not to human C5a. In some aspects of the disclosure, an anti-C5a antibody described herein does not bind to uncleaved, native (fully-folded) mouse C5. In some aspects of the disclosures, an anti-C5a antibody described does not bind to paralogs of mouse C5a such as mouse C3a or mouse C4a.

[0210] An anti-mouse C5a antibody, or an antigen-binding fragment thereof, can bind to a mouse C5a protein comprising, or consisting of, the following amino acid sequence: LRQKIEEQA AKYKHSVPKCCYD GARVNFYETCEERVARVTIGPLCIRAFNECCT IANKIRKESPHKPVQLGR (SEQ ID NO:51). See also, e.g., Wetsel et al. (1987) *Biochem* 26:737-743. In some aspects of the disclosure, an anti-mouse C5a antibody, or an antigen-binding fragment thereof, can bind to a desarginated form of mouse C5a protein comprising, or consisting of, the following amino acid sequence: LRQKIEEQA AKYKHSVPKCCYD GARVNFYETCEERVARVTIGPLCIRAFNECCT IANKIRKESPHKPVQLG (SEQ ID NO:52). In some aspects of the disclosure, the anti-mouse C5a antibody binds to both the full-length mouse C5a protein and the desarginated form of the mouse C5a protein.

[0211] An anti-mouse C5a antibody described herein can, e.g., contain a light chain CDR set obtained from a light chain variable region polypeptide comprising the following amino acid sequence: EIVLTQSPA IMSASLG EKVTMSCRASSSVNYTYWYQQKSDASPKLWIYYT SNLAP GVPARFSGSGSGNSYSLTISMEGEDAATYYCQQFTSSPLTFGVG TKLELKR (SEQ ID NO:53). For example, an anti-mouse C5a antibody can contain: (i) a Kabat-defined light chain CDR1 comprising, or consisting of, the following amino acid sequence: RASSSVNYIY (SEQ ID NO:54); (ii) a Kabat-defined light chain CDR2 comprising, or consisting of, the following amino acid sequence: YTSNLAP (SEQ ID NO:55); and/or (iii) a Kabat-defined light chain CDR3 comprising, or consisting of, the following amino acid sequence: QQFTSSPLT (SEQ ID NO:56).

[0212] The anti-mouse C5a antibody can contain a light chain constant region, e.g., the mouse kappa light chain constant region comprising, or consisting of, the following amino acid sequence: ADAAPT VSIFFPSSEQLTSGGASVVCFLN NFYPKDIN/KWKIDG SERQNGVLNSW TDQDSKDSTYSMSSTLT LTKDEYERHNSYTCEATHKTSTSPVKSFNKNEC (SEQ ID NO:57).

[0213] In some aspects of the disclosure, an anti-mouse C5a antibody described herein can contain an amino-terminal signal peptide, e.g., a signal peptide comprising, or consisting of, the following amino acid sequence: MGWSCIILFLVATATGVHS (SEQ ID NO:58).

[0214] In some aspects of the disclosure, an anti-mouse C5a antibody described herein can contain a light chain polypeptide comprising, or consisting of, the following amino acid sequence: REIVLTQSPA IMSASLG EKVTMSCRASSSVNYTYWYQQKSDASPKLWIYYT SNLA PGVPARFSGSGSGNSYSLTISMEGEDAATYYCQQFTSSPLTFGVG TKLELKRAD AAPT VSIFFPSSEQLTSGGASVVCFLN NFYPKDIN/KWKIDG SERQNGVLNSWTD QDSKDSTYSMSSTLT LTKDEYERHNSYTCEATHKTSTSPVKSFNKNEC (SEQ ID NO:59) or MGWSCIILFLVATATGVHSREIVLTQSPA IMSASLG EKVTMSCRASSSVNYTYWY QQKSDASPKLWIYYT SNLAPGVPARFSGSGSGNSYSLTISMEGEDAATYYCQQF TSSPLTFGVG TKLELKRADAAPT VSIFFPSSEQLTSGGASVVCFLN NFYPKDINVK WKIDG SERQNGVLNSWTDQDSKDSTYSMSSTLT LTKDEYERHNSYTCEATHKTS TSPIVKSFNKNEC (SEQ ID NO:60). In some aspects of the disclosure, an anti-mouse C5a antibody described herein contains a light chain polypeptide comprising amino acids 2 to 214 of SEQ ID NO:59. In some aspects of the disclosure, an anti-mouse C5a antibody described herein contains a light chain polypeptide comprising amino acids 1 to 19 and 21 to 233 of SEQ ID NO:60.

[0215] An anti-mouse C5a antibody described herein can, e.g., contain a heavy chain CDR set obtained from a heavy chain variable region polypeptide comprising the following amino acid sequence:

LEVQLQQSGPELVKPGASVKISCKASGYTFTDYYINWVKQSHGKSLEWIGYYP

NDGDTNYNQKFKGKATLTVDKSSSTAYMELRSLTSEDSAVYYCARPYSDYGM DYWGQGTSTVTVSS (SEQ ID NO:61). For example, an anti-mouse C5a antibody can contain: (i) a Kabat-defined heavy chain CDR1 comprising, or consisting of, the following amino acid sequence: DYYIN (SEQ ID NO:62); (ii) a Kabat-defined heavy chain CDR2 comprising, or consisting of, the following amino acid sequence: YYPNDGDTNYNQKFKG (SEQ ID NO:63); and/or (iii) a Kabat-defined heavy chain CDR3 comprising, or consisting of, the following amino acid sequence: PYSDYGM (SEQ ID NO:64).

[0216] The anti-mouse C5a antibody can contain a heavy chain constant region. In some aspects of the disclosure, an anti-mouse C5a antibody described herein can contain an amino-terminal signal peptide, e.g., a signal peptide comprising, or consisting of, the following amino acid sequence: MGWSCILFLVATATGVHS (SEQ ID NO:65).

[0217] In some aspects of the disclosure, an anti-mouse C5a antibody described herein can contain a heavy chain polypeptide comprising, or consisting of, the following amino acid sequence:

LEVQLQQSGPELVKPGASVKISCKASGYTFTDYYINWVKQSHGKSLEWIGYYP

NDGDTNYNQKFKGKATLTVDKSSSTAYMELRSLTSEDSAVYYCARPYSDYGM DYWGQGTSTVTVSS (SEQ ID NO:66) or

MGWSCILFLVATATGVHSELEVQLQQSGPELVKPGASVKISCKASGYTFTDYYI

NWVKQSHGKSLEWIGYYPNDGDTNYNQKFKGKATLTVDKSSSTAYMELRSLT SEDSAVYYCARPYSDYGM DYWGQGTSTVTVSS

(SEQ ID NO:67). In some aspects of the disclosure, an anti-mouse C5a antibody described herein contains a heavy chain polypeptide comprising amino acids 2 to 121 of SEQ ID NO:66. In some aspects of the disclosure, an anti-mouse C5a antibody described herein contains a heavy chain polypeptide comprising amino acids 1 to 19 and 21 to 140 of SEQ ID NO:67. In some aspects of the disclosure, an anti-mouse C5a antibody described herein contains a heavy chain constant region polypeptide comprising one or more amino acid substitutions from the above described sequence.

[0218] In some aspects of the disclosure, an anti-mouse C5a antibody described herein contains a light chain polypeptide comprising: (i) a light chain CDR1 comprising, or consisting of, the amino acid sequence depicted in SEQ ID NO:54; (ii) a light chain CDR2 comprising, or consisting of, the amino acid sequence depicted in SEQ ID NO:55; and (iii) a light chain CDR3 comprising, or consisting of, the amino acid sequence depicted in SEQ ID NO:56; (iv) a heavy chain CDR1 comprising, or consisting of, the amino acid sequence depicted in SEQ ID NO:62; (v) a heavy chain CDR2 comprising, or consisting of, the amino acid sequence depicted in SEQ ID NO:63; and/or (vi) a heavy chain CDR3 comprising, or consisting of, the amino acid sequence depicted in SEQ ID NO:64.

[0219] In some aspects of the disclosure, an anti-mouse C5a antibody described herein contains a light chain polypeptide comprising, or consisting of, the amino acid sequence depicted in SEQ ID NO:59 and a heavy chain polypeptide comprising, or consisting of, the amino acid sequence depicted in SEQ ID NO:66.

[0220] In some aspects of the disclosure, an anti-C5a antibody described herein can bind to human C5a and to mouse C5a.

Methods for Producing the Anti-C5a Antibodies and Antigen-binding Fragments Thereof

[0221] The disclosure also features methods for producing any of the anti-C5a antibodies or antigen-binding fragments thereof described herein. In some aspects of the disclosure, methods for preparing an antibody described herein can include immunizing a subject (e.g., a non-human mammal) with an appropriate immunogen. Suitable immunogens for generating any of the antibodies described herein are set forth herein. For example, to generate an antibody that binds to C5a, a skilled artisan can immunize a suitable subject (e.g., a non-human mammal such as a rat, a mouse, a gerbil, a hamster, a dog, a cat, a pig, a goat, a horse, or a non-human primate) with a full-length C5a polypeptide such as a full-length C5a polypeptide comprising the amino acid sequence depicted in SEQ ID NO:1 or the desarginated form of C5a (e.g., the human C5a desarg comprising the amino acid sequence depicted in SEQ ID NO:2). In some aspects of the disclosure, the non-human mammal is C5 deficient, e.g., a C5-deficient mouse described in, e.g., Levy and Ladda (1971) *Nat New Biol* 229(2):51-52; Crocker et al. (1974) *J Clin Pathol* 27(2):122-124; Wetsel et al. (1990) *J Biol Chem* 265:2435-2440; and Jungi and Pepys (1981) *Immunology* 43(2):271-279. Human C5a can be purified from human serum as described in, e.g., McCarthy and Henson (1979) *J Immunol* 123(6):2511-2517 and Manderino et al. (1982) *J Immunol Methods* 53(1):41-50. See also the working examples. Human C5a can also be generated *in vitro* as described in, e.g., Vallota and Müller-Eberhard (1973) *J Exp Med* 137:1109. Purified human C5a is also commercially available from, e.g., Complement Technology, Inc. (catalog number A144; Tyler, Texas). Recombinant C5a can also be generated by one of ordinary skill in the art as described in, e.g., Tothe et al. (1994) *Prot Sci* 3:1159-1168.

[0222] A suitable subject (e.g., a non-human mammal) can be immunized with the appropriate antigen along with subsequent

booster immunizations a number of times sufficient to elicit the production of an antibody by the mammal. The immunogen can be administered to a subject (e.g., a non-human mammal) with an adjuvant. Adjuvants useful in producing an antibody in a subject include, but are not limited to, protein adjuvants; bacterial adjuvants, e.g., whole bacteria (BCG, *Corynebacterium parvum* or *Salmonella minnesota*) and bacterial components including cell wall skeleton, trehalose dimycolate, monophosphoryl lipid A, methanol extractable residue (MER) of tubercle *bacillus*, complete or incomplete Freund's adjuvant; viral adjuvants; chemical adjuvants, e.g., aluminum hydroxide, and iodoacetate and cholesteryl hemisuccinate. Other adjuvants that can be used in the methods for inducing an immune response include, e.g., cholera toxin and parapoxvirus proteins. See also Bieg et al. (1999) *Autoimmunity* 31(1):15-24. See also, e.g., Lodmell et al. (2000) *Vaccine* 18:1059-1066; Johnson et al. (1999) *J Med Chem* 42:4640-4649; Baldridge et al. (1999) *Methods* 19:103-107; and Gupta et al. (1995) *Vaccine* 13(14): 1263-1276.

[0223] In some aspect of the disclosure, the methods include preparing a hybridoma cell line that secretes a monoclonal antibody that binds to the immunogen. For example, a suitable mammal such as a laboratory mouse is immunized with a C5a polypeptide as described above. Antibody-producing cells (e.g., B cells of the spleen) of the immunized mammal can be isolated two to four days after at least one booster immunization of the immunogen and then grown briefly in culture before fusion with cells of a suitable myeloma cell line. The cells can be fused in the presence of a fusion promoter such as, e.g., vaccinia virus or polyethylene glycol. The hybrid cells obtained in the fusion are cloned, and cell clones secreting the desired antibodies are selected. For example, spleen cells of Balb/c mice immunized with a suitable immunogen can be fused with cells of the myeloma cell line PA1 or the myeloma cell line Sp2/0-Ag 14. After the fusion, the cells are expanded in suitable culture medium, which is supplemented with a selection medium, for example HAT medium, at regular intervals in order to prevent normal myeloma cells from overgrowing the desired hybridoma cells. The obtained hybrid cells are then screened for secretion of the desired antibodies, e.g., an antibody that binds to C5a and inhibits the interaction between C5a and a C5a receptor (e.g., C5aR1).

[0224] In some aspect of the disclosure, a skilled artisan can identify an anti-C5a antibody from a non-immune biased library as described in, e.g., U.S. patent no. 6,300,064 (to Knappik et al.; Morphosys AG) and Schoonbroodt et al. (2005) *Nucleic Acids Res* 33(9):e81.

[0225] In some aspects of the disclosure, the methods described herein can involve, or be used in conjunction with, e.g., phage display technologies, bacterial display, yeast surface display, eukaryotic viral display, mammalian cell display, and cell-free (e.g., ribosomal display) antibody screening techniques (see, e.g., Etz et al. (2001) *J Bacteriol* 183:6924-6935; Cornelis (2000) *Curr Opin Biotechnol* 11:450-454; Klemm et al. (2000) *Microbiology* 146:3025-3032; Kieke et al. (1997) *Protein Eng* 10:1303-1310; Yeung et al. (2002) *Biotechnol Prog* 18:212-220; Boder et al. (2000) *Methods Enzymology* 328:430-444; Grabherr et al. (2001) *Comb Chem High Throughput Screen* 4:185-192; Michael et al. (1995) *Gene Ther* 2:660-668; Pereboev et al. (2001) *J Virol* 75:7107-7113; Schaffitzel et al. (1999) *J Immunol Methods* 231:119-135; and Hanes et al. (2000) *Nat Biotechnol* 18:1287-1292).

[0226] Methods for identifying antibodies using various phage display methods are known in the art. In phage display methods, functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them. Such phage can be utilized to display antigen-binding domains of antibodies, such as Fab, Fv, or disulfide-bond stabilized Fv antibody fragments, expressed from a repertoire or combinatorial antibody library (e.g., human or murine). Phage used in these methods are typically filamentous phage such as fd and M13. The antigen binding domains are expressed as a recombinantly fused protein to any of the phage coat proteins pIII, pVIII, or pIX. See, e.g., Shi et al. (2010) *JMB* 397:385-396. Examples of phage display methods that can be used to make the immunoglobulins, or fragments thereof, described herein include those disclosed in Brinkman et al. (1995) *J Immunol Methods* 182:41-50; Ames et al. (1995) *J Immunol Methods* 184:177-186; Kettleborough et al. (1994) *Eur J Immunol* 24:952-958; Persic et al. (1997) *Gene* 187:9-18; Burton et al. (1994) *Advances in Immunology* 57:191-280; and PCT publication nos. WO 90/02809, WO 91/10737, WO 92/01047, WO 92/18619, WO 93/11236, WO 95/15982, and WO 95/20401. Suitable methods are also described in, e.g., U.S. patent nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743 and 5,969,108.

[0227] In some aspects of the disclosure, the phage display antibody libraries can be generated using mRNA collected from B cells from the immunized mammals. For example, a splenic cell sample comprising B cells can be isolated from mice immunized with C5a polypeptide as described above. mRNA can be isolated from the cells and converted to cDNA using standard molecular biology techniques. See, e.g., Sambrook et al. (1989) *"Molecular Cloning: A Laboratory Manual, 2nd Edition,"* Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.; Harlow and Lane (1988), *supra*; Benny K. C. Lo (2004), *supra*; and Borrebaek (1995), *supra*. The cDNA coding for the variable regions of the heavy chain and light chain polypeptides of immunoglobulins are used to construct the phage display library. Methods for generating such a library are described in, e.g., Merz et al. (1995) *J Neurosci Methods* 62(1-2):213-9; Di Niro et al. (2005) *Biochem J* 388(Pt 3):889-894; and Engberget al. (1995) *Methods Mol Biol* 51:355-376.

[0228] In some aspects of the disclosure, a combination of selection and screening can be employed to identify an antibody of interest from, e.g., a population of hybridoma-derived antibodies or a phage display antibody library. Suitable methods are known in the art and are described in, e.g., Hoogenboom (1997) *Trends in Biotechnology* 15:62-70; Brinkman et al. (1995), *supra*; Ames et al. (1995), *supra*; Kettleborough et al. (1994), *supra*; Persic et al. (1997), *supra*; and Burton et al. (1994), *supra*. For example, a plurality of phagemid vectors, each encoding a fusion protein of a bacteriophage coat protein (e.g., pIII, pVIII, or pIX of M13 phage) and a different antigen-combining region are produced using standard molecular biology techniques and then introduced into a population of bacteria (e.g., *E. coli*). Expression of the bacteriophage in bacteria can, in some embodiments, require use of a helper phage. In some embodiments, no helper phage is required (see, e.g., Chasteen et al. (2006) *Nucleic Acids Res* 34(21):e145). Phage produced from the bacteria are recovered and then contacted to, e.g., a target antigen bound to a solid support (immobilized). Phage may also be contacted to antigen in solution, and the complex is subsequently bound to a solid support.

[0229] In some aspects of the disclosure, the immobilized phage are the phage of interest. Accordingly, the unbound phage are removed by washing the support. Following the wash step, bound phage are then eluted from the solid support, e.g., using a low pH buffer or a free target antigen competitor, and recovered by infecting bacteria. In some aspects of the disclosure, the phage that are not immobilized are the phage of interest. In such aspects of the disclosure, the population of phage can be contacted to the antigen two or more times to deplete from the population any of the phage that bind to the support. Unbound phage are then collected and used for subsequent screening steps.

[0230] To enrich the phage population for phage particles that contain antibodies having a higher affinity for the target antigen (while reducing the proportion of phage that may bind to the antigen non-specifically), the eluted phage (described above) can be used to re-infect a population of bacterial host cells. The expressed phage are then isolated from the bacteria and again contacted to a target antigen. The concentration of antigen, pH, temperature and inclusion of detergents and adjuvants during contact can be modulated to enrich for higher affinity antibody fragments. The unbound phage are removed by washing the solid support. The number of cycles, duration, pH, temperature and inclusion of detergents and adjuvants during washing can also be modulated to enrich for higher affinity antibody fragments. Following the wash step, bound phage are then eluted from the solid support. Anywhere from one to six iterative cycles of panning may be used to enrich for phage containing antibodies having higher affinity for the target antigen. In some embodiments, a deselection step can also be performed in conjunction with any of the panning approaches described herein.

[0231] Individual phage of the population can be isolated by infecting bacteria and then plating at a density to allow formation of monoclonal antibodies.

[0232] For example, to identify using phage display techniques an antibody that binds to C5a, but not to C5, the following panning approach can be employed. The population can first be contacted to a surface containing bound native, full-length human C5. The process can be repeated two or more times, each time collecting the unbound phage. The population can also be contacted to a solid support containing surface-bound C4 and/or C3 proteins. Unbound phage from the foregoing steps are then contacted to a surface containing bound C5a or desarginated C5a. Phage that bind to C5a are eluted from the surface and recovered by infecting bacteria. Iterative rounds of phage selection may be performed. After one to six rounds of selection, individual recovered phagemid can be screened for expression of antibody fragments with the desired specificity and affinity.

[0233] A subpopulation of antibodies screened using the above methods can be characterized for their specificity and binding affinity for a particular immunogen (e.g., C5a) using any immunological or biochemical based method known in the art. For example, specific binding of an antibody to C5a, as compared to native, full-length C5, may be determined for example using immunological or biochemical based methods such as, but not limited to, an ELISA assay, SPR assays, immunoprecipitation assay, affinity chromatography, and equilibrium dialysis as described above. Immunoassays which can be used to analyze immunospecific binding and cross-reactivity of the antibodies include, but are not limited to, competitive and non-competitive assay systems using techniques such as Western blots, RIA, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoprecipitation assays, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, and protein A immunoassays. Such assays are routine and well known in the art.

[0234] Antibodies can also be assayed using any SPR-based assays known in the art for characterizing the kinetic parameters of the interaction of the antibody with C5a. Any SPR instrument commercially available including, but not limited to, BIAcore Instruments (Biacore AB; Uppsala, Sweden); IAsys instruments (Affinity Sensors; Franklin, Massachusetts); IBIS system (Windsor Scientific Limited; Berks, UK), SPR-CELLIA systems (Nippon Laser and Electronics Lab; Hokkaido, Japan), and SPR Detector Spreeta (Texas Instruments; Dallas, Texas) can be used in the methods described herein. See, e.g., Mullett et al. (2000) *Methods*

22: 77-91; Dong et al. (2002) *Reviews in Mol Biotech* 82: 303-323; Fivash et al. (1998) *Curr Opin Biotechnol* 9: 97-101; and Rich et al (2000) *Curr Opin Biotechnol* 11: 54-61.

[0235] It is understood that the above methods can also be used to determine if, e.g., an anti-C5a antibody does not bind to full-length, native C5, C3, and/or C4 proteins. The above methods can also be used to determine if an antibody that binds to C5a also inhibits the interaction between C5a and a C5a receptor. The above methods can also be used to determine if an antibody that binds to C5a also inhibits the activity of C5a.

[0236] As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies, including human antibodies, or any desired fragments, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described in detail below. For example, techniques to recombinantly produce Fab, Fab' and F(ab')₂ fragments can also be employed using methods known in the art such as those disclosed in PCT publication no. WO 92/22324; Mullinax et al. (1992) *BioTechniques* 12(6):864-869; and Sawai et al. (1995) *Am J Repr Immunol* 34:26-34; and Better et al. (1988) *Science* 240:1041-1043. Examples of techniques which can be used to produce single-chain Fvs and antibodies include those described in U.S. patent nos. 4,946,778 and 5,258,498; Huston et al. (1991) *Methods in Enzymology* 203:46-88; Shu et al. (1993) *Proc Nat Acad Sci USA* 90:7995-7999; and Skerra et al. (1988) *Science* 240:1038-1040.

[0237] Phage display technology can also be used to, e.g., increase the affinity of an antibody for its cognate antigen. The technology, referred to as affinity maturation, can employ mutagenesis or CDR walking and re-selection to identify antibodies that bind with higher affinity to an antigen as compared to the initial or parental antibody. See, e.g., Glaser et al. (1992) *J Immunol* 149:3903-3913. Libraries can be constructed consisting of a pool of variant clones, each differing by one or more amino acid substitutions. Mutants with increased binding affinity for the antigen can be selected for by contacting the immobilized mutants with labeled antigen or any combination of methods described above. Any screening method known in the art can be used to identify mutant antibodies with increased affinity to the antigen (e.g., SPR or ELISA techniques).

[0238] In some aspects of the disclosure, epitope mapping can be used to identify, e.g., the region of C5a that interacts with an antibody, e.g., a region of C5a that binds to C5aR1. Methods for identifying the epitope to which a particular antibody binds are also known in the art and are described above.

[0239] The antibodies and fragments thereof identified herein can be or can be made "chimeric." Chimeric antibodies and antigen-binding fragments thereof comprise portions from two or more different species (e.g., mouse and human). Chimeric antibodies can be produced with mouse variable regions of desired specificity fused to human constant domains (for example, U.S. Patent No. 4,816,567). In this manner, non-human antibodies can be modified to make them more suitable for human clinical application (e.g., methods for treating or preventing a complement-mediated disorder in a subject).

[0240] The monoclonal antibodies of the present disclosure include "humanized" forms of the non-human (e.g., mouse) antibodies. Humanized or CDR grafted mAbs are particularly useful as therapeutic agents for humans because they are not cleared from the circulation as rapidly as mouse antibodies and do not typically provoke an adverse immune reaction. Generally, a humanized antibody has one or more amino acid residues introduced into it from a non-human source. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Methods of preparing humanized antibodies are generally well known in the art. For example, humanization can be essentially performed following the method of Winter and co-workers (see, e.g., Jones et al (1986) *Nature* 321:522-525; Riechmann et al. (1988) *Nature* 332:323-327; and Verhoeyen et al. (1988) *Science* 239:1534-1536), by substituting rodent frameworks or CDR sequences for the corresponding sequences of a human antibody. Also see, e.g., Staelens et al. (2006) *Mol Immunol* 43:1243-1257. In some embodiments, humanized forms of non-human (e.g., mouse) antibodies are human antibodies (recipient antibody) in which the CDR region amino acid residues of the non-human antibody (e.g., mouse, rat, rabbit, or non-human primate antibody) having the desired specificity, affinity, and binding capacity are grafted onto the framework scaffold of a human antibody. Additional humanization methods are described below in the working examples.

[0241] Methods for grafting CDR sequences from a donor antibody (e.g., a non-human antibody) to the framework regions of an acceptor antibody (e.g., a human antibody) are well known in the art and are described in, e.g., Jones et al. (1986) *Nature* 321:522-525; Verhoeyen et al. (1988) *Science* 239(4847):1534-1536; Riechmann et al (1988) *Nature* 332:323-327; Queen et al. (1989) *Proc Natl Acad Sci USA* 86:10029-10033; PCT publication no. WO 93/011237; Kettleborough et al. (1991) *Protein Engineering, Design and Selection* 4:773-783; Benny K. C. Lo (2004) "Antibody Engineering: Methods and Protocols," Humana Press (ISBN: 1588290921); Borrebaek (1992) "antibody Engineering, A Practical Guide," W.H. Freeman and Co., NY; and Borrebaek (1995) "Antibody Engineering," 2nd Edition, Oxford University Press, NY, Oxford. For example, CDRs from a donor

antibody can be grafted onto framework regions of an acceptor antibody using overlap extension polymerase chain reaction (PCR) techniques as described in, e.g., Daugherty et al. (1991) *Nucleic Acids Res* 19(9):2471-2476; Roguska et al. (1996) *Protein Engineering* 9(10):895-904; and Yazaki et al. (2004) *Protein Engineering" Design & Selection* 17(5):481-489.

[0242] In aspects of the disclosure where the selected CDR amino acid sequences are short sequences (e.g., fewer than 10-15 amino acids in length), nucleic acids encoding the CDRs can be chemically synthesized as described in, e.g., Shiraishi et al. (2007) *Nucleic Acids Symposium Series* 51(1):129-130 and U.S. Patent No. 6,995,259. For a given nucleic acid sequence encoding an acceptor antibody, the region of the nucleic acid sequence encoding the CDRs can be replaced with the chemically synthesized nucleic acids using standard molecular biology techniques. The 5' and 3' ends of the chemically synthesized nucleic acids can be synthesized to comprise sticky end restriction enzyme sites for use in cloning the nucleic acids into the nucleic acid encoding the variable region of the donor antibody.

[0243] In some instances, one or more framework region amino acid residues of the human immunoglobulin are also replaced by corresponding amino acid residues of the non-human antibody (so called "back mutations"). In addition, phage display libraries can be used to vary amino acids at chosen positions within the antibody sequence. The properties of a humanized antibody are also affected by the choice of the human framework. Furthermore, humanized and chimerized antibodies can be modified to comprise residues that are not found in the recipient antibody or in the donor antibody in order to further improve antibody properties, such as, for example, affinity or effector function.

[0244] Fully human antibodies are also provided in the disclosure. The term "human antibody" includes antibodies having variable and constant regions (if present) derived from human immunoglobulin sequences, preferably human germline sequences. Human antibodies can include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis *in vitro* or by somatic mutation *in vivo*). However, the term "human antibody" does not include antibodies in which CDR sequences derived from another mammalian species, such as a mouse, have been grafted onto human framework sequences (i.e., humanized antibodies). Fully human or human antibodies may be derived from transgenic mice carrying human antibody genes (carrying the variable (V), diversity (D), joining (J), and constant (C) exons) or from human cells. For example, it is now possible to produce transgenic animals (e.g., mice) that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production. See, e.g., Jakobovits et al. (1993) *Proc Natl Acad Sci USA* 90:2551; Jakobovits et al. (1993) *Nature* 362:255-258; Bruggemann et al. (1993) *Year in Immunol.* 7:33; and Duchosal et al. (1992) *Nature* 355:258. Transgenic mouse strains can be engineered to contain gene sequences from unrearranged human immunoglobulin genes. One example of such a mouse is the HuMAb Mouse® (Medarex, Inc.), which contains human immunoglobulin transgene miniloci that encode unrearranged human μ heavy and κ light chain immunoglobulin sequences, together with targeted mutations that inactivate the endogenous μ and κ chain loci. See, e.g., Lonberg, et al. (1994) *Nature* 368(6474):856-859. The preparation and use of HuMAb mice, and the genomic modifications carried by such mice, are further described in Taylor et al. (1992) *Nucleic Acids Res* 20:6287-6295; Chen, J. et al. (1993) *International Immunology* 5: 647-656; Tuaillon et al. (1993) *Proc Natl Acad Sci USA* 90:3720-3724; Choi et al. (1993) *Nature Genetics* 4:1 17-123; Tuaillon et al. (1994) *J Immunol* 152:2912-2920; Taylor et al. (1994) *International Immunology* 6:579-591; and Fishwild et al. (1996) *Nature Biotechnol* 14:845-851. An alternative transgenic mouse system for expressing human immunoglobulin genes is referred to as the Xenomouse (Abgenix, Inc.) and is described in, e.g., U.S. patent nos. 6,075,181; 6,114,598; 6,150,584; and 6,162,963. Like the HuMAb Mouse® system, the Xenomouse system involves disruption of the endogenous mouse heavy and light chain genes and insertion into the genome of the mouse transgenes carrying unrearranged human heavy and light chain immunoglobulin loci that contain human variable and constant region sequences. Other systems known in the art for expressing human immunoglobulin genes include the KM Mouse® system, described in detail in PCT Publication WO 02/43478 and the TC mouse system described in Tomizuka et al. (2000) *Proc Natl Acad Sci USA* 97:722-727.

[0245] The human sequences may code for both the heavy and light chains of human antibodies and would function correctly in the mice, undergoing rearrangement to provide a wide antibody repertoire similar to that in humans. The transgenic mice can be immunized with the target protein immunogen to create a diverse array of specific antibodies and their encoding RNA. Nucleic acids encoding the antibody chain components of such antibodies may then be cloned from the animal into a display vector. Typically, separate populations of nucleic acids encoding heavy and light chain sequences are cloned, and the separate populations then recombined on insertion into the vector, such that any given copy of the vector receives a random combination of a heavy and a light chain. The vector is designed to express antibody chains so that they can be assembled and displayed on the outer surface of a display package containing the vector. For example, antibody chains can be expressed as fusion proteins with a phage coat protein from the outer surface of the phage. Thereafter, display packages can be selected and screened for display of antibodies binding to a target.

[0246] In addition, the phage-display libraries screened above can include human antibodies (Hoogenboom et al. (1992) *J Mol Biol* 227:381; Marks et al. (1991) *J Mol Biol* 222:581-597; and Vaughan et al. (1996) *Nature Biotech* 14:309). Synthetic phage

libraries can be created which use randomized combinations of synthetic human antibody V-regions. By selection on antigen, fully human antibodies can be made in which the V-regions are very human-like in nature. See, e.g., U.S. Patent Nos. 6,794,132; 6,680,209; 4,634,666; and Ostberg et al (1983) Hybridoma 2:361-367.

[0247] For the generation of human antibodies, also see Mendez et al. (1998) Nature Genetics 15:146-156 and Green and Jakobovits (1998) J Exp Med 188:483-495.

[0248] Human antibodies are further discussed and delineated in U.S. Patent Nos.: 5,939,598; 6,673,986; 6,114,598; 6,075,181; 6,162,963; 6,150,584; 6,713,610; and 6,657,103 as well as U.S. Patent Publication Nos. 20030229905 A1, 20040010810 A1, 20040093622 A1, 20060040363 A1, 20050054055 A1, 20050076395 A1, and 20050287630 A1. See also International Publication Nos. WO 94/02602, WO 96/34096, and WO 98/24893, and European Patent No. EP 0 463 151 B1.

[0249] In an alternative approach, others, including GenPharm International, Inc., have utilized a "minilocus" approach. In the minilocus approach, an exogenous Ig locus is mimicked through the inclusion of pieces (individual genes) from the Ig locus. Thus, one or more V_H genes, one or more D_H genes, one or more J_H genes, a mu constant region, and a second constant region (preferably a gamma constant region) are formed into a construct for insertion into an animal. This approach is described in, e.g., U.S. Patent Nos.: 5,545,807; 5,545,806; 5,625,825; 5,625,126; 5,633,425; 5,661,016; 5,770,429; 5,789,650; and 5,814,318; 5,591,669; 5,612,205; 5,721,367; 5,789,215; 5,643,763; 5,569,825; 5,877,397; 6,300,129; 5,874,299; 6,255,458; and 7,041,871.

[0250] See also European Patent No. 0 546 073 B1, International Patent Publication Nos. WO 92/03918, WO 92/22645, WO 92/22647, WO 92/22670, WO 93/12227, WO 94/00569, WO 94/25585, WO 96/14436, WO 97/13852, and WO 98/24884.

[0251] See further Taylor et al. (1992) Nucleic Acids Res 20: 6287; Chen et al (1993) Int Immunol 5: 647; Tuaillon et al. (1993) Proc Natl Acad Sci USA 90: 3720-4; Choi et al. (1993) Nature Genetics 4: 117; Lonberg et al. (1994) Nature 368: 856-859; Taylor et al. (1994) International Immunology 6:579-591; Tuaillon et al. (1995) J. Immunol 154: 6453-65; Fishwild et al. (1996) Nature. Biotechnology 14: 845; and Tuaillon et al. (2000) EurJImmunol. 10: 2998-3005.

[0252] In certain aspects of the disclosure, de-immunized forms of the antibodies, or antigen-binding fragments described herein are provided. De-immunized antibodies or antigen-binding fragments thereof are antibodies that have been modified so as to render the antibody or antigen-binding fragment thereof non-immunogenic, or less immunogenic, to a given species. De-immunization can be achieved by modifying the antibody or antigen-binding fragment thereof utilizing any of a variety of techniques known to those skilled in the art (see, e.g., PCT Publication Nos. WO 04/108158 and WO 00/34317). For example, an antibody or antigen-binding fragment thereof may be de-immunized by identifying potential T cell epitopes and/or B cell epitopes within the amino acid sequence of the antibody or antigen-binding fragment thereof and removing one or more of the potential T cell epitopes and/or B cell epitopes from the antibody or antigen-binding fragment thereof, for example, using recombinant techniques. The modified antibody or antigen-binding fragment thereof may then optionally be produced and tested to identify antibodies or antigen-binding fragments thereof that have retained one or more desired biological activities, such as, for example, binding affinity, but have reduced immunogenicity. Methods for identifying potential T cell epitopes and/or B cell epitope may be carried out using techniques known in the art, such as, for example, computational methods (see e.g., PCT Publication No. WO 02/069232), *in vitro* or *in silico* techniques, and biological assays or physical methods (such as, for example, determination of the binding of peptides to MHC molecules, determination of the binding of peptide:MHC complexes to the T cell receptors from the species to receive the antibody or antigen-binding fragment thereof, testing of the protein or peptide parts thereof using transgenic animals with the MHC molecules of the species to receive the antibody or antigen-binding fragment thereof, or testing with transgenic animals reconstituted with immune system cells from the species to receive the antibody or antigen-binding fragment thereof, etc.). In various aspects of the disclosure, the de-immunized antibodies described herein include de-immunized antigen-binding fragments, Fab, Fv, scFv, Fab' and F(ab')₂, monoclonal antibodies, murine antibodies, fully human antibodies, engineered antibodies (such as, for example, chimeric, single chain, CDR-grafted, humanized, and artificially selected antibodies), synthetic antibodies and semisynthetic antibodies.

[0253] In the therapeutic aspects of the present disclosure, bispecific antibodies are contemplated. Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for C5a, the other one is for any other antigen.

[0254] Methods for making bispecific antibodies are within the purview of those skilled in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chain/ light-chain pairs have different specificities (Milstein and Cuello (1983) Nature 305:537-539). Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain

sequences. The fusion of the heavy chain variable region is preferably is with an immunoglobulin heavy-chain constant domain, including at least part of the hinge, C_H2, and C_H3 regions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of illustrative currently known methods for generating bispecific antibodies see, .e.g., Suresh et al. (1986) *Methods in Enzymology* 121:210; PCT Publication No. WO 96/27011; Brennan et al. (1985) *Science* 229:81; Shalaby et al., *J Exp Med* (1992) 175:217-225; Kostelny et al. (1992) *J Immunol* 148(5):1547-1553; Hollinger et al (1993) *Proc Natl Acad Sci USA* 90:6444-6448; Gruber et al. (1994) *J Immunol* 152:5368; and Tutt et al (1991) *J Immunol* 147:60. Bispecific antibodies also include cross-linked or heteroconjugate antibodies. Heteroconjugate antibodies may be made using any convenient cross-linking methods. Suitable cross-linking agents are well known in the art, and are disclosed in U.S. Patent No. 4,676,980, along with a number of cross-linking techniques.

[0255] Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. See, e.g., Kostelny et al. (1992) *J Immunol* 148(5):1547-1553. The leucine zipper peptides from the Fos and Jun proteins may be linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers may be reduced at the hinge region to form monomers and then reoxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The "diabody" technology described by Hollinger et al. (1993) *Proc Natl Acad Sci USA* 90:6444-6448 has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (VH) connected to a light-chain variable domain (VL) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the VH and VL domains of one fragment are forced to pair with the complementary VL and VH domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (scFv) dimers has also been reported. See, e.g., Gruber et al. (1994) *J Immunol* 152:5368. Alternatively, the antibodies can be "linear antibodies" as described in, e.g., Zapata et al. (1995) *Protein Eng.* 8(10):1057-1062. Briefly, these antibodies comprise a pair of tandem Fd segments (V_H-C_H1-V_H-C_H1) which form a pair of antigen binding regions. Linear antibodies can be bispecific or monospecific.

[0256] Antibodies with more than two valencies (e.g., trispecific antibodies) are contemplated and described in, e.g., Tutt et al. (1991) *J Immunol* 147:60.

[0257] The disclosure also embraces variant forms of multi-specific antibodies such as the dual variable domain immunoglobulin (DVD-Ig) molecules described in Wu et al. (2007) *Nat Biotechnol* 25(11):1290-1297. The DVD-Ig molecules are designed such that two different light chain variable domains (VL) from two different parent antibodies are linked in tandem directly or via a short linker by recombinant DNA techniques, followed by the light chain constant domain. Similarly, the heavy chain comprises two different heavy chain variable domains (VH) linked in tandem, followed by the constant domain C_H1 and Fc region. Methods for making DVD-Ig molecules from two parent antibodies are further described in, e.g., PCT Publication Nos. WO 08/0241188 and WO 07/024715.

[0258] The disclosure also provides camelid or dromedary antibodies (e.g., antibodies derived from *Camelus bactrianus*, *Camelus dromaderius*, or *Lama paccos*). Such antibodies, unlike the typical two-chain (fragment) or four-chain (whole antibody) antibodies from most mammals, generally lack light chains. See U.S. patent no. 5,759,808; Stijlemans et al. (2004) *J Biol Chem* 279:1256-1261; Dumoulin et al (2003) *Nature* 424:783-788; and Pleschberger et al. (2003) *Bioconjugate Chem* 14:440-448. Engineered libraries of camelid antibodies and antibody fragments are commercially available, for example, from Ablynx (Ghent, Belgium). As with other antibodies of non-human origin, an amino acid sequence of a camelid antibody can be altered recombinantly to obtain a sequence that more closely resembles a human sequence, i.e., the nanobody can be "humanized" to thereby further reduce the potential immunogenicity of the antibody.

[0259] In some aspects of the disclosure, the anti-C5a antibodies herein comprise an altered heavy chain constant region that has reduced (or no) effector function relative to its corresponding unaltered constant region. Effector functions involving the constant region of the anti-C5a antibody may be modulated by altering properties of the constant or Fc region. Altered effector functions include, for examples a modulation in one or more of the following activities: antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), apoptosis, binding to one or more Fc-receptors, and pro-inflammatory responses. Modulation refers to an increase, decrease, or elimination of an effector function activity exhibited by a subject antibody containing an altered constant region as compared to the activity of the unaltered form of the constant region. In particular aspects of the disclosure, modulation includes situations in which an activity is abolished or completely absent

[0260] An altered constant region with altered FcR binding affinity and/or ADCC activity and/or altered CDC activity is a polypeptide which has either an enhanced or diminished FcR binding activity and/or ADCC activity and/or CDC activity compared

to the unaltered form of the constant region. An altered constant region which displays increased binding to an FcR binds at least one FcR with greater affinity than the unaltered polypeptide. An altered constant region which displays decreased binding to an FcR binds at least one FcR with lower affinity than the unaltered form of the constant region. Such variants which display decreased binding to an FcR may possess little or no appreciable binding to an FcR, e.g., 0 to 50% (e.g., less than 50, 49, 48, 47, 46, 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1%) of the binding to the FcR as compared to the level of binding of a native sequence immunoglobulin constant or Fc region to the FcR. Similarly, an altered constant region that displays modulated ADCC and/or CDC activity may exhibit either increased or reduced ADCC and/or CDC activity compared to the unaltered constant region. For example, in some aspects of the disclosure, the anti-C5a antibody comprising an altered constant region can exhibit approximately 0 to 50% (e.g., less than 50, 49, 48, 47, 46, 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1%) of the ADCC and/or CDC activity of the unaltered form of the constant region. An anti-C5a antibody described herein comprising an altered constant region displaying reduced ADCC and/or CDC may exhibit reduced or no ADCC and/or CDC activity as exemplified herein.

[0261] In certain aspects of the disclosure, the altered constant region has at least one amino acid substitution, insertion, and/or deletion, compared to a native sequence constant region or to the unaltered constant region, e.g. from about one to about one hundred amino acid substitutions, insertions, and/or deletions in a native sequences constant region or in the constant region of the parent polypeptide. In some aspects of the disclosure, the altered constant region herein will possess at least about 70% homology (similarity) or identity with the unaltered constant region and in some instances at least about 75% and in other instances at least about 80% homology or identity therewith, and in other embodiments at least about 85%, 90% or 95% homology or identity therewith. The altered constant region may also contain one or more amino acid deletions or insertions. Additionally, the altered constant region may contain one or more amino acid substitutions, deletions, or insertions that results in altered post translational modifications, including, for example, an altered glycosylation pattern (e.g., the addition of one or more sugar components, the loss of one or more sugar components, or a change in composition of one or more sugar components relative to the unaltered constant region).

[0262] Antibodies with altered or no effector functions may be generated by engineering or producing antibodies with variant constant, Fc, or heavy chain regions; recombinant DNA technology and/or cell culture and expression conditions may be used to produce antibodies with altered function and/or activity. For example, recombinant DNA technology may be used to engineer one or more amino acid substitutions, deletions, or insertions in regions (such as, for example, Fc or constant regions) that affect antibody function including effector functions. Alternatively, changes in post-translational modifications, such as, e.g., glycosylation patterns, may be achieved by manipulating the cell culture and expression conditions by which the antibody is produced. Suitable methods for introducing one or more substitutions, additions, or deletions into an Fc region of an antibody are well known in the art and include, e.g., standard DNA mutagenesis techniques as described in, e.g., Sambrook et al. (1989) "Molecular Cloning: A Laboratory Manual, 2nd Edition," Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.; Harlow and Lane (1988), *supra*; Borrebaek (1992), *supra*; John et al. (1993), *supra*; PCT publication no. WO 06/53301; and U.S. patent no. 7,704,497.

[0263] In some aspects of the disclosure, an anti-C5a antibody described herein exhibits reduced or no effector function. In some aspects of the disclosure, an anti-C5a antibody comprises a hybrid constant region, or a portion thereof, such as a G2/G4 hybrid constant region (see e.g., Burton et al (1992) *Adv Immun* 51:1-18; Canfield et al. (1991) *J Exp Med* 173:1483-1491; and Mueller et al. (1997) *Mol Immunol* 34(6):441-452). See above.

[0264] In addition to using a G2/G4 construct as described above, an anti-C5a antibody described herein having reduced effector function may be produced by introducing other types of changes in the amino acid sequence of certain regions of the antibody. Such amino acid sequence changes include but are not limited to the Ala-Ala mutation described in, e.g., PCT Publication nos. WO 94/28027 and WO 98/47531; and Xu et al (2000) *Cell Immunol* 200:16-26. Thus, in some aspects of the disclosure, an anti-C5a antibody with one or more mutations within the constant region including the Ala-Ala mutation has reduced or no effector function. According, to these aspects, the constant region of the antibody can comprise a substitution to an alanine at position 234 or a mutation to an alanine at position 235. Additionally, the altered constant region may contain a double mutation: a mutation to an alanine at position 234 and a second mutation to an alanine at position 235. In one aspect of the disclosure, an anti-C5a antibody comprises an IgG4 framework, wherein the Ala-Ala mutation would describe a mutation(s) from phenylalanine to alanine at position,234 and/or a mutation from leucine to alanine at position 235. In another aspect of the disclosure, the anti-C5a antibody comprises an IgG1 framework, wherein the Ala-Ala mutation would describe a mutation(s) from leucine to alanine at position 234 and/or a mutation from leucine to alanine at position 235. An anti-C5a antibody may alternatively or additionally carry other mutations, including the point mutation K322A in the CH2 domain (Hezareh metal. (2001) *J Virol* 75:12161-12168). An antibody with said mutation(s) in the constant region may furthermore be a blocking or non-blocking antibody.

[0265] Additional substitutions that, when introduced into a heavy chain constant region, result in decreased effector function are set forth in, e.g., Shields et al. (2001) J Biol Chem 276(9):6591-6604. See particularly Table 1 ("Binding of human IgG1 variants to human FcRn and FcγR) of Shields et al.; the disclosure of which is incorporated herein by reference in its entirety. By screening a library of anti-IgE antibodies, each antibody of the library differing by one or more substitutions in the heavy chain constant region, for binding to a panel of Fc receptors (including FcRn, FcγRI, FcγRIIA, FcγRIIB, and FcγRIIIA), the authors identified a number of substitutions that modulate specific Fc-Fc receptor interactions. For example, a variant IgG2a heavy chain constant region in which the CH2 domain contains a D265A substitution (heavy chain amino acid numbering according to Kabat et al. (*supra*)) results in a complete loss of interaction between the variant constant region and IgG Fc receptors FcγRIIB, FcγRIII, FcγRI, and FcγRIV. Shields et al. (2001) at page 6595, Table 1. See also Baudino et al. (2008) J Immunol 181:6664-6669 (*supra*).

[0266] Changes within the hinge region also affect effector functions. For example, deletion of the hinge region may reduce affinity for Fc receptors and may reduce complement activation (Klein et al. (1981) Proc-Natl Acad Sci USA 78: 524-528). The present disclosure therefore also relates to antibodies with alterations in the hinge region.

[0267] In some aspects of the disclosure, an anti-C5a antibody may contain an altered constant region exhibiting enhanced or reduced complement dependent cytotoxicity (CDC). Modulated CDC activity may be achieved by introducing one or more amino acid substitutions, insertions, or deletions in an Fc region of the antibody. See, e.g., U.S. patent no. 6,194,551. Alternatively or additionally, cysteine residue(s) may be introduced in the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated may have improved or reduced internalization capability and/or increased or decreased complement-mediated cell killing. See, e.g., Caron et al. (1992) J Exp Med 176:1191-1195 and Shopes (1992) Immunol 148:2918-2922; PCT publication nos. WO 99/51642 and WO 94/29351; Duncan and Winter (1988) Nature 322:738-40; and U.S. Patent Nos. 5,648,260 and 5,624,821.

[0268] Another potential means of modulating effector function of antibodies includes changes in glycosylation, which is summarized in, e.g., Raju (2003) BioProcess International 1(4):44-53. According to Wright and Morrison, the microheterogeneity of human IgG oligosaccharides can affect biological functions such as CDC and ADCC, binding to various Fc receptors, and binding to C1q protein. (1997) TIBTECH 15:26-32. Glycosylation patterns of antibodies can differ depending on the producing cell and the cell culture conditions (Raju, *supra*). Such differences can lead to changes in both effector function and pharmacokinetics. See, e.g., Israel et al. (1996) Immunology 89(4):573-578; Newkirk et al. (1996) Clin Exp Immunol 106(2):259-264. Differences in effector function may be related to the IgG's ability to bind to the Fcγ receptors (FcγRs) on the effector cells. Shields et al. have shown that IgG, with alterations in amino acid sequence that have improved binding to FcγR, can exhibit up to 100% enhanced ADCC using human effector cells. (2001) J Biol Chem 276(9):6591-6604. While these alterations include changes in amino acids not found at the binding interface, both the nature of the sugar component as well as its structural pattern may also contribute to the differences observed. In addition, the presence or absence of fucose in the oligosaccharide component of an IgG can improve binding and ADCC. See, e.g., Shields et al. (2002) J Biol Chem 277(30):26733-26740. An IgG that lacked a fucosylated carbohydrate linked to Asn²⁹⁷ exhibited normal receptor binding to the FcγRI receptor. In contrast, binding to the FcγRIIIA receptor was improved 50-fold and accompanied by enhanced ADCC, especially at lower antibody concentrations.

[0269] Shinkawa et al. demonstrated that an antibody to the human IL-5 receptor produced in a rat hybridoma showed more than 50% higher ADCC when compared to the antibody produced in Chinese hamster ovary cells (CHO) (Shinkawa et al. (2003) J Biol Chem 278(5):3466-73). Monosaccharide composition and oligosaccharide profiling showed that the rat hybridoma-produced IgG had a lower content of fucose than the CHO-produced protein. The authors concluded that the lack of fucosylation of an IgG1 has a critical role in enhancement of ADCC activity.

[0270] A different approach was taken by Umana et al. who changed the glycosylation pattern of chCE7, a chimeric IgG1 anti-neuroblastoma antibody. (1999) Nat Biotechnol 17(2):176-180). Using tetracycline, they regulated the activity of a glycosyltransferase enzyme (GnTIII) which bisects oligosaccharides that have been implicated in ADCC activity. The ADCC activity of the parent antibody was barely above background level. Measurement of ADCC activity of the chCE7 produced at different tetracycline levels showed an optimal range of GnTIII expression for maximal chCE7 *in vitro* ADCC activity. This activity correlated with the level of constant region-associated, bisected complex oligosaccharide. Newly optimized variants exhibited substantial ADCC activity. Similarly, Wright and Morrison produced antibodies in a CHO cell line deficient in glycosylation and showed that antibodies produced in this cell line were incapable of complement-mediated cytotoxicity. (1994) J Exp Med 180:1087-1096. Thus, as known alterations that affect effector function include modifications in the glycosylation pattern or a change in the number of glycosylated residues, the present disclosure relates to an anti-C5a antibody wherein glycosylation is altered to either enhance or

decrease effector function(s) including ADCC and CDC. Altered glycosylation includes a decrease or increase in the number of glycosylated residues as well as a change in the pattern or location of glycosylated residues.

[0271] Still other approaches exist for altering the effector function of antibodies. For example, antibody-producing cells can be hypermutagenic, thereby generating antibodies with randomly altered polypeptide residues throughout an entire antibody molecule. See, e.g., PCT publication no. WO 05/011735. Hypermutagenic host cells include cells deficient in DNA mismatch repair. Antibodies produced in this manner may be less antigenic and/or have beneficial pharmacokinetic properties. Additionally, such antibodies may be selected for properties such as enhanced or decreased effector function(s). Additional details of molecular biology techniques useful for preparing an antibody or antigen-binding fragment thereof described herein are set forth below.

Recombinant Antibody Expression and Purification

[0272] The antibodies or antigen-binding fragments thereof described herein can be produced using a variety of techniques known in the art of molecular biology and protein chemistry. For example, a nucleic acid encoding one or both of the heavy and light chain polypeptides of an antibody can be inserted into an expression vector that contains transcriptional and translational regulatory sequences, which include, e.g., promoter sequences, ribosomal binding sites, transcriptional start and stop sequences, translational start and stop sequences, transcription terminator signals, polyadenylation signals, and enhancer or activator sequences. The regulatory sequences include a promoter and transcriptional start and stop sequences. In addition, the expression vector can include more than one replication system such that it can be maintained in two different organisms, for example in mammalian or insect cells for expression and in a prokaryotic host for cloning and amplification.

[0273] Several possible vector systems are available for the expression of cloned heavy chain and light chain polypeptides from nucleic acids in mammalian cells. One class of vectors relies upon the integration of the desired gene sequences into the host cell genome. Cells which have stably integrated DNA can be selected by simultaneously introducing drug resistance genes such as *E. coli* gpt (Mulligan and Berg (1981) Proc Natl Acad Sci USA 78:2072) or *Tn5* neo (Southern and Berg (1982) Mol. Appl Genet 1:327). The selectable marker gene can be either linked to the DNA gene sequences to be expressed, or introduced into the same cell by co-transfection (Wigler et al. (1979) Cell 16:77). A second class of vectors utilizes DNA elements which confer autonomously replicating capabilities to an extrachromosomal plasmid. These vectors can be derived from animal viruses, such as bovine papillomavirus (Sarver et al. (1982) Proc. Natl Acad Sci USA, 79:7147), cytomegalovirus, polyoma virus (Deans et al. (1984) Proc Natl Acad Sci USA 81:1292), or SV40 virus (Lusky and Botchan (1982) Nature 293:79).

[0274] The expression vectors can be introduced into cells in a manner suitable for subsequent expression of the nucleic acid. The method of introduction is largely dictated by the targeted cell type, discussed below. Exemplary methods include CaPO₄ precipitation, liposome fusion, cationic liposomes, electroporation, viral infection, dextran-mediated transfection, polybrene-mediated transfection, protoplast fusion, and direct microinjection.

[0275] Appropriate host cells for the expression of antibodies or antigen-binding fragments thereof include yeast, bacteria, insect, plant, and mammalian cells. Of particular interest are bacteria such as *E. coli*, fungi such as *Saccharomyces cerevisiae* and *Pichia pastoris*, insect cells such as SF9, mammalian cell lines (e.g., human cell lines), as well as primary cell lines.

[0276] In some aspects of the disclosure, an antibody or fragment thereof can be expressed in, and purified from, transgenic animals (e.g., transgenic mammals). For example, an antibody can be produced in transgenic non-human mammals (e.g., rodents) and isolated from milk as described in, e.g., Houdebine (2002) Curr Opin Biotechnol 13(6):625-629; van Kuik-Romeijn et al. (2000) Transgenic Res 9(2):155-159; and Pollock et al. (1999) J Immunol Methods 231(1-2):147-157.

[0277] The antibodies and fragments thereof can be produced from the cells by culturing a host cell transformed with the expression vector containing nucleic acid encoding the antibodies or fragments, under conditions, and for an amount of time, sufficient to allow expression of the proteins. Such conditions for protein expression will vary with the choice of the expression vector and the host cell, and will be easily ascertained by one skilled in the art through routine experimentation. For example, antibodies expressed in *E. coli* can be refolded from inclusion bodies (see, e.g., Hou et al. (1998) Cytokine 10:319-30). Bacterial expression systems and methods for their use are well known in the art (see Current Protocols in Molecular Biology, Wiley & Sons, and Molecular Cloning A Laboratory Manual -3rd Ed., Cold Spring Harbor Laboratory Press, New York (2001)). The choice of codons, suitable expression vectors and suitable host cells will vary depending on a number of factors, and may be easily optimized as needed. An antibody (or fragment thereof) described herein can be expressed in mammalian cells or in other expression systems including but not limited to yeast, baculovirus, and *in vitro* expression systems (see, e.g., Kaszubska et al.

(2000) Protein Expression and Purification 18:213-220).

[0278] Following expression, the antibodies and fragments thereof can be isolated. The term "purified" or "isolated" as applied to any of the proteins (antibodies or fragments) described herein refers to a polypeptide that has been separated or purified from components (e.g., proteins or other naturally-occurring biological or organic molecules) which naturally accompany it, e.g., other proteins, lipids, and nucleic acid in a prokaryote expressing the proteins. Typically, a polypeptide is purified when it constitutes at least 60 (e.g., at least 65, 70, 75, 80, 85, 90, 92, 95, 97, or 99) %, by weight, of the total protein in a sample.

[0279] An antibody or fragment thereof can be isolated or purified in a variety of ways known to those skilled in the art depending on what other components are present in the sample. Standard purification methods include electrophoretic, molecular, immunological, and chromatographic techniques, including ion exchange, hydrophobic, affinity, and reverse-phase HPLC chromatography. For example, an antibody can be purified using a standard anti-antibody column (e.g., a protein-A or protein-G column). Ultrafiltration and diafiltration techniques, in conjunction with protein concentration, are also useful. See, e.g., Scopes (1994) "protein Purification, 3rd edition," Springer-Verlag, New York City, New York. The degree of purification necessary will vary depending on the desired use. In some instances, no purification of the expressed antibody or fragments thereof will be necessary.

[0280] Methods for determining the yield or purity of a purified antibody or fragment thereof are known in the art and include, e.g., Bradford assay, UV spectroscopy, Biuret protein assay, Lowry protein assay, amido black protein assay, high pressure liquid chromatography (HPLC), mass spectrometry (MS), and gel electrophoretic methods (e.g., using a protein stain such as Coomassie Blue or colloidal silver stain).

[0281] In some aspects of the disclosure, endotoxin can be removed from the antibodies or fragments. Methods for removing endotoxin from a protein sample are known in the art and exemplified in the working examples. For example, endotoxin can be removed from a protein sample using a variety of commercially available reagents including, without limitation, the ProteoSpin™ Endotoxin Removal Kits (Norgen Biotek Corporation), Detoxi-Gel Endotoxin Removal Gel (Thermo Scientific; Pierce Protein Research Products), MiraCLEAN® Endotoxin Removal Kit (Mirus), or Acrodisc™ - Mustang® E membrane (Pall Corporation).

[0282] Methods for detecting and/or measuring the amount of endotoxin present in a sample (both before and after purification) are known in the art and commercial kits are available. For example, the concentration of endotoxin in a protein sample can be determined using the QCL-1000 Chromogenic kit (BioWhittaker), the limulus ameobocyte lysate (LAL)-based kits such as the Pyrotell®, Pyrotell®-T, Pyrochrome®, Chromo-LAL, and CSE kits available from the Associates of Cape Cod Incorporated.

[0283] While in no way intended to be limiting, exemplary methods for generating the antibodies described herein are set forth in the working Examples.

Modification of the Antibodies or Antigen-Binding Fragments Thereof

[0284] The antibodies or antigen-binding fragments thereof can be modified following their expression and purification. The modifications can be covalent or non-covalent modifications. Such modifications can be introduced into the antibodies or fragments by, e.g., reacting targeted amino acid residues of the polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or terminal residues. Suitable sites for modification can be chosen using any of a variety of criteria including, e.g., structural analysis or amino acid sequence analysis of the antibodies or fragments.

[0285] In some aspects of the disclosure, the antibodies or antigen-binding fragments thereof can be conjugated to a heterologous moiety. The heterologous moiety can be, e.g., a heterologous polypeptide, a therapeutic agent (e.g., a toxin or a drug), or a detectable label such as, but not limited to, a radioactive label, an enzymatic label, a fluorescent label, a heavy metal label, a luminescent label, or an affinity tag such as biotin or streptavidin. Suitable heterologous polypeptides include, e.g., an antigenic tag (e.g., FLAG (DYKDDDDK (SEQ ID NO:50)), polyhistidine (6-His; HHHHHH (SEQ ID NO:81), hemagglutinin (HA; YPYDVPDYA (SEQ ID-NO:82), glutathione-S-transferase (GST), or maltose-binding protein (MBP)) for use in purifying the antibodies or fragments. Heterologous polypeptides also include polypeptides (e.g., enzymes) that are useful as diagnostic or detectable markers, for example, luciferase, a fluorescent protein (e.g., green fluorescent protein (GFP)), or chloramphenicol acetyl transferase (CAT). Suitable radioactive labels include, e.g., ³²P, ³³P, ¹⁴C, ¹²⁵I, ¹³¹I, ¹³¹I, ³⁵S, and ³H. Suitable fluorescent labels include, without limitation, fluorescein, fluorescein isothiocyanate (FITC), green fluorescent protein (GFP), DyLight™ 488, phycoerythrin (PE), propidium iodide (PI), PerCP, PE-Alexa Fluor® 700, Cy5, allophycocyanin, and Cy7. Luminescent labels include, e.g., any of a variety of luminescent lanthanide (e.g., europium or terbium) chelates. For example, suitable europium

chelates include the europium chelate of diethylene triamine pentaacetic acid (DTPA) or tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). Enzymatic labels include, e.g., alkaline phosphatase, CAT, luciferase, and horseradish peroxidase.

[0286] Two proteins (e.g., an antibody and a heterologous moiety) can be cross-linked using any of a number of known chemical cross linkers. Examples of such cross linkers are those which link two amino acid residues via a linkage that includes a "hindered" disulfide bond. In these linkages, a disulfide bond within the cross-linking unit is protected (by hindering groups on either side of the disulfide bond) from reduction by the action, for example, of reduced glutathione or the enzyme disulfide reductase. One suitable reagent, 4-succinimidylloxycarbonyl- α -methyl- α -(2-pyridyldithio) toluene (SMPT), forms such a linkage between two proteins utilizing a terminal lysine on one of the proteins and a terminal cysteine on the other. Heterobifunctional reagents that crosslink by a different coupling moiety on each protein can also be used. Other useful crosslinkers include, without limitation, reagents which link two amino groups (e.g., N-5-azido-2-nitrobenzoyloxysuccinimide), two sulfhydryl groups (e.g., 1,4-bis-maleimidobutane), an amino group and a sulfhydryl group (e.g., m-maleimidobenzoyl-N-hydroxysuccinimide ester), an amino group and a carboxyl group (e.g., 4-[p-azidosalicylamido]butylamine), and an amino group and a guanidinium group that is present in the side chain of arginine (e.g., p-azidophenyl glyoxal monohydrate).

[0287] In some aspects of the disclosure, a radioactive label can be directly conjugated to the amino acid backbone of the antibody. Alternatively, the radioactive label can be included as part of a larger molecule (e.g., ^{125}I in Meta-[^{125}I]iodophenyl-N-hydroxysuccinimide ([^{125}I]mIPNHS) which binds to free amino groups to form meta-iodophenyl (mIP) derivatives of relevant proteins (see, e.g., Rogers et al. (1997) J Nucl Med 38:1221-1229) or chelate (e.g., to DOTA or DTPA) which is in turn bound to the protein backbone. Methods of conjugating the radioactive labels or larger molecules/chelates containing them to the antibodies or antigen-binding fragments described herein are known in the art. Such methods involve incubating the proteins with the radioactive label under conditions (e.g., pH, salt concentration, and/or temperature) that facilitate binding of the radioactive label or chelate to the protein (see, e.g., U.S. Patent No. 6,001,329).

[0288] Methods for conjugating a fluorescent label (sometimes referred to as a "fluorophore") to a protein (e.g., an antibody) are known in the art of protein chemistry. For example, fluorophores can be conjugated to free amino groups (e.g., of lysines) or sulfhydryl groups (e.g., cysteines) of proteins using succinimidyl (NHS) ester or tetrafluorophenyl (TFP) ester moieties attached to the fluorophores. In some aspects of the disclosure, the fluorophores can be conjugated to a heterobifunctional cross-linker moiety such as sulfo-SMCC. Suitable conjugation methods involve incubating an antibody protein, or fragment thereof, with the fluorophore under conditions that facilitate binding of the fluorophore to the protein. See, e.g., Welch and Redvanly (2003) "Handbook of Radiopharmaceuticals: Radiochemistry and Applications," John Wiley and Sons (ISBN 0471495603).

[0289] In some aspects of the disclosure, the antibodies or fragments can be modified, e.g., with a moiety that improves the stabilization and/or retention of the antibodies in circulation, e.g., in blood, serum, or other tissues. For example, the antibody or fragment can be PEGylated as described in, e.g., Lee et al. (1999) Bioconjug Chem 10(6): 973-8; Kinstler et al. (2002) Advanced Drug Deliveries Reviews 54:477-485; and Roberts et al. (2002) Advanced Drug Delivery Reviews 54:459-476 or HESylated (Fresenius Kabi, Germany; see, e.g., Pavisić et al. (2010) Int J Pharm 387(1-2):110-119). The stabilization moiety can improve the stability, or retention of, the antibody (or fragment) by at least 1.5 (e.g., at least 2, 5, 10, 15, 20, 25, 30, 40, or 50 or more) fold.

[0290] In some aspects of the disclosure, the antibodies or antigen-binding fragments thereof described herein can be glycosylated. In some aspects of the disclosure, an antibody or antigen-binding fragment thereof described herein can be subjected to enzymatic or chemical treatment, or produced from a cell, such that the antibody or fragment has reduced or absent glycosylation. Methods for producing antibodies with reduced glycosylation are known in the art and described in, e.g., U.S. patent no. 6,933,368; Wright et al. (1991) EMBO J 10(10):2717-2723; and Co et al. (1993) Mol Immunol 30:1361.

Pharmaceutical Compositions

[0291] Compositions containing an antibody or an antigen-binding fragment thereof described herein can be formulated as a pharmaceutical composition, e.g., for administration to a subject for the treatment or prevention of a complement-associated disorder. The pharmaceutical compositions will generally include a pharmaceutically acceptable carrier. As used herein, a "pharmaceutically acceptable carrier" refers to, and includes, any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. The compositions can include a pharmaceutically acceptable salt, e.g., an acid addition salt or a base addition salt (see, e.g., Berge et al. (1977) J Pharm Sci 66: 1-19).

[0292] The compositions can be formulated according to standard methods. Pharmaceutical formulation is a well-established art, and is further described in, e.g., Gennam (2000) "Remington: The Science and Practice of Pharmacy," 20th Edition, Lippincott, Williams & Wilkins (ISBN: 0683306472); Ansel et al. (1999) "Pharmaceutical Dosage Forms and Drug Delivery Systems," 7th Edition, Lippincott Williams & Wilkins Publishers (ISBN: 0683305727); and Kibbe (2000) "Handbook of Pharmaceutical Excipients American Pharmaceutical Association," 3rd Edition (ISBN: 091733096X). In some aspects of the disclosure, a composition can be formulated, for example, as a buffered solution at a suitable concentrations and suitable for storage at 2-8°C (e.g., 4°C). In some aspects of the disclosure, a composition can be formulated for storage at a temperature below 0°C (e.g., -20°C or -80°C). In some aspects of the disclosure, composition can be formulated for storage for up to 2 years (e.g., one month, two months, three months, four months, five months, six months, seven months, eight months, nine months, 10 months, 11 months, 1 year, 1½ years, or 2 years) at 2-8°C (e.g., 4°C). Thus, in some aspects of the disclosure, the compositions described herein are stable in storage for at least 1 year at 2-8°C (e.g., 4°C).

[0293] The pharmaceutical compositions can be in a variety of forms. These forms include, e.g., liquid, semi-solid and solid dosage forms, such as liquid solutions (e.g., injectable and infusible solutions), dispersions or suspensions, tablets, pills, powders, liposomes and suppositories. The preferred form depends, in part, on the intended mode of administration and therapeutic application. For example, compositions containing an antibody or fragment intended for systemic or local delivery can be in the form of injectable or infusible solutions. Accordingly, the compositions can be formulated for administration by a parenteral mode (e.g., intravenous, subcutaneous, intraperitoneal, or intramuscular injection). "Parenteral administration," "administered parenterally," and other grammatically equivalent phrases, as used herein, refer to models of administration other than enteral and topical administration, usually by injection, and include, without limitation, intravenous, intranasal, intraocular, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural, intracerebral, intracranial, intracarotid and intrasternal injection and infusion.

[0294] The compositions can be formulated as a solution, microemulsion, dispersions, liposome, or other ordered structure suitable for stable storage at high concentration. Sterile injectable solutions can be prepared by incorporating an antibody (or a fragment of the antibody) described herein in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating an antibody or fragment described herein into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods for preparation include vacuum drying and freeze-drying that yield a powder of an antibody, or an antigen-binding fragment thereof, described herein plus any additional desired ingredient (see below) from a previously sterile-filtered solution thereof. The proper fluidity of a solution can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prolonged absorption of injectable compositions can be brought about by including in the composition a reagent that delays absorption, for example, monostearate salts, and gelatin.

[0295] The anti-C5a antibodies, or antigen-binding fragments thereof, described herein can also be formulated in immunoliposome compositions. Liposomes containing the antibody can be prepared by methods known in the art such as, e.g., the methods described in Epstein et al. (1985) Proc Natl Acad Sci USA 82:3688; Hwang et al. (1980) Proc Natl Acad Sci USA 77:4030; and U.S. Patent Nos. 4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in, e.g., U.S. Patent No. 5,013,556.

[0296] In certain aspects of the disclosure, an antibody or an antigen-binding fragment thereof can be prepared with a carrier that will protect the compound against rapid release, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Many methods for the preparation of such formulations are known in the art. See, e.g., J.R. Robinson (1978) "Sustained and Controlled Release Drug Delivery Systems," Marcel Dekker, Inc., New York.

[0297] In some aspects of the disclosure, an antibody or antigen-binding fragment described herein can be formulated in a composition suitable for intrapulmonary administration (e.g., for administration via nebulizer; see below) to a mammal such as a human. Methods for preparing such compositions are well known in the art and described in, e.g., U.S. patent application publicationno. 20080202513; U.S. patent nos. 7,112,341 and 6,019,968; and PCT application publication nos. WO 00/061178 and WO 06/122257, the disclosures of each of which are incorporated herein by reference in their entirety. Dry powder inhalers formulations and suitable systems for administration of the formulations are described in, e.g., U.S. patent application publication no. 20070235029, PCT Publication No. WO 00/69887; and U.S. patent no. 5,997,848.

[0298] In some aspects of the disclosure, an anti-C5a antibody or antigen-binding fragment thereof described herein can be formulated in a composition suitable for delivery to the eye. In some aspects of the disclosure, one or more of the anti-C5a antibodies (or antigen-binding fragments thereof) described herein can be administered locally, for example, by way of topical application or intravitreal injection. For example, in some embodiments, the anti-C5a antibodies can be formulated for administration by way of an eye drop.

[0299] The therapeutic preparation for treating the eye can contain one or more of the anti-C5a antibodies in a concentration from about 0.01 to about 1% by weight, preferably from about 0.05 to about 0.5% in a pharmaceutically acceptable solution, suspension or ointment. The preparation will preferably be in the form of a sterile aqueous solution containing, e.g., additional ingredients such as, but not limited to, preservatives, buffers, tonicity agents, antioxidants and stabilizers, nonionic wetting or clarifying agents, and viscosity-increasing agents.

[0300] Suitable preservatives for use in such a solution include benzalkonium chloride, benzethonium chloride, chlorobutanol, thimerosal and the like. Suitable buffers include, e.g., boric acid, sodium and potassium bicarbonate, sodium and potassium borates, sodium and potassium carbonate, sodium acetate, and sodium biphosphate, in amounts sufficient to maintain the pH at between about pH 6 and pH 8, and preferably, between about pH 7 and pH 7.5. Suitable tonicity agents are dextran 40, dextran 70, dextrose, glycerin, potassium chloride, propylene glycol, and sodium chloride.

[0301] Suitable antioxidants and stabilizers include sodium bisulfite, sodium metabisulfite, sodium thiosulfite, and thiourea. Suitable wetting and clarifying agents include polysorbate 80, polysorbate 20, poloxamer 282 and tyloxapol. Suitable viscosity-increasing agents include dextran 40, dextran 70, gelatin, glycerin, hydroxyethylcellulose, hydroxymethylpropylcellulose, lanolin, methylcellulose, petrolatum, polyethylene glycol, polyvinyl alcohol, polyvinylpyrrolidone, and carboxymethylcellulose. The preparation can be administered topically to the eye of the subject in need of treatment (e.g., a subject afflicted with AMD) by conventional methods, e.g., in the form of drops, or by bathing the eye in a therapeutic solution, containing one or more anti-C5a antibodies.

[0302] In addition, a variety of devices have been developed for introducing drugs into the vitreal cavity of the eye. For example, U.S. patent application publication no. 20020026176 describes a pharmaceutical-containing plug that can be inserted through the sclera such that it projects into the vitreous cavity to deliver the pharmaceutical agent into the vitreous cavity. In another example, U.S. patent no. 5,443,505 describes an implantable device for introduction into a suprachoroidal space or an avascular region for sustained release of drug into the interior of the eye. U.S. patent nos. 5,773,019 and 6,001,386 each disclose an implantable drug delivery device attachable to the scleral surface of an eye. The device comprises an inner core containing an effective amount of a low solubility agent covered by a non-bioerodible polymer that is permeable to the low solubility agent. During operation, the low solubility agent permeates the bioerodible polymer cover for sustained release out of the device. Additional methods and devices (e.g., a transscleral patch and delivery via contact lenses) for delivery of a therapeutic agent to the eye are described in, e.g., Ambati and Adamis (2002) *Prog Retin Eye Res* 21(2): 145-151; Ranta and Urtti (2006) *Adv Drug Delivery Rev* 58(11):1164-1181; Barocas and Balachandran (2008) *Expert Opin Drug Delivery* 5(1): 1-10(10); Gulsen and Chauhan (2004) *Invest Ophthalmol Vis Sci* 45:2342-2347; Kim et al. (2007) *Ophthalmic Res* 39:244-254; and PCT publication no. WO 04/073551.

[0303] Nucleic acids encoding an antibody (or an antigen-binding fragment thereof) can be incorporated into a gene construct to be used as a part of a gene therapy protocol to deliver nucleic acids that can be used to express and produce agents within cells (see below). Expression constructs of such components may be administered in any therapeutically effective carrier, e.g., any formulation or composition capable of effectively delivering the component gene to cells *in vivo*. Approaches include insertion of the subject gene in viral vectors including recombinant retroviruses, adenovirus, adeno-associated virus, lentivirus, and herpes simplex virus-1 (HSV-1), or recombinant bacterial or eukaryotic plasmids. Viral vectors can transfect cells directly; plasmid DNA can be delivered with the help of, for example, cationic liposomes (lipofectin) or derivatized (e.g., antibody conjugated), polylysine conjugates, gramicidin S, artificial viral envelopes or other such intracellular carriers, as well as direct injection of the gene construct or CaPO₄ precipitation (see, e.g., WO04/060407) carried out *in vivo*. (See also, "Ex vivo Approaches," below.) Examples of suitable retroviruses include pLJ, pZIP, pWE and pEM which are known to those skilled in the art (see, e.g., Eglitis et al. (1985) *Science* 230:1395-1398; Danos and Mulligan (1988) *Proc Natl Acad Sci USA* 85:6460-6464; Wilson et al. (1988) *Proc Natl Acad Sci USA* 85:3014-3018; Armentano et al. (1990) *Proc. Natl. Acad. Sci. USA* 87:6141-6145; Huber et al. (1991) *Proc Natl Acad Sci USA* 88:8039-8043; Ferry et al. (1991) *Proc Natl Acad Sci USA* 88:8377-8381; Chowdhury et al. (1991) *Science* 254:1802-1805; van Beusechem et al. (1992) *Proc Natl Acad Sci USA* 89:7640-7644; Kay et al. (1992) *Human Gene Therapy* 3:641-647; Dai et al. (1992) *Proc Natl Acad Sci USA* 89:10892-10895; Hwu et al. (1993) *J Immunol.* 150:4104-4115; U.S. Patent Nos. 4,868,116 and 4,980,286; PCT Publication Nos. WO89/07136, WO89/02468, WO89/05345, and WO92/07573). Another viral gene delivery system utilizes adenovirus-derived vectors (see, e.g., Berkner et al. (1988) *BioTechniques* 6:616; Rosenfeld et al. (1991) *Science* 252:431-434; and Rosenfeld et al. (1992) *Cell* 68:143-155). Suitable adenoviral vectors derived from the adenovirus strain Ad

type 5 dl324 or other strains of adenovirus (e.g., Ad2, Ad3, Ad7, etc.) are known to those skilled in the art. Yet another viral vector system useful for delivery of the subject gene is the adeno-associated virus (AAV). See, e.g., Flotte et al. (1992) *Am J Respir Cell Mol Biol* 7:349-356; Samulski et al. (1989) *J Virol* 63:3822-3828; and McLaughlin et al. (1989) *J Virol* 62:1963-1973.

[0304] In some aspects of the disclosure, an antibody, or antigen-binding fragment thereof, described herein can be formulated with one or more additional active agents useful for treating or preventing a complement-associated disorder in a subject. Additional agents for treating a complement-associated disorder in a subject will vary depending on the particular disorder being treated, but can include, without limitation, an antihypertensive (e.g., an angiotensin-converting enzyme inhibitor), an anticoagulant, a corticosteroid (e.g., prednisone), or an immunosuppressive agent (e.g., vincristine or cyclosporine A). Examples of anticoagulants include, e.g., warfarin (Coumadin), heparin, phenindione, fondaparinux, idraparinux, and thrombin inhibitors (e.g., argatroban, lepirudin, bivalirudin, or dabigatran). An antibody or fragment thereof described herein can also be formulated with a fibrinolytic agent (e.g., anicrod, ϵ -aminocaproic acid, antiplasmin-a₁, prostacyclin, and defibrotide) for the treatment of a complement-mediated disorder. In some aspects of the disclosure, an antibody can be formulated with a lipid-lowering agent such as an inhibitor of hydroxymethylglutaryl CoA reductase. In some aspects of the disclosure, an antibody can be formulated with, or for use with, an anti-CD20 agent such as rituximab (Rituxan™; Biogen Idec, Cambridge, MA). In some aspects of the disclosure, e.g., for the treatment of RA, the antibody or antigen binding fragment thereof can be formulated with one or both of infliximab (Remicade®; Ceptacor, Inc.) and methotrexate (Rheumatrex®, Trexall®). In some aspects of the disclosure, an antibody or an antigen-binding fragment thereof described herein can be formulated with a non-steroidal anti-inflammatory drug (NSAID). Many different NSAIDs are available, some over the counter including ibuprofen (Advil®, Motrin®, Nuprin®) and naproxen (Alleve®) and many others are available by prescription including meloxicam (Mobic®), etodolac (Lodine®), nabumetone (Relafen®), sulindac (Clinoril®), tolemin (Tolectin®), choline magnesium salicylate (Trilasate®), diclofenac (Cataflam®, Voltaren®, Arthrotec®), Diflusinal (Dolobid®), indomethacin (Indocin®), Ketoprofen (Orudis®, Oruvail®), oxaprozin (Daypro®), and piroxicam (Feldene®). In some aspects of the disclosure, an antibody or a fragment thereof can be formulated for use with an anti-hypertensive, an anti-seizure agent (e.g., magnesium sulfate), or an anti-thrombotic agent. Anti-hypertensives include, e.g., labetalol, hydralazine, nifedipine, calcium channel antagonists, nitroglycerin, or sodium nitroprussiate. See, e.g., Mihi et al. (2007) *J Gastrointest Liver Dis* 16(4):419-424. Anti-thrombotic agents include, e.g., heparin, antithrombin, prostacyclin, or low dose aspirin.

[0305] In some aspects of the disclosure, an antibody or antigen-binding fragment thereof can be formulated for administration to a subject along with intravenous gamma globulin therapy (IVIG), plasmapheresis, or plasma exchange. In some aspects of the disclosure, an anti-C5a antibody or antigen-binding fragment thereof can be formulated for use before, during, or after, a kidney transplant.

[0306] When an antibody or antigen-binding fragment thereof is to be used in combination with a second active agent, the agents can be formulated separately or together. For example, the respective pharmaceutical compositions can be mixed, e.g., just prior to administration, and administered together or can be administered separately, e.g., at the same or different times (see below).

[0307] As described above, a composition can be formulated such that it includes a therapeutically effective amount of an anti-C5a antibody or antigen-binding fragment thereof described herein. In some aspects of the disclosure, a composition can be formulated to include a sub-therapeutic amount of the antibody (or fragment) and a sub-therapeutic amount of one or more additional active agents such that the components in total are therapeutically effective for treating or preventing a complement-associated disorder. Methods for determining a therapeutically effective dose of an agent such as a therapeutic antibody are known in the art and described herein.

Applications

[0308] The antibodies, antigen-binding fragments thereof, conjugates, and compositions of any of the foregoing can be used in a number of diagnostic and therapeutic applications. For example, detectably-labeled anti-C5a antibodies (e.g., anti-human C5a antibodies or anti-mouse C5a antibodies) can be used in assays to detect the presence or amount of C5a present in a biological sample. Determining the amount of C5a in a sample, e.g., a patient blood sample, can be useful to evaluate the level of complement activation in the sample. Suitable methods for using the antibodies in diagnostic assays are known in the art and include, without limitation, ELISA, fluorescence resonance energy transfer applications, Western blot, and dot blot techniques. See, e.g., Sambrook et al., *supra* and Ausubel et al., *supra*.

[0309] In some aspects of the disclosure, the antibodies and antigen-binding fragments described herein can be used as

positive controls in assays designed to identify additional novel compounds for treating complement mediated disorders. For example, an anti-C5a antibody that inhibits C5a activity can be used as a positive control in an assay to identify additional compounds (e.g., small molecules, aptamers, or antibodies) that inhibit C5a or C5a-dependent C5a receptor signaling.

[0310] In some aspects of the disclosure, the cross-reactive anti-C5a antibodies or antigen-binding fragments thereof (e.g., cross-reactive with human C5a and, e.g., cynomolgus macaque C5a) described herein can be used for pre-clinical testing in non-human mammals, e.g., pharmacokinetic or pharmacodynamic studies in non-human primates. Accordingly, a researcher wishing to evaluate the efficacy of an anti-C5a antibody in treating a complement-associated disorder of interest (e.g., RA or sepsis) can use a cross-reactive anti-C5a antibody described herein in an appropriate non-human primate model of the disease. If the researcher, for example, establishes efficacy of the antibody in the non-human primate model, these results may provide sufficient proof-of-concept support for regulatory approval for use of the antibody in treating humans. Alternatively, or in addition, a researcher may administer the cross-reactive antibody to a non-human primate to study, e.g., antibody clearance and/or pharmacodynamics properties. Based on such studies using the cross-reactive antibody, the researcher can better approximate the dose required to treat human disease.

[0311] In some aspects of the disclosure, the anti-mouse C5a antibodies or antigen-binding fragments thereof described herein, as well as antibodies that crossreact with human and mouse C5a, can be used as a surrogate antibody in mouse models of human disease. This can be especially useful where a humanized anti-human C5a antibody does not cross-react with mouse C5a and/or is likely to cause an anti-human antibody response in a mouse to which the humanized antibody is administered. Accordingly, a researcher wishing to study the effect of an anti-C5a antibody in treating a disease (e.g., ischemia-reperfusion injury) can use an anti-mouse C5a antibody described herein in an appropriate mouse model of the disease. If the researcher can establish efficacy in the mouse model of disease using the anti-mouse C5a antibody, the results may establish proof-of-concept for use of an anti-human C5a antibody in treating the disease in humans. The working examples disclose an exemplary study using an anti-mouse C5a antibody surrogate in a mouse model of RA establishing proof-of-concept for the use of an anti-human C5a antibody to treat RA in man.

[0312] The anti-C5a antibodies described herein can also be used in methods for purifying C5a from a sample (e.g., a biological sample). In some aspects of the disclosure, an anti-C5a antibody can be immobilized on a solid phase support using methods well known in the art. A sample containing the antigen to be purified, in this case C5a, is contacted to the antibody on the solid support under conditions and for a time sufficient to allow the antigen to bind to the antibody. The solid support is then washed one or more times with a suitable buffer to remove unbound material. The solid support can be then contacted with a second buffer that results in the release of the antigen from the antibody. The released antigen is then collected and characterized (e.g., for purity and activity) using well known methods in the art.

[0313] The anti-C5a antibodies and antigen-binding fragments thereof described herein can also be used in therapeutic methods as elaborated on below.

Methods for Treatment

[0314] The above-described compositions are useful in, *inter alia*, methods for treating or preventing a variety of complement-associated disorders in a subject. The compositions can be administered to a subject, e.g., a human subject, using a variety of methods that depend, in part, on the route of administration. The route can be, e.g., intravenous injection or infusion (IV), subcutaneous injection (SC), intraperitoneal (IP) injection, or intramuscular injection (IM).

[0315] Administration can be achieved by, e.g., local infusion, injection, or by means of an implant. The implant can be of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. The implant can be configured for sustained or periodic release of the composition to the subject. See, e.g., U.S. Patent Application Publication No. 20080241223; U.S. Patent Nos. 5,501,856; 4,863,457; and 3,710,795; EP488401; and EP 430539. The composition can be delivered to the subject by way of an implantable device based on, e.g., diffusive, erodible, or convective systems, e.g., osmotic pumps, biodegradable implants, electrodiffusion systems, electroosmosis systems, vapor pressure pumps, electrolytic pumps, effervescent pumps, piezoelectric pumps, erosion-based systems, or electromechanical systems.

[0316] In some aspects of the disclosure, an anti-C5a antibody or antigen-binding fragment thereof is therapeutically delivered to a subject by way of local administration. As used herein, "local administration" or "local delivery," refers to delivery that does not rely upon transport of the composition or agent to its intended target tissue or site via the vascular system. For example, the composition may be delivered by injection or implantation of the composition or agent or by injection or implantation of a device

containing the composition or agent. Following local administration in the vicinity of a target tissue or site, the composition or agent, or one or more components thereof, may diffuse to the intended target tissue or site.

[0317] In some aspects of the disclosure, an anti-C5a antibody or antigen-binding fragment thereof can be locally administered to a joint (e.g., an articulated joint). For example, in embodiments where the complement-associated disorder is arthritis, the complement inhibitor can be administered directly to a joint (e.g., into a joint space) or in the vicinity of a joint. Examples of intraarticular joints to which an anti-C5a antibody or antigen-binding fragment thereof can be locally administered include, e.g., the hip, knee, elbow, wrist, sternoclavicular, temporomandibular, carpal, tarsal, ankle, and any other joint subject to arthritic conditions. An anti-C5a antibody or antigen-binding fragment thereof can also be administered to bursa such as, e.g., acromial, bicipitoradial, cubitoradial, deltoid, infrapatellar, ischial, and any other bursa known in the art of medicine.

[0318] In some aspects of the disclosure, an anti-C5a antibody or antigen-binding fragment thereof can be locally administered to the eye. As used herein, the term "eye" refers to any and all anatomical tissues and structures associated with an eye. The eye has a wall composed of three distinct layers: the outer sclera, the middle choroid layer, and the inner retina. The chamber behind the lens is filled with a gelatinous fluid referred to as the vitreous humor. At the back of the eye is the retina, which detects light. The cornea is an optically transparent tissue, which conveys images to the back of the eye. The cornea includes one pathway for the permeation of drugs into the eye. Other anatomical tissue structures associated with the eye include the lacrimal drainage system, which includes a secretory system, a distributive system and an excretory system. The secretory system comprises secretors that are stimulated by blinking and temperature change due to tear evaporation and reflex secretors that have an efferent parasympathetic nerve supply and secrete tears in response to physical or emotional stimulation. The distributive system includes the eyelids and the tear meniscus around the lid edges of an open eye, which spread tears over the ocular surface by blinking, thus reducing dry areas from developing.

[0319] In some aspects of the disclosure, an anti-C5a antibody or antigen-binding fragment thereof is administered to the posterior chamber of the eye. In some aspects of the disclosure, an anti-C5a antibody or antigen-binding fragment thereof is administered intravitreally. In some aspects of the disclosure, an anti-C5a antibody or antigen-binding fragment thereof is administered trans-sclerally.

[0320] In some aspects of the disclosure, e.g., in aspects for treatment or prevention of a complement-associated pulmonary disorder such as COPD or asthma, an anti-C5a antibody or antigen-binding fragment thereof described herein can also be administered to a subject by way of the lung. Pulmonary drug delivery may be achieved by inhalation, and administration by inhalation herein may be oral and/or nasal. Examples of pharmaceutical devices for pulmonary delivery include metered dose inhalers, dry powder inhalers (DPIs), and nebulizers. For example, an anti-C5a antibody or an antigen-binding fragment thereof can be administered to the lungs of a subject by way of a dry powder inhaler. These inhalers are propellant-free devices that deliver dispersible and stable dry powder formulations to the lungs. Dry powder inhalers are well known in the art of medicine and include, without limitation: the TurboHaler® (AstraZeneca; London, England) the AIR® inhaler (Alkermes®; Cambridge, Massachusetts); Rotahaler® (GlaxoSmithKline; London, England); and Eclipse™ (Sanofi-Aventis; Paris, France). See also, e.g.; PCT Publication Nos. WO 04/026380, WO 04/024156, and WO 01/78693. DPI devices have been used for pulmonary administration of polypeptides such as insulin and growth hormone. In some aspect of the disclosure, an anti-C5a antibody or an antigen-binding fragment thereof can be intrapulmonarily administered by way of a metered dose inhaler. These inhalers rely on a propellant to deliver a discrete dose of a compound to the lungs. Examples of compounds administered by metered dose inhalers include, e.g., Astovent® (Boehringer-Ingelheim; Ridgefield, Connecticut) and Flovent® (GlaxoSmithKline). See also, e.g., U.S. Patent Nos. 6,170,717; 5,447,150; and 6,095,141.

[0321] In some aspects of the disclosure, an anti-C5a antibody or antigen-binding fragment thereof can be administered to the lungs of a subject by way of a nebulizer. Nebulizers use compressed air to deliver a compound as a liquefied aerosol or mist. A nebulizer can be, e.g., a jet nebulizer (e.g., air or liquid-jet nebulizers) or an ultrasonic nebulizer. Additional devices and intrapulmonary administration methods are set forth in, e.g., U.S. Patent Application Publication Nos. 20050271660 and 20090110679.

[0322] In some aspects of the disclosure, the antibodies or antigen-binding fragments thereof provided herein are present in unit dosage form, which can be particularly suitable for self-administration. A formulated product of the present disclosure can be included within a container, typically, for example, a vial, cartridge, prefilled syringe or disposable pen. A doser such as the doser device described in U.S. Patent No. 6,302,855 may also be used, for example, with an injection system of the present disclosure.

[0323] An injection system of the present disclosure may employ a delivery pen as described in U.S. Patent No. 5,308,341. Pen devices, most commonly used for self-delivery of insulin to patients with diabetes, are well known in the art. Such devices can comprise at least one injection needle (e.g., a 31 gauge needle of about 5 to 8 mm in length), are typically pre-filled with one or

more therapeutic unit doses of a therapeutic solution, and are useful for rapidly delivering the solution to a subject with as little pain as possible.

[0324] One medication delivery pen includes a vial holder into which a vial of insulin or other medication may be received. The vial holder is an elongate generally tubular structure with proximal and distal ends. The distal end of the vial holder includes mounting means for engaging a double-ended needle cannula. The proximal end also includes mounting means for engaging a pen body which includes a driver and dose setting apparatus. A disposable medication (e.g., a high concentration solution of an anti-C5a antibody or antigen-binding fragment thereof) containing vial for use with the prior art vial holder includes a distal end having a pierceable elastomeric septum that can be pierced by one end of a double-ended needle cannula. The proximal end of this vial includes a stopper slidably disposed in fluid tight engagement with the cylindrical wall of the vial. This medication delivery pen is used by inserting the vial of medication into the vial holder. A pen body then is connected to the proximal end of the vial holder. The pen body includes a dose setting apparatus for designating a dose of medication to be delivered by the pen and a driving apparatus for urging the stopper of the vial distally for a distance corresponding to the selected dose. The user of the pen mounts a double-ended needle cannula to the distal end of the vial holder such that the proximal point of the needle cannula pierces the septum on the vial. The patient then selects a dose and operates the pen to urge the stopper distally to deliver the selected dose. The dose selecting apparatus returns to zero upon injection of the selected dose. The patient then removes and discards the needle cannula, and keeps the medication delivery pen in a convenient location for the next required medication administration. The medication in the vial will become exhausted after several such administrations of medication. The patient then separates the vial holder from the pen body. The empty vial may then be removed and discarded. A new vial can be inserted into the vial holder, and the vial holder and pen body can be reassembled and used as explained above. Accordingly, a medication delivery pen generally has a drive mechanism for accurate dosing and ease of use.

[0325] A dosage mechanism such as a rotatable knob allows the user to accurately adjust the amount of medication that will be injected by the pen from a prepackaged vial of medication. To inject the dose of medication, the user inserts the needle under the skin and depresses the knob once as far as it will depress. The pen may be an entirely mechanical device or it may be combined with electronic circuitry to accurately set and/or indicate the dosage of medication that is injected into the user. See U.S. Patent No. 6,192,891.

[0326] In some aspects of the disclosure, the needle of the pen device is disposable and the kits include one or more disposable replacement needles. Pen devices suitable for delivery of the any one of the presently featured antibodies or antigen-binding fragments thereof are also described in, e.g., U.S. patent nos. 6,277,099; 6,200,296; and 6,146,361.

[0327] A microneedle-based pen device is described in, e.g., U.S. patent no. 7,556,615.

[0328] See also the Precision Pen Injector (PPI) device, Molly™, manufactured by Scandinavian Health Ltd.

[0329] The present disclosure also presents controlled-release or extended-release formulations suitable for chronic and/or self-administration of a medication such as an anti-C5a antibody or an antigen-binding fragment thereof described herein. The various formulations can be administered to a patient in need of treatment with the medication as a bolus or by continuous infusion over a period of time.

[0330] In some aspects of the disclosure, a high concentration anti-C5a antibody (or antigen-binding fragment thereof) described herein is formulated for sustained-release, extended-release, timed-release, controlled-release, or continuous-release administration. In some aspects of the disclosure, depot formulations are used to administer the antibody to the subject in need thereof. In this method, the antibody is formulated with one or more carriers providing a gradual release of active agent over a period of a number of hours or days. Such formulations are often based upon a degrading matrix which gradually disperses in the body to release the active agent.

[0331] In some aspects of the disclosure, a C5a-binding fragment (e.g., a single chain antibody, a diabody, or a Fab' fragment) of an anti-C5a antibody described herein is administered by way of intrapulmonary administration to a subject in need thereof. For example, a single chain antibody form of any of the anti-C5a antibodies described herein can be delivered by way of a nebulizer or an inhaler to a subject (e.g., a human) afflicted with a complement-associated pulmonary disorder such as asthma or COPD.

[0332] A suitable dose of an antibody or fragment thereof described herein, which dose is capable of treating or preventing a complement-associated disorder in a subject, can depend on a variety of factors including, e.g., the age, sex, and weight of a subject to be treated and the particular inhibitor compound used. For example, a different dose of a whole anti-C5a antibody may

be required to treat a subject with RA as compared to the dose of a C5a-binding Fab' antibody fragment required to treat the same subject. Other factors affecting the dose administered to the subject include, e.g., the type or severity of the complement-mediated disorder. For example, a subject having RA may require administration of a different dosage of an anti-C5a antibody than a subject with AMD. Other factors can include, e.g., other medical disorders concurrently or previously affecting the subject, the general health of the subject, the genetic disposition of the subject, diet, time of administration, rate of excretion, drug combination, and any other additional therapeutics that are administered to the subject. It should also be understood that a specific dosage and treatment regimen for any particular subject will also depend upon the judgment of the treating medical practitioner (e.g., doctor or nurse).

[0333] An antibody described herein can be administered, as a fixed dose, or in a milligram per kilogram (mg/kg) dose. In some aspects of the disclosure, the dose can also be chosen to reduce or avoid production of antibodies or other host immune responses against one or more of the active antibodies in the composition. While in no way intended to be limiting, exemplary dosages of an antibody, such as an anti-C5a antibody include, e.g., 1-1000 µg/kg, 1-100 µg/kg, 0.5-50 µg/kg, 0.1-100 µg/kg, 0.5-25 µg/kg, 1-20 µg/kg, and 1-10 µg/kg, 1-100 mg/kg, 0.5-50 mg/kg, 0.1-100 mg/kg, 0.5-25 mg/kg, 1-20 mg/kg, 0.100 mg/kg to 1 mg/kg, and 1-10 mg/kg. Exemplary dosages of an antibody or antigen-binding fragment thereof described herein include, without limitation, 0.1 µg/kg, 0.5 µg/kg, 1.0 µg/kg, 2.0 µg/kg, 4 µg/kg, and 8 µg/kg, 0.1 mg/kg, 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 4 mg/kg, 8 mg/kg, and 20 mg/kg.

[0334] A pharmaceutical composition can include a therapeutically effective amount of an anti-C5a antibody or antigen-binding fragment thereof described herein. Such effective amounts can be readily determined by one of ordinary skill in the art based, in part, on the effect of the administered antibody, or the combinatorial effect of the antibody and one or more additional active agents, if more than one agent is used. A therapeutically effective amount of an antibody or fragment thereof described herein can also vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the antibody (and one or more additional active agents) to elicit a desired response in the individual, e.g., amelioration of at least one condition parameter, e.g., amelioration of at least one symptom of the complement-mediated disorder. For example, a therapeutically effective amount of an anti-C5a antibody can inhibit (lessen the severity of or eliminate the occurrence of) and/or prevent a particular disorder, and/or any one of the symptoms of the particular disorder known in the art or described herein. A therapeutically effective amount is also one in which any toxic or detrimental effects of the composition are outweighed by the therapeutically beneficial effects.

[0335] Suitable human doses of any of the antibodies or fragments thereof described herein can further be evaluated in, e.g., Phase I dose escalation studies. See, e.g., van Gurp et al. (2008) *Am J Transplantation* 8(8):1711-1718; Hanouska et al. (2007) *Clin Cancer Res* 13(2, part 1):523-531; and Hetherington et al. (2006) *Antimicrobial Agents and Chemotherapy* 50(10): 3499-3500.

[0336] The terms "therapeutically effective amount" or "therapeutically effective dose," or similar terms used herein are intended to mean an amount of an agent (e.g., an anti-C5a antibody or an antigen-binding fragment thereof) that will elicit the desired biological or medical response (e.g., an improvement in one or more, symptoms of a complement-associated disorder). In some aspects of the disclosure, a composition described herein contains a therapeutically effective amount of an antibody, or antigen-binding fragment thereof, which specifically binds to a neo-epitope present in C5a. In aspects of the disclosure, the composition contains any of the antibodies or antigen-binding fragments thereof described herein and one or more (e.g., two, three, four, five, six, seven, eight, nine, 10, or 11 or more) additional therapeutic agents such that the composition as a whole is therapeutically effective. For example, a composition can contain an anti-C5a antibody described herein and an immunosuppressive agent, wherein the antibody and agent are each at a concentration that when combined are therapeutically effective for treating or preventing a complement-associated disorder (e.g., a complement-associated inflammatory disorder such as COPD, asthma, sepsis, or RA) in a subject.

[0337] Toxicity and therapeutic efficacy of such compositions can be determined by known pharmaceutical procedures in cell cultures or experimental animals (e.g., animal models of any of the complement-mediated disorders described herein). Use of an antiC5a antibody in an animal model of RA is exemplified in the working examples. These procedures can be used, e.g., for determining the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD₅₀/ED₅₀. An antibody or antigen-binding fragment thereof that exhibits a high therapeutic index is preferred. While compositions that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue and to minimize potential damage to normal cells and, thereby, reduce side effects.

[0338] The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use

in humans. The dosage of such antibodies or antigen-binding fragments thereof lies generally within a range of circulating concentrations of the antibodies or fragments that include the ED₅₀ with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For an anti-C5a antibody described herein, the therapeutically effective dose can be estimated initially from cell culture assays. A dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC₅₀ (i.e., the concentration of the antibody which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography. In some aspects of the disclosure e.g., where local administration (e.g., to the eye or a joint) is desired, cell culture or animal modeling can be used to determine a dose required to achieve a therapeutically effective concentrations within the local site.

[0339] In some aspects of the disclosure, the methods can be performed in conjunction with other therapies for complement-associated disorders. For example, the composition can be administered to a subject at the same time, prior to, or after, plasmapheresis, IVIG therapy, or plasma exchange. See, e.g., Appel et al. (2005) *J Am Soc Nephrol* 16:1392-1404. In some aspects of the disclosure, the composition can be administered to a subject at the same time, prior to, or after, a kidney transplant

[0340] A "subject," as used herein, can be any mammal. For example, a subject can be a human, a non-human primate (e.g., monkey, baboon, or chimpanzee), a horse, a cow, a pig, a sheep, a goat, a dog, a cat, a rabbit, a guinea pig, a gerbil, a hamster, a rat, or a mouse. In some embodiments, the subject is an infant (e.g., a human infant).

[0341] As used herein, a subject "in need of prevention," "in need of treatment," or "in need thereof," refers to one, who by the judgment of an appropriate medical practitioner (e.g., a doctor, a nurse, or a nurse practitioner in the case of humans; a veterinarian in the case of non-human mammals), would reasonably benefit from a given treatment (such as treatment with a composition comprising an anti-C5a antibody).

[0342] The term "preventing" is art-recognized, and when used in relation to a condition, is well understood in the art, and includes administration of a composition which reduces the frequency of, or delays the onset of, symptoms of a medical condition in a subject relative to a subject which does not receive the composition. Thus, prevention of a complement-associated disorder such as asthma includes, for example, reducing the extent or frequency of coughing, wheezing, or chest pain in a population of patients receiving a prophylactic treatment relative to an untreated control population, and/or delaying the occurrence of coughing or wheezing in a treated population versus an untreated control population, e.g., by a statistically and/or clinically significant amount

[0343] As described above, the antibodies and biologically-active fragments described herein can be used to treat a variety of complement-associated disorders such as, but not limited to: rheumatoid arthritis (RA); lupus nephritis; ischemia-reperfusion injury; atypical hemolytic uremic syndrome (aHUS); typical or infectious hemolytic uremic syndrome (tHUS); dense deposit disease (DDD); paroxysmal nocturnal hemoglobinuria (PNH); multiple sclerosis (MS); macular degeneration (e.g., age-related macular degeneration (AMD)); hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome; sepsis; dermatomyositis; diabetic retinopathy; thrombotic thrombocytopenic purpura (TTP); spontaneous fetal loss; Pauci-immune vasculitis; epidermolysis bullosa; recurrent fetal loss; multiple sclerosis (MS); and traumatic brain injury. See, e.g., Holers (2008) *Immunological Reviews* 223:300-316 and Holers and Thurman (2004) *Molecular Immunology* 41:147-152. In some aspects of the disclosure, the complement-mediated disorder is a complement-mediated vascular disorder such as, but not limited to, a cardiovascular disorder, myocarditis, a cerebrovascular disorder, a peripheral (e.g., musculoskeletal) vascular disorder, a renovascular disorder, a mesenteric/enteric vascular disorder, revascularization to transplants and/or replants, vasculitis, Henoch-Schönlein purpura nephritis, systemic lupus erythematosus-associated vasculitis, vasculitis associated with rheumatoid arthritis, immune complex vasculitis, Takayasu's disease, capillary leak syndrome, dilated cardiomyopathy, diabetic angiopathy, thoracic-abdominal aortic aneurism, Kawasaki's disease (arteritis), venous gas embolus (VGE), and restenosis following stent placement, rotational atherectomy, and percutaneous transluminal coronary angioplasty (PTCA). (See, e.g., U.S. patent application publication no. 20070172483.) In some embodiments, the complement-associated disorder is myasthenia gravis, cold-agglutinin disease (CAD), paroxysmal cold hemoglobinuria (PCH), dermatomyositis, scleroderma, warm autoimmune hemolytic anemia, Graves' disease, Hashimoto's thyroiditis, type I diabetes, psoriasis, pemphigus, autoimmune hemolytic anemia (AIHA), idiopathic thrombocytopenic purpura (ITP), Goodpasture syndrome, antiphospholipid syndrome (APS), Degos disease, and catastrophic APS (CAPS).

[0344] In some aspects of the disclosure, an anti-C5a antibody or antigen-binding fragment thereof described herein, alone or in combination with a second anti-inflammatory agent, can be used to treat an inflammatory disorder such as, but not limited to, RA (above), inflammatory bowel disease, sepsis (above), septic shock, acute lung injury, disseminated intravascular coagulation (DIC), or Crohn's disease. In some aspects of the disclosure, the second anti-inflammatory agent can be one selected from the group consisting of NSAIDs, corticosteroids, methotrexate, hydroxychloroquine, anti-TNF agents such as etanercept and

infliximab, a B cell depleting agent such as rituximab, an interleukin-1 antagonist, or a T cell costimulatory blocking agent such as abatacept.

[0345] In some aspects of the disclosure, the complement-associated disorder is a complement-associated neurological disorder such as, but not limited to, amyotrophic lateral sclerosis (ALS), brain injury, Alzheimer's disease, and chronic inflammatory demyelinating neuropathy.

[0346] Complement-associated disorders also include complement-associated pulmonary disorders such as, but not limited to, asthma, bronchitis, a chronic obstructive pulmonary disease (COPD), an interstitial lung disease, α -1 anti-trypsin deficiency, emphysema, bronchiectasis, bronchiolitis obliterans, alveolitis, sarcoidosis, pulmonary fibrosis, and collagen vascular disorders.

[0347] In the case of complement-associated hemolytic disorders such as PNH, CAD, and PCH, a medical practitioner will appreciate that C5 fragment C5b (by way of the terminal complement complex) contributes significantly to the pathogenesis of these disorders. See, e.g., Kaplan (2002) *Curr Opin Investig Drugs* 3(7):1017-23; Hill (2005) *Clin Adv Hematol Oncol* 3(11):849-50; and Rother et al. (2007) *Nature Biotechnology* 25(11):1256-1488. Accordingly, a medical practitioner may elect to administer one or more of the anti-C5a antibodies described herein in conjunction with one or more additional therapies for the hemolytic disorder such as a complement inhibitor that prevents formation of the C5b-9 terminal complement complex. In some aspects of the methods described herein, the complement-associated disorder is, not a complement-associated hemolytic disorder. In some aspects of the disclosure, an anti-C5a antibody or an antigen-binding fragment thereof is administered to a subject to treat, prevent, or ameliorate at least one symptom of a complement-associated inflammatory response (e.g., the complement-associated inflammatory response aspect of a complement-associated disorder) in a subject. For example, an anti-C5a antibody described herein can be used to treat, prevent, and/or ameliorate one or more symptoms associated with a complement-associated inflammatory response such as graft rejection/graft-versus-host disease (GVHD), reperfusion injuries (e.g., following cardiopulmonary bypass or a tissue transplant), and tissue damage following other forms of traumatic injury such as a burn (e.g., a severe burn), blunt trauma, spinal injury, or frostbite. See, e.g., Park et al. (1999) *Anesth Analg* 99(1):42-48; Tofukuji et al. (1998) *J Thorac Cardiovasc Surg* 116(6):1060-1068; Schmid et al. (1997) *Shock* 8(2):119-124; and Bless et al. (1999) *Am J Physiol* 276(1):L57-L63.

[0348] In some aspects of the disclosure, an anti-C5a antibody or an antigen-binding fragment thereof described herein can be administered to a subject as a monotherapy. Alternatively, as described above, the antibody or fragment thereof can be administered to a subject as a combination therapy with another treatment, e.g., another treatment for a complement-associated disorder or a complement-associated inflammatory response. For example, the combination therapy can include administering to the subject (e.g., a human patient) one or more additional agents (e.g., anti-coagulants, anti-hypertensives, or anti-inflammatory drugs (e.g., steroids)) that provide a therapeutic benefit to a subject who has, or is at risk of developing, sepsis. In another example, the combination therapy can include administering to the subject one or more additional agents (e.g., an anti-IgE antibody, an anti-IL-4 antibody, an anti-IL-5 antibody, or an anti-histamine) that provide therapeutic benefit to a subject who has, is at risk of developing, or is suspected of having a complement-associated pulmonary disorder such as COPD or asthma. In some aspects of the disclosure, an anti-c5a antibody and the one or more additional active agents are administered at the same time. In other aspects of the disclosure, the anti-C5a antibody is administered first in time and the one or more additional active agents are administered second in time. In some aspects of the disclosure, the one or more additional active agents are administered first in time and the anti-C5a antibody is administered second in time.

[0349] An anti-C5a antibody or an antigen-binding fragment thereof described herein can replace or augment a previously or currently administered therapy. For example, upon treating with an anti-C5a antibody or antigen-binding fragment thereof, administration of the one or more additional active agents, can cease or diminish, e.g., be administered at lower levels. In some aspects of the disclosure, administration of the previous therapy can be maintained. In some aspects of the disclosure, a previous therapy will be maintained until the level of the anti-C5a antibody reaches a level sufficient to provide a therapeutic effect. The two therapies can be administered in combination.

[0350] Monitoring a subject (e.g., a human patient) for an improvement in a complement-associated disorder (e.g., sepsis, severe burn, RA, lupus nephritis, Goodpasture syndrome, or asthma), as defined herein, means evaluating the subject for a change in a disease parameter, e.g., an improvement in one or more symptoms of a given disorder. The symptoms of complement-associated disorders are well known in the art of medicine. In some aspects of the disclosure, the evaluation is performed at least one (1) hour, e.g., at least 2, 4, 6, 8, 12, 24, or 48 hours, or at least 1 day, 2 days, 4 days, 10 days, 13 days, 20 days or more, or at least 1 week, 2 weeks, 4 weeks, 10 weeks, 13 weeks, 20 weeks or more, after an administration. The subject can be evaluated in one or more of the following periods: prior to beginning of treatment; during the treatment; or after one or more elements of the treatment have been administered. Evaluation can include evaluating the need for further treatment, e.g., evaluating whether a dosage, frequency of administration, or duration of treatment should be altered. It can also include

evaluating the need to add or drop a selected therapeutic modality, e.g., adding or dropping any of the treatments for a complement-associated disorder described herein.

Therapeutic and Diagnostic Kits

[0351] The disclosure also features therapeutic and diagnostic kits containing, among other things, one or more of the anti-C5a antibodies, and/or antigen-binding fragments thereof, described herein. The therapeutic kits can contain, e.g., a suitable means for delivery of the antibody or antigen-binding fragment to a subject. In some aspects of the disclosure, the means is suitable for subcutaneous delivery of the antibody or antigen-binding fragment thereof to the subject. The means can be, e.g., a syringe or an osmotic pump. That is, a therapeutic kit described herein can contain a syringe pre-filled with an anti-C5a antibody or antigen-binding fragment thereof (e.g., a pen device containing the antibody or fragment) described herein or the kit can contain a pump (e.g., an osmotic pump) and one or more disposable cassettes configured for use with the pump, the cassettes pre-filled with an anti-C5a antibody or antigen-binding fragment thereof described herein (e.g., pre-filled with an aqueous solution containing the anti-C5a antibody or antigen-binding fragment thereof). In another example, the kit can contain a transscleral or implantable delivery device (e.g., a plug) that is pre-filled with (or otherwise contains) a solution containing an anti-C5a antibody or antigen-binding fragment thereof described herein.

[0352] In some aspects of the disclosure, the means for delivering an anti-C5a antibody or antigen-binding fragment thereof is a pen device for drug delivery.

[0353] In some aspects of the disclosure, the means is suitable for intrapulmonary delivery of the antibody or antigen-binding fragment thereof to a subject, e.g., for use in treatment or prevention of a complement-associated pulmonary disorder such as, but not limited to, COPD or asthma. Accordingly, the means can be, e.g., an oral or nasal inhaler (see above). The inhaler can be, e.g., a metered dose inhaler (MDI), dry powder inhaler (DPI), or a nebulizer. Such a kit can also, optionally, include instructions for administering (e.g., self-administration of) the anti-C5a antibody or antigen-binding fragment thereof to a subject.

[0354] The therapeutic kits can include, e.g., one or more additional active agents for treating or preventing a complement-associated disorder and/or ameliorating a symptom thereof. For example, therapeutic kits designed for use in treating or preventing a complement-associated pulmonary disorder can include one or more additional active agents including, but not limited to, another antibody therapeutic (e.g., an anti-IgE antibody, an anti-IL-4 antibody, or an anti-IL-5 antibody), a small molecule anti-IgE inhibitor (e.g., montelukast sodium), a sympathomimetic (e.g., albuterol), an antibiotic (e.g., tobramycin), a deoxyribonuclease (e.g., pulmozyme), an anticholinergic drug (e.g., ipratropium bromide), a corticosteroid (e.g., dexamethasone), a β -adrenoreceptor agonist, a leukotriene inhibitor (e.g., zileuton), a 5-lipoxygenase inhibitor, a phosphodiesterase (PDE) inhibitor, a CD23 antagonist, an IL-13 antagonist, a cytokine release inhibitor, a histamine H1 receptor antagonist, an anti-histamine, an anti-inflammatory agent (e.g., cromolyn sodium or any other anti-inflammatory agent known in the art or described herein), or a histamine release inhibitor.

[0355] In some aspects of the disclosure, the means can be suitable for intraocular administration of an anti-C5a antibody, or an antigen-binding fragment thereof, described herein to a subject in need thereof, e.g., a subject afflicted with AMD or any other complement-associated ocular disorder. The means can be, e.g., a syringe, a trans-scleral patch, or even a contact lens containing the antibody or fragment. The means can, in some aspects of the disclosure, be an eye dropper, wherein the anti-C5a antibody or antigen-binding fragment thereof is formulated for such administration. Such therapeutic kits can also include, e.g., one or more additional therapeutic agents for use in treating complement-associated disorder of the eye. The therapeutic agents can be, e.g., bevacizumab or the Fab fragment of bevacizumab, ranibizumab, both sold by Roche Pharmaceuticals, Inc., or pegaptanib sodium (Mucogen®; Pfizer, Inc.). Such a kit can also, optionally, include instructions for administering the anti-C5a antibody or antigen-binding fragment thereof to a subject.

[0356] In some aspects of the disclosures, the means can be suitable for intraarticular administration of an anti-C5a antibody, or antigen-binding fragment thereof, described herein to a subject in need thereof, e.g., a subject afflicted with RA. The means can be, e.g., a syringe or a double-barreled syringe. See, e.g., U.S. Patent Nos. 6,065,645 and 6,698,622. A double-barreled syringe is useful for administering to a joint two different compositions with only one injection. Two separate syringes may be incorporated for use in administering the therapeutic while drawing off knee fluid for analysis (tapping) in a push-pull fashion. Additional therapeutic agents that can be administered with the anti-C5a antibodies or fragments in conjunction with the double-barreled syringe, or which can otherwise be generally included in the therapeutic kits described herein, include, e.g., NSAIDs, corticosteroids, methotrexate, hydroxychloroquine, anti-TNF agents such as etanercept and infliximab, a B cell depleting agent such as rituximab, an interleukin-1 antagonist, or a T cell costimulatory blocking agent such as abatacept. Such a kit can also,

optionally, include instructions for administering the anti-C5a antibody or antigen-binding fragment thereof to a subject. It will be appreciated that the disclosure embraces kits comprising one or more of the anti-C5a antibodies described herein and one or more anti-inflammatory agents selected from the group consisting of NSAIDs, corticosteroids, methotrexate, hydroxychloroquine, anti-TNF agents such as etanercept and infliximab, a B cell depleting agent such as rituximab, an interleukin-1 antagonist, or a T cell costimulatory blocking agent such as abatacept. The antibodies and agents can be, e.g., formulated separately or together. The kits can be used to treat an inflammatory condition such as RA, Crohn's disease, inflammatory bowel disease, or any other inflammatory disorder known in the art or recited herein.

[0357] Also featured are diagnostic kits containing the anti-C5a antibodies or antigen-binding fragments thereof described herein. For example, the kits can contain a detectably-labeled form of an anti-C5a antibody (e.g., an anti-C5a antibody or an anti-mouse C5a antibody) described herein for use in detecting or quantitating the amount of C5a in a biological sample. In some aspects of the disclosure, the kits can contain isolated C5a protein (e.g., one or both of human and mouse C5a protein) and/or a control sample comprising one or both of human and mouse C5a protein. In some aspects of the disclosure, the kit contains a multi-well plate coated with a first anti-C5a antibody having a first specificity. The kit also contains a second anti-C5a antibody (e.g., a detectably-labeled second anti-C5a antibody) having a second specificity. Such a kit is designed for use in capturing, with the first antibody bound to the plate, C5a protein (e.g., human C5a protein) in a sample (e.g., a biological sample) contacted to the plate and then detecting the captured C5a protein using the second antibody. In some aspect of the disclosure, diagnostic kits include both an anti-mouse C5a antibody and an anti-human C5a antibody described herein. In some aspects of the disclosure, the diagnostic kits include an anti-C5a antibody that binds to both mouse C5a and human C5a.

[0358] The following examples are intended to illustrate, not limit, the invention.

Examples

Example 1. Immunization methods

[0359] The presently described anti-C5a antibodies are humanized forms of murine antibodies generated under the following immunization protocol. Immunizations to raise antibodies against human desarginated C5a were performed on four mice including two mice of the strain DBA/2J and two mice of the strain A/J. These strains were selected because they carry the allele *Hc⁰*, which makes them deficient in endogenous C5. All immunizations were repeated at 14 day intervals for a total of three immunizations. All animals received a subcutaneous booster immunization of approximately 50 µg of purified C5a in 200 µL of adjuvant emulsion approximately 14 days after the last immunization and 5 to 7 days before harvesting. Titering of serum from immunized mice, using an ELISA assay, showed that the mice exhibited a strong antibody response against the human desarginated C5a immunogen.

Example 2. Determining the specificity of the mouse antibodies for human C5a

[0360] A subset of five mouse anti-human C5a Fabs that were representative of neoepitope selective Fabs were converted to full length mouse IgG2a antibodies designated as - 5an048ME, 5an101ME, 5an178ME, 5an179ME, and 5an180ME. These antibodies were evaluated for specificity using Biolayer Interferometry on an Octet (ForteBio Inc.). (The amino acid sequences of the light chain and heavy chain CDR sets of each antibody, as defined by Kabat, are set forth in Table 3.) Briefly, human C5a, human C5a des Arg, human full-length C5, or C5a paralogs human C3a and human C4a were conjugated to biotin at a stoichiometry of < 1(biotin):1 (antibody) through amine groups and immobilized on a streptavidin tip. Loaded tips were then exposed to a solution containing 20 nM of anti-C5a IgG antibody. Each of the antibodies bound to C5a and desarginated C5a. None of the anti-C5a IgG antibodies bound to C3a or to C4a. However, 5an178ME and 5an179ME each bound to full-length human C5. A small amount of binding was observed between 5an048ME and full-length human C5. However, the binding of 5an048ME to C5 was much less than the binding observed to C5a.

[0361] These results confirmed that mouse anti-human C5a antibodies - 5an048ME, 5an101ME, and 5an180ME - bound to a neoepitope on C5a that was occluded in native, full-length C5 or generated after the cleavage of C5 into fragments C5a and C5b. The results also indicated that the three antibodies were selective for human C5a as compared to paralogs C3a or C4a.

Table 3. Amino Acid Sequences for Five Murine Anti-Human C5a Antibodies

Ab	SIN:	Description	Amino Acid Sequence
5an048 ME	151	V _L Amino Acid Sequence	EIVLTQSPAIMASASPGEKVTMTCRASSSVSSS YLHWYQQKSGASPKLWIYSTSNLASGVPAR FSGSGSGTSYSLTISSVEAEDAATYYCQQYS GYPLTFGGGKLEIKR
	140	Light Chain CDR1	RASSSVSSSYLH
	96	Slight Chain CDR2	STSNLAS
	142	Light Chain CDR3	QQYSGYPLT
	152	V _H Amino Acid Sequence	EVRLQQSGPELVKPGASVRISCKASGYTFN DYYYMNVVKQSHGKSLEWIGYIFPKTGGT HYNQRFK GKATLTVDKSSSTAYMELRSLTS EDSAVYYCASGPFAYWGQGLTVTVSA
	115	Heavy Chain CDR1	DYYVMN
	144	Heavy Chain CDR2	YIFPKTGGTHYNQRFKG
	117	Heavy Chain CDR3	GPFAY
5an101 ME	153	V _L Amino Acid Sequence	DIVMTQSPASLAVSLGQRATISCRASESVDS YGNSFMHWYQQKPGQPPKLLIYRASNLESG IPARFSGSGSRTDFTLTINPVEADDVATYYC QQSNEDPYTFGGGKLEIKR
	20	Light Chain CDR1	RASESVDSYGNSFMH
	21	Light Chain CDR2	RASNLES
	22	Light Chain CDR3	OOSNEDPYT
	154	V _H Amino Acid Sequence	EVQLQQSGPELVKPGSSVKISCKASGYTFTD YSMDWVKQSHGKSLEWIGAINPNSGGTNY SQKFVKDKATLTVDKSSSTAYMELRSLTSED SAVYYCASSGSYDGYAMDYWGQGTSTV VSS
	28	Heavy Chain CDR1	DYSMD
	67	Heavy Chain CDR2	AINPNSGGTNYSQKFVKD
	30	Heavy Chain CDR3	SGSYDGYAMDY
5an180 ME	155	V _L Amino Acid Sequence	DIQMTQSPASLSASVGETVTITCRASENIYSY LAWYQQKQKSPQLLVYNAKTLAEGVPSR FSGSGSGTQFSLKINSLQPEDFGSYQCQHHY GTPYTFGGGKLEIKR
	156	Light Chain CDR1	RASENIYSYLA
	157	Light Chain CDR2	NAKTLAE
	158	Light Chain CDR3	QHHYGTPT
	159	V _H Amino Acid Sequence	EVQLQQPGAIEIVRPGASVKLSRASGYTFT DYWMNVVKQRPQGQLEWIGTIDPSDSYTI YNQKFVKGKATLTVDTSSTAYIQLSSLTSED SAVYFCARGEDYDVSSYTMDYWGQGTSTV VSS
	160	Heavy Chain CDR1	DYWMN
	161	Heavy Chain CDR2	TIDPSDSYTIYNQKFVK
	162	Heavy Chain CDR3	GEDYDVSSYTMDY

Ab	SIN:	Description	Amino Acid Sequence
5an178 ME	163	V _L Amino Acid Sequence	EIVLTQSPASLAVSLGQRATISCSASESVEYF GTSLMQWYQQKPGQPPKLLIYAASNVESG VPARFSGSGSGTDFSLNIHPVEEDDIAMYFC
			QQSRKVPWTFGGGKLEIKR
	164	Light Chain CDR1	SASESVEYFGTSLMQ
	165	Light Chain CDR2	AASNVES
	166	Light Chain CDR3	QQSRKVPWT
	167	V _H Amino Acid Sequence	EVKLVESGGGLVQPGGSRKLSCAASGFTFS DYGMVWVRQAPGKGLEWVAFISSGSSNIY YADTVKGRFTISRDNPKNTLFLQMNSLRSE DTAIYYCGRAFSFYGYDYWGQTTLVSS
	168	Heavy Chain CDR1	DYGMV
	169	Heavy Chain CDR2	FISSGSSNIYYADTVKG
	170	Heavy Chain CDR3	AFSFYGYDY
5an179 ME	171	V _L Amino Acid Sequence	DVVMQTQPLSLPVSLGDQASISCRSSQSLVH SNGNTYLHWYLQKPGQSPKLLIYKVSNRFS GVPDRFSGSGSGTDFTLKISRVEAEDLGYYF CSQSTHVPLTFGAGTKLELKR
	172	Light Chain CDR1	RSSQSLVHSNGNTYLH
	173	Light Chain CDR2	KVSNRFS
	174	Light Chain CDR3	SQSTHVPLT
	175	V _H Amino Acid Sequence	EVQLQDSGPPELVKPGASVVRMSCKASGYTFT SYLIHWVKQKPGGLEWIGYIYPFNDGTKN NENFKGKATLTSDKSSSTVYMEVSSLTSEDS AVYYCARSHGPHYGGSYGYHFDYWGQG TTLTVSS
	176	Heavy Chain CDR1	SYLIH
	177	Heavy Chain CDR2	YYPFNDGTKNNENFKG
	178	Heavy Chain CDR3	SHGPHYGGSYGYHFDY
"SIN" in the Table refers to "SEQ ID NO."			
* CDR amino acid sequence defined according to Kabat et al. (<i>supra</i>).			

[0362] A series of sandwich assays were performed by Octet on the selected subset of mouse anti-human C5a IgG2a antibodies to determine the degree of overlap of the C5a epitopes for each of the five representative IgG2a antibodies. Briefly, a first antibody was biotinylated and immobilized on a streptavidin coated tip on the Octet platform. Next, human C5a was captured from a 20 nM solution on the immobilized antibody. The tip carrying the antibody-C5a complex was then exposed to a solution containing 20 nM of an unlabeled second anti-C5a IgG antibody. The elicitation of an additional association profile in the sensogram would indicate that the two antibodies bound C5a simultaneously in a ternary complex and that the binding epitopes for the two antibodies were non-overlapping. A failure to obtain a second association profile upon addition of the second antibody would indicate that the two antibodies bound C5a in a competitive manner, i.e., the epitope on C5a to which the second antibody bound was occluded after binding by the first antibody. In contrast to non-competitive binding, competitive binding does not necessarily indicate that the first and second antibodies recognized the same, or even overlapping, epitopes on human C5a. Using this approach the binding sites of the five representative anti-C5a antibodies were assigned to 4 distinct epitopes on human C5a (Fig. 1). Antibodies 5an048ME, 5an180ME, and 5an101ME competed with each other. While 5an048 and 5an180 also competed with the non-neoepitope selective 5an179ME, 5an101ME did not, which indicated that 5an048ME and 5an180ME recognize a neoepitope that is different than the epitope recognized by 5an101ME. In addition, while the non-neoepitope selective antibody 5an178ME competed with non-neoepitope selective 5an179ME, only the latter competed with 5an180ME and

5an048ME, showing that 5an179ME and 5an178ME bind different epitopes that are accessible both in C5 and C5a. The results also indicate that some combinations of the antibodies could be used in sandwich-based assays to detect and/or quantify the amount of C5a in a sample.

Example 3. Humanization of select mouse anti-human C5a antibodies

[0363] The variable regions of two related mouse anti-human C5a antibodies - 5an101ME and 5an185ME - were selected for humanization as full length IgG antibodies. Humanization of light and heavy chain variable regions was based on identifying individual framework regions from human antibodies (with a preference given to germline v-genes) with a high degree of sequence identity to the original murine parent antibody. Methods for identifying suitable candidate framework regions are described in U.S. patent no. 7,393,648 to Rother and Wu. Definitions of framework (FW) and complementarity determining regions (CDRs) were performed according to methods described by Kabat, Chothia and IMGT® (International ImmunoGenetics Information System; France). Briefly, database queries were performed independently for both the light and heavy chain variable regions with a variety of antibody fragments including: intact murine variable region from FW1 through FW4, intact murine variable regions excluding CDRs and all possible fragments of murine variable regions including one, two or three frameworks with or without their flanking CDRs. Human frameworks were selected from this candidate pool based on their overall sequence identity to the original murine antibodies and fragments thereof. Routine molecular biological methods were employed to assemble small combinatorial libraries, of less than 10^3 members, in which each set of murine CDRs were flanked by all possible combinations of selected human frameworks. These humanized antibodies were expressed as soluble Fabs and evaluated for binding to desarginated C5a using ELISA. Fabs that bound to C5a were then subjected to DNA sequence analysis.

[0364] From these binders a subset of six humanized Fabs were reformatted as full length IgGs (human IgG2 or human IgG2/G4). Additional humanization was performed in two antibodies (BNJ371 and BNJ381) by replacing murine residues in CDR2 of the light chain with their corresponding human germline amino acids. The amino acid sequences of the humanized anti-C5a antibodies - BNJ364, BNJ367, BNJ371, BNJ378, BNJ366, BNJ369, BNJ381, and BNJ383 - are set forth in Table 2 above.

Example 4. Determining the affinity of the humanized anti-human C5a antibodies for C5a

[0365] The humanized antibodies were subjected to BIAcore analysis to quantify their respective affinities for human C5a. See, e.g., Karlsson and Larsson (2004) Methods Mol Biol 248:389-415. Briefly, each of the humanized antibodies were screened with 3-4 concentrations of human C5a (antigen) using a capture technique. The antibodies were captured by an Anti-Fc (human) directly immobilized on a CM5 sensor chip with various concentrations in the range from 0.6 nM to 5.9 nM of human C5a passed over the sensor chip surface. The surface was regenerated with 20 mM HCl, 0.02% P20 after each cycle to remove bound antibody and antigen. The data was evaluated using Biacore BIAevaluation software using a 1:1 Langmuir Model Fit (Rmax:Global Fit; RI:Local Fit). Kinetics information such as (k_a : Association Rate constant), (k_d :Dissociation Rate constant) and K_D (Equilibrium Dissociation constant) was obtained from the fit. The results of the analyses are set forth in Table 4. These experiments were for screening purposes with a minimal number of analyte concentrations (3 to 4) with 1 duplicate. Therefore, the approximate kinetics values are reported in Table 4.

Table 4. Affinity Measurements for Select Humanized Anti-C5a Antibodies

Antibody Designation	k_a (1/Ms) ($\times 10^6$)	k_d (1/s) ($\times 10^{-4}$)	K_D (M) ($\times 10^{-12}$)	χ^2
BNJ364	0.991	6.38	644	0.819
BNJ367	3.94	7.78	198	0.848
BNJ371	2.38	28.2	1180	9.52
BNJ378	1.93	5.76	298	3.63
BNJ366	1.05	1.58	150	1.23
BNJ369	4.19	2.23	53.1	0.642
BNJ381	2.57	2.09	81.5	1.93
BNJ383	2.12	1.5	70.4	2.52

[0366] All of the humanized antibodies specifically bound to human C5a with a k_D less than 1.20 nanomolar. All of the antibodies

with the exception of BNJ371 bound to human C5a with a K_D less than 1 nanomolar. Three of the antibodies, BNJ369, BNJ381, and BNJ383 bound to human C5a with a K_D less than 100 picomolar.

Example 5. Anti-C5a antibodies inhibit C5a-mediated signaling *in vitro*

[0367] An *in vitro* neutrophil activation assay was used to evaluate the activity of the humanized antibodies. The assay is generally described in, e.g., Paczkowski et al. (1999) *Br J Pharmacol* 128(7):1461-1466, and serves to quantitate the amount of myeloperoxidase (MPO) produced by neutrophils as a measure of neutrophil activation. Briefly, polymorphonuclear cells, the majority of which being neutrophils, were isolated using density centrifugation (mono-poly resolving medium catalogue number: 91698049; MP Biochemicals; Solon, Ohio) from whole blood from a healthy donor. The cells were washed once with phosphate-buffered saline (PBS) and the red blood cells (RBC) removed from the cell population by lysis in a hypotonic solution (ACK lysis buffer catalogue number 10-548E; Lonza). After two more washes with PBS, the RBC-free cells were resuspended at a concentration of 4×10^6 cells/mL in Hank's Balanced Salt Solution (HBSS; Mediatech, catalogue number: 21-023-CV), which was supplemented with calcium and magnesium and further supplemented with 0.1% gelatin (Sigma Aldrich; St. Louis, Missouri) [hereinafter the assay buffer].

[0368] Cytochalasin B (Sigma Aldrich) was added to the cell suspension in an amount sufficient to reach a concentration of 10 μ g/mL. The suspension was then incubated for 10 minutes at 37°C. 100 μ L of cells was added to wells of U-bottomed 96-well plates. The wells of the plate were grouped into several different sets. Each of several of the different sets of wells contained an anti-C5a antibody: each well of set 1 contained a humanized antibody that binds to uncleaved, native C5, but not to free C5a; each well of set 2 contained the BNJ367 humanized anti-C5a antibody; each well of set 3 contained the BNJ369 humanized anti-C5a antibody; each well of set 4 contained the BNJ371 humanized anti-C5a antibody; each well of set 5 contained the BNJ378 humanized anti-C5a antibody; each well of set 6 contained the BNJ381 humanized anti-C5a antibody; and each well of set 7 contained the BNJ383 humanized anti-C5a antibody. Each well of an eighth set of wells contained no antibody. A range of antibody concentrations was evaluated in each set of wells, the range including 0.08 nM, 0.4 nM, 2 nM, and 10 nM antibody.

[0369] C5a (obtained from Complement Technologies, Inc.) was evaluated at a concentration of 2 nM. A 10X working concentration of 20 nM was prepared in the aforementioned assay buffer and 20 μ L was added to each well. After addition of C5a to the wells, the plate was incubated for 10 minutes at 37°C. Following the incubation, 60 μ L of PBS was added to each well of the plate. The plates were subjected to centrifugation at 1200 rpm (approximately 335 x g) for 10 minutes at room temperature. 100 μ L of the supernatant from each well was transferred to the corresponding well of a second plate. 25 μ L of substrate (Sigma Aldrich catalogue number T0440) was added to each well of the second plate and the peroxidase reaction was allowed to develop for approximately two to five minutes. The reaction was terminated by the addition of 25 μ L of 1N HCl. The OD at 450 nm was recorded.

[0370] As shown in Fig. 2, all of the humanized anti-C5a antibodies inhibited neutrophil activation *in vitro*. These results indicate that the humanized anti-C5a antibodies described herein are potent inhibitors of C5a-mediated signaling *in vitro* and support the conclusion by the inventors that the antibodies are useful for treating a variety of complement-associated disorders (e.g., complement-associated inflammatory disorders) in humans.

Example 6. Characterization of a surrogate mouse anti-mouse C5a antibody

[0371] A series of sandwich assays were performed on a selected mouse anti-mouse C5a IgG antibody - 5an195ME - to determine the specificity of the antibody for C5a. Briefly, the wells of an assay plate were coated with the 5an195ME antibody. The plate was washed thoroughly to remove unbound antibody. Next, wells containing 5an195ME were contacted with mouse C5a for a time and under conditions sufficient to allow the antigen to bind to the antibody. Unbound protein was removed with washing. Following the wash step, the wells were further contacted with a solution containing a second, biotinylated anti-C5a antibody. The wells were again washed to remove any unbound second antibody. The amount of binding of the second antibody to the well was quantified using streptavidin-conjugated horseradish peroxidase (HRP). The amount of binding of the second antibody was a function of the binding of C5a to 5an195ME.

[0372] In a parallel experiment, a set of 5an195ME-coated wells were incubated with full-length mouse C5 protein, rather than C5a. Following a wash step, the wells were contacted with a solution containing a second antibody: a biotinylated anti-mouse C5 antibody. The amount of binding of the second antibody, as a function of the amount of C5 bound by 5an195ME, was quantified

using the streptavidin-conjugated HRP construct. A lack of binding of the second antibody indicates that 5an195ME does not bind to full-length mouse C5.

[0373] While 5an195ME bound to C5a in a dose-dependent manner, no binding between the antibody and full-length mouse C5 was detected using this assay. These results indicate that 5an195ME binds to a neo-epitope present in C5a.

[0374] The relative binding affinity of 5an195ME for mouse C5a was further quantified using BIAcore. The kinetics of 5an195ME were measured using a capture technique. The antibody was captured by an Anti-Fc (mouse) directly immobilized on a CM5 sensor chip with various concentrations between and inclusive of 0.4 nM and 25 nM of mouse C5a passed over the sensor chip surface. Duplicates of each concentration were also run. The surface of the chip was regenerated with 10 mM glycine HCl pH 1.7 after each cycle to remove bound antibody and antigen. The data were evaluated using Biacore BIAevaluation software using a 1:1 Langmuir Model Fit (Rmax:Global Fit; RI:Local Fit). Kinetics information such as k_a (Association Rate constant), k_d (Dissociation Rate constant) and K_D (Equilibrium Dissociation constant) was obtained from the fit. The results of the kinetics analyses are shown in Table 5.

Table 5. Measured Kinetics of 5an195ME for Mouse C5a

Parameter:	k_a (1/Ms)	k_d (1/s)	K_D (M)	χ^2
5an195ME	8.47×10^5	1.27×10^{-3}	1.5×10^{-9}	1.17

[0375] These results indicate that the mouse anti-mouse C5a antibody is not only specific for C5a, as compared to full-length mouse C5, but also that the antibody binds with high affinity to mouse C5a.

Example 7. Use of the surrogate anti-mouse C5a antibody 5an195ME in an RA animal model

[0376] The 5an195ME anti-mouse C5a antibody was evaluated in a mouse model of collagen-induced arthritis. Male DBA/1LacJ mice (9 to 12 weeks old) were immunized by intradermal injection at the base of the tail with 300 μ g of bovine type II collagen emulsified with equal volumes of Freund's complete adjuvant. The procedure was repeated two weeks after the first immunization. Mice were inspected daily to identify inflammation at an initial knee joint. Once the initial inflammation was identified, mice were intraperitoneally administered three times/week the 5an195ME anti-mouse C5a antibody (40mg/kg) or a control antibody (40mg/kg). The thickness of the initially inflamed joint (in mm) was measured daily to day 12.

[0377] As shown in Fig. 3, 5an195ME reduced knee joint thickness as compared to the control antibody. 5an195ME appeared to provide the benefit of maintaining a knee joint thickness below 4.5 mm.

[0378] In addition to evaluating the ability of the 5an195ME antibody to reduce swelling of the initially inflamed knee joint, the ability of the 5an195ME anti-C5a antibody to prevent migration of inflammation to new joints was also evaluated. The number of newly recruited joints was measured daily from day1 to day 12. The results of the experiment are set forth in Table 6.

Table 6. Efficacy of 5an195ME in RA Model

Treatment	Number of Mice	Number of joints inflamed on day 1	Number of newly inflamed joints on day 12	Average number of newly inflamed joints per mouse
Control Ab	6	7	12	2
5an195ME	6	7	2	0.3

[0379] As shown in Table 6, mice treated with 5an195ME had markedly fewer newly inflamed joints as compared with control Ab treated animals by day 12. 5an195ME-treated mice also had on average markedly fewer newly inflamed joints.

[0380] The arthritis in the mice was also monitored and defined using a clinical score/arthritis index. Each limb was graded daily according to an established scoring system (0, normal joint; 1, mild/moderate visible erythema and swelling; 2, severe erythema and swelling affecting an entire paw or joint; 3, deformed paw or joint with ankylosis.), with a maximum score of twenty-four per animal. See, e.g., Wang et al. (2000) J Immunol 164:4340-4347. As shown in Fig. 4, mice treated with the anti-mouse C5a antibody 5an195ME exhibited a marked reduction in clinical score (average score of less than 1), as compared to mice treated with the control antibody (average score above 6), over the course of the study.

[0381] In summary, these results indicate that the surrogate anti-mouse C5a is effective in treating RA - both at an initial joint and the migration of inflammation to secondary joints - in the mouse model of disease. The results also strongly suggest that a therapeutic anti-human C5a antibody, such as any of the humanized anti-C5a antibodies described herein, is useful for treating humans with RA.

Example 8. Use of an anti-C5a antibody to treat rheumatoid arthritis

[0382] A human patient is identified by a medical practitioner as having rheumatoid arthritis in a single articulated joint. The patient is shortly thereafter administered intraarticularly or intraperitoneally a composition containing a humanized anti-C5a antibody described herein in an amount sufficient to reduce C5a-mediated C5aR1 signaling locally within the joint space. The patient and medical practitioner observe a substantial improvement in at least two known symptoms of rheumatoid arthritis following the treatment. The patient receives intravenously administered "maintenance doses" of the antibody every month to prevent reoccurrence of the symptoms, to prevent the progression of RA at the single joint, or to prevent the migration of RA symptoms to a second joint.

Example 9. Use of an anti-C5a antibody to treat sepsis

[0383] A human patient is identified by a medical practitioner as having sepsis. The patient is shortly thereafter administered a composition containing a humanized anti-C5a antibody described herein at a dose of approximately 600 to 900 mg by way of intravenous infusion. The patient and medical practitioner observe a substantial improvement in at least two known symptoms of sepsis during the treatment. The patient receives intravenously administered "maintenance doses" of the antibody every two weeks until the patient leaves the hospital.

Example 10. Use of an anti-C5a antibody to treat complement-associated pulmonary inflammatory disorders

[0384] A human patient is identified by a medical practitioner as having a severe form of COPD. Once every two weeks for four weeks the patient is administered a composition containing a humanized anti-C5a antibody at a dose of approximately 600 mg to 900 mg by intravenous infusion. The patient and medical practitioner observe a substantial improvement in at least two known symptoms of COPD during the initial treatment. For example, the patient receiving the anti-C5a antibody has a reduced frequency and/or severity of COPD-related exacerbations. The patient continues to receive intravenously administered "maintenance doses" of the antibody every two weeks to maintain the reduced frequency and/or severity of COPD-related exacerbations.

[0385] A human patient is identified by a medical practitioner as having a severe form of asthma. The patient is prescribed a therapeutic, humanized anti-C5a antibody to be administered by way of an inhaler. During the next attack of bronchospasms, the patient self-administers the anti-C5a antibody in an amount sufficient to reduce the C5a-mediated inflammatory response in the lungs of the patient. The patient continues to use the inhaler as needed to prevent or lessen the severity of asthma attacks.

Example 11. Additional anti-C5a antibodies identified from the immunized mice

[0386] Several additional antibodies were obtained from the immunized mice (see Example 1) and further identified by ELISA as capable of binding to human C5a. The additional antibodies include 15 unique light chain CDR sets (set forth in Table 7) and 14 unique heavy chain CDR sets (as set forth in Table 8).

Table 7. Amino Acid Sequences of Several Unique V_L and Kabat-defined Light Chain CDR sequences from Additional Murine Anti-human C5a Antibodies

Ab	SIN:	Description	Amino Acid Sequence*
5an110	83	V _L Amino Acid Sequence	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGT NVAWYQQKPGQSPKALIYSASYRYSYGVPDF TGSGSGTDFTLTISNVQSEDLAEYFCQQYNSYP FTFGSGTKLEIKR

Ab	SIN:	Description	Amino Acid Sequence*
	84	Light Chain CDR1	KASQNVGTNVA
	85	Light Chain CDR2	SASYRYS
	86	Light Chain CDR3	QQYNSYPFT
5an177	87	V _L Amino Acid Sequence	EIVLTQSPAIMASASPGEKVTMTCSASSSVSYMH WYQQKSGTSPKRWIYDTSKLASGVPARFSGS GSGTSYSLTISSMEAEDAATYYCQQWSSNPLT FGAGTKLEIKR
	88	Light Chain CDR1	SASSSVSYMH
	89	Light Chain CDR2	DTSKLAS
	90	Light Chain CDR3	QQWSSNPLT
5anG12	91	V _L Amino Acid Sequence	QIVLTQSPAIMASASPGEKVTMTCSASSSISYMH WYQQKPGTSPKRWIYDTSKLASGVPARFSGS GSGTSYSLTISSMEAEDAATYYCHQRSSYPWT FGGGTKLEIKR
	92	Light Chain CDR1	SASSSISYMH
	89	Light Chain CDR2	DTSKLAS
	93	Light Chain CDR3	HQRSSYPWT
5an052	94	V _L Amino Acid Sequence	QIVLTQSPAIMASASPGEKVTLTCSASSSVSSSYL YWYQQKPGSSPKLWIYSTSNLASGVPARFSGS GSGTSYSLTISTVEAEDAASYFCHQWSSYPPTF GGGKLEIKR
	95	Light Chain CDR1	SASSSVSSSYLY
	96	Light Chain CDR2	STSNLAS
	97	Chain CDR3	HQWSSYPPT
5an107	98	V _L Amino Acid Sequence	DIQMTQSPAPMLVSVGETVTITCRGSENIYSNL AWYQQKQGKSPQLLVYAATNLADGVPSRFSG SGSGTQYSLKINSLSQSEDFGSYYCQHFHWGTPR TFGGGKLEIKR
	99	Light Chain CDR1	RSENIYSNLA
	100	Light Chain CDR2	AATNLAD
	101	Light Chain CDR3	

Ab	SIN:	Description	Amino Acid Sequence*
5anE11	102	V _L Amino Acid Sequence	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGT NVAWYQQKPGQSPKALITYSASYRYSQVDRF TSGSGTDFTLTISNVQSEDLAEYFCQQYNSYP WTFGGGKLEIKR
	84	Light Chain CDR1	KASQNVGTNVA
	85	Light Chain CDR2	SASYRYS
	103	Light Chain CDR3	QQYNSYPWT
5an054	104	V _L Amino Acid Sequence	QIVLTQSPVIMSASPGEKVTMTCSASSSVSYM YWYQQKPGSSPRLIYDTSNLAGVVPVRFSGS GSGTSYSLTISRMEAEDAATYYCQQWSSYPPT FGAGTKLELKR
	105	Light Chain CDR1	SASSSVSYMY
	106	Light Chain CDR2	DTSNLAG
	107	Light Chain CDR3	QQWSSYPPT
5anG10	141	V _L Amino Acid Sequence	QIVLTQSPAIMSASPGEKVTMTCSASSSISYMH WYQQKPGTSPKRWIYDTSKLASGVPARFSGS GSGTSYSLTISSMEAEDAATYYCHQRRSYPWT FGGGTKLEIKR
	92	Light Chain CDR1	SASSSISYMH
	89	Light Chain CDR2	DTSKLAS
	108	Light Chain CDR3	HQRRSYPWT
5an188	109	V _L Amino Acid Sequence	DIVLTQSPASLAVSLGQRATISCRASESVDSYG NSFMHWYQQKPGQPPKLLIYASNLESGVPAR FSGSGSRDFTLTIDPVEADDAATYYCQQNNE DPLTFGAGTKLELKR
	20	Light Chain CDR1	RASESVDSYGNSFMH
	110	Light Chain CDR2	LASNLES
	111	Light Chain CDR3	QQNNEPLT
5an185	112	V _L Amino Acid Sequence	DIVLTQSPASLAVSLGQRATISCRASESVDSYG NSFMHWYQQKPGQPPKLLIYASNLESGIPAR FSGSGSRDFTLTINPVEADDAATYYCQQSNE DPLTFGAGTKLELKR
	20	Light Chain CDR1	RASESVDSYGNSFMH

Ab	SIN:	Description	Amino Acid Sequence*
	21	Light Chain CDR2	RASNLES
	113	Light Chain CDR3	QQSNEDPLT

"SIN" in the Table refers to "SEQ ID NO."

*CDR amino acid sequences are defined according to Kabat et al. (*supra*).

Table 8. Amino Acid Sequences of Several Unique V_H and Kabat-defined Heavy Chain CDR sequences from Additional Murine

Anti-human C5a Antibodies

Ab	SIN:	Description	Amino Acid Sequence*
5an110	114	V _H Amino Acid Sequence	EVQLQQSGPELVKPGASVKISCKASGYTFSDY YYMNWVKKSHGKSLEWIGYIFPKTGGTNYS QRFKGKATLTVDKSSSTAYMELRSLTSEDSA VYYCASGPFAYWGQGLTVTSA
	115	Heavy Chain CDR1	DYYMN
	116	Heavy Chain CDR2	YIFPKTGGTNYSQRFKG
	117	Heavy Chain CDR3	GPFAY
5an177	118	V _H Amino Acid Sequence	EVKLVESGGGLVKPGGSLKLSAASGITFSSY YMAWVRQTPDKRLEWVATISSGGSYTYYP NVKGRFTISRDNAKNTLYLQMSSLKSEDTAM YYCTRYEDDAMDYWGQGSVTSS
	119	Heavy Chain CDR1	SYMA
	120	Heavy Chain CDR2	TISSGGSYTYYPDNVKG
	121	Heavy Chain CDR3	YEDDAMDY
5an055	122	V _H Amino Acid Sequence	EVQLQQSGPELVKPGASVKISCKASGYTFSDY YYMNWVKKSHGKSLEWIGYIFPKTGGTNYN QRFKGKATLTVDKSSSTAYMELRSLTSEDSA VYYCASGPFAYWGQGLTVTSA
	115	Heavy Chain CDR1	DYYMN
	123	Heavy Chain CDR2	YIFPKTGGTNYNQRFKG
	117	Heavy Chain CDR3	GPFAY
5an054	145	V _H Amino Acid Sequence	EVQLQQSGPELVKPGASVKISCKASGYTFSDY YYMNWVKQSHGKSLEWIGYIFPKTGGTTYN QRFKGKATLTVDKSSSTAYMELRSLTSEDSA VYYCASGPFAYWGQGLTVTSA
	115	Heavy Chain CDR1	DYYMN

Ab	SIN:	Description	Amino Acid Sequence*
	124	Heavy Chain CDR2	YFPNTGGTTYNQRFKG
	117	Heavy Chain CDR3	GPFAY
5an107	125	V _H Amino Acid Sequence	EVKLVESGGGLVKPGGSLKLSCAASGYTFSS YYMAWVRQTPDKRLEWVATISSGGSYYTYR DNVKGRFTISRDNAKNTLYLQMSSLKSEDTA MYYCTRYFEDYPMDYWGQGTSVTVSS
	119	Heavy Chain CDR1	SYMA
	126	Heavy Chain CDR2	TISSGGSYYTYRDNVKG
	127	Heavy Chain CDR3	YFEDYPMDY
5an111	128	V _H Amino Acid Sequence	EVQLQQSGPELGKPGASGKISCKASGYTFDY YYMNWVKQSHGKSLEWIGYIFPNTGGTSYN QRFKDKATLTVDKSSSTAYMELRSLTSEDSA VYYCASGPFAYWGQGLTVTVSA
	115	Heavy Chain CDR1	DYYMN
	129	Heavy Chain CDR2	YFPNTGGTSYNQRFKD
	117	Heavy Chain CDR3	GPFAY
5an183	130	V _H Amino Acid Sequence	EVQLQQPGSVLVRPGATVKLSCKASGFTFTSS WMHWAKQRPQGQLEWIGEIHTSGHTNYNEK FKGKATLTLDTSSTAYVDISLTSSEDSAVYY CARGGLRRGYAMDYWGQGTSVTVSS
	131	Heavy Chain CDR1	SSWMH
	132	Heavy Chain CDR2	EIHTSGHTNYNEKFKG
	133	Heavy Chain CDR3	GGLRRGYAMDY
5an185	134	V _H Amino Acid Sequence	EVQPQQSGPELVKPGSSVKISCKASGYTFDY SMDWVKQSHGKSLEWIGAIHLNTGYTNYNQ KFKGKATLTVDKSSSTAYMELRSLTSEDSAV YYCARGFYDGYSPMDYWGQGTSVTVSS
	28	Heavy Chain CDR1	DYSMD
	46	Heavy Chain CDR2	AIHLNTGYTNYNQKFKG
	47	Heavy Chain CDR3	GFYDGYSPMDY

Ab	SIN:	Description	Amino Acid Sequence*
5an188	135	V _H Amino Acid Sequence	EVQLQQSGAELVKPGTSVKLSCKASGYTFTS YWMHWVKQRPQGLEYIGEHPSSGHTNYH EKFKSKATLTVDKSSSTAYMQLSSLTSEDSÄV YYCARASLLRAYAMDYWGQGTSTVTVSS
	136	Heavy Chain CDR1	SYWMH
	137	Heavy Chain CDR2	EIHPSSGHTNYHEKFKS
	138	Heavy Chain CDR3	ASLLRAYAMDY
"SIN" in the Table refers to "SEQ ID NO."			
*CDR amino acid sequences are defined according to Kabat et al. (<i>supra</i>).			

[0387] V_L and V_H pairings giving rise to the 5an177ME, 5an054ME, 5an110ME, 5an188ME, 5an185ME, and 5an107ME antibodies are evident from Tables 7 and 8. Additional exemplary pairings of the heavy chain and light chain variable regions and/or CDR sets are set forth in Table 9 below.

Table 9. Amino Acid Sequences for Additional Mouse Anti-Human C5a Antibodies-CDR Sets

Ab	SIN:	Description	Amino Acid Sequence*
5an047	139	V _L Amino Acid Sequence	EIVLTQSPAIMASAPGEKVTMTCRASSSVSSSY LHWYQQKSGASPKLWIYSTSNLASGVPARFS GSGSGTSYSLTISSVEAEDAATYYCQYSGYP LTFGAGTKLELKR
	140	Light Chain CDR1	RASSSVSSSYLH
	96	Light Chain CDR2	STSNLAS
	142	Light Chain CDR3	QQYSGYELT
	143	V _H Amino Acid Sequence	EVQLQQSGPELVKPGASVRISCKASGYTFSY YYMNWVKKSHGKSLEWIGYIFPKTGGTHYN QRFKKGATLTVDKSSSTAYMELRSLTSEDSA VYYCASGPFAYWGQGLTVSA
	115	Heavy Chain CDR1	DYYMN
	144	Heavy Chain CDR2	YFPKTGGTHYNQRFKG
	117	Heavy Chain CDR3	GPFAV
5an181	139	V _L Amino Acid Sequence	EIVLTQSPAIMASAPGEKVTMTCRASSSVSSSY LHWYQQKSGASPKLWIYSTSNLASGVPARFS
			GSGSGTSYSLTISSVEAEDAATYYCQYSGYP LTFGAGTKLELKR
	140	Light Chain CDR1	RASSSVSSSYLH
	96	Light Chain CDR2	STSNLAS
	142	Light-Chain CDR3	QQYSGYPLT
	122	V _H Amino Acid Sequence	EVQLQQSGPELVKPGASVKISCKASGYTFSY YYMNWVKKSHGKSLEWIGYIFPKTGGTNYN QRFKKGATLTVDKSSSTAYMELRSLTSEDSA VYYCASGPFAYWGQGLTVSA

Ab	SIN:	Description	Amino Acid Sequence*
	115	Heavy Chain CDR1	DYYMN
	123	Heavy Chain CDR2	YIFPKTGGTNYNQRFKG
	117	Heavy Chain CDR3	GPFAY
5an109	146	V _L Amino Acid Sequence	EVLTQSPAISASPGKVTMTCSASSSVSYM YWYQQKPGSSPRLLIYDTSNLASGVPVRFSGS SGGTSYSLTISRMEAEDAATYYCQWSSYP TFGGGKLEIKR
	105	Light Chain CDR1	SASSSVSYMY
	106	Light Chain CDR2	DTSNLAS
	107	Light Chain CDR3	QWSSYPPT
	122	V _H Amino Acid Sequence	EVQLQQSGPELVKPGASVKISCKASGYTFSY YYMNWVKKSHGKSLEWIGYIFPKTGGTNYN QRFKGKATLTVDKSSSTAYMELRSLTSEDSA VYYCASGPFAYWGQGLVTVSA
	115	Heavy Chain CDR1	DYYMN
	123	Heavy Chain CDR2	YIFPKTGGTNYNQRFKG
	117	Heavy Chain CDR3	GPFAY
5anG10	141	V _L Amino Acid Sequence	QIVLTQSPAISASPGKVTMTCSASSSISYM HWYQQKPGTSPKRWIYDTSKLASGVPARFSG SGGTSYSLTISSMEAEDAATYYCHQRRSYP WTFGGGKLEIKR
	92	Light Chain CDR1	SASSSISYMH
	89	Light Chain CDR2	DTSKLAS
	108	Light Chain CDR3	HQRRSYPWT
	147	V _H Amino Acid Sequence	EVQLQQSGPELVKPGASVRISCKASGYTFND YYYMNWVKQSHGKSLEWIGYIFPKTGGTHY NQRFKGKATLTVDKSSSTAYMELRSLTSEDS AVYYCASGPFAYWGQGLVTVSA
	115	Heavy Chain CDR1	DYYMN
	144	Heavy Chain CDR2	YIFPKTGGTHYNQRFKG
	117	Heavy Chain CDR3	GPFAY
5an053	148	V _L Amino Acid Sequence	EMLTQSPVIMSASPGKVTMTCSASSSISYMH WYQQKPGTSPKRWIYDTSKLASGVPARFSGS SGGTSYSLTISIMEAEDAATYYCHQRRSYPWT FGGGKLEIKR
	92	Light Chain CDR1	SASSSISYMH
	89	Light Chain CDR2	DTSKLAS
	93	Light Chain CDR3	HQRRSYPWT
	149	V _H Amino Acid Sequence	EVQMQQSGPELVKPGASVKISCKASGYTFSY YYYMNWVKKSHGKSLEWIGYIFPKTGGTNY NQRFKGKATLTVDKSSSTAYMELRSLTSEDS AVYYCASGPFAYWGQGLVTVSA
	115	Heavy Chain CDR1	DYYMN

Ab	SIN:	Description	Amino Acid Sequence*
5anG12	123	Heavy Chain CDR2	YIFPKTGGTNYNQRFKG
	117	Heavy Chain CDR3	GPFAY
	91	V _L Amino Acid Sequence	QIVLTQSPAIMASAPGEKVTMTCSASSSISYM HWYQQKPGTSPKRWIYDTSKLASGVPARFSG SGSGTSYSLTISSMEAEDAATYYCHQRSSYPW TFGGGTKEIKR
	92	Light Chain CDR1	SASSSISYMH
	89	Light Chain CDR2	DTSKLAS
	93	Light Chain CDR3	HQRSSYPWT
	147	V _H Amino Acid Sequence	EVQLQQSGPELVKPGASVRISCKASGYTFND YYYMNWVKQSHGKSLEWIGYIFPKTGGTHY NQRFGKATLTVDKSSSTAYMELRSLTSEDS AVYYCASGPFAYWGQGLTVSA
	115	Heavy Chain CDR1	DYYMN
	144	Heavy Chain CDR2	YIFPKTGGTHYNQRFKG
	117	Heavy Chain CDR3	GPFAY
5an052	94	V _L Amino Acid Sequence	QIVLTQSPAIMASAPGEKVTLTCSASSSVSSSY LYWYQQKPGSSPKLWIYSTSNLASGVPARFS GSGSGTSYSLTISTVEAEDAASYFCHQWSSYP PTFGGGTKEIKR
	95	Light Chain CDR1	SASSSVSSSYLY
	96	Light Chain CDR2	STSNLAS
	97	Light Chain CDR3	HOWSSYPPT
	147	V _H Amino Acid Sequence	EVQLQQSGPELVKPGASVRISCKASGYTFND YYYMNWVKQSHGKSLEWIGYIFPKTGGTHY NQRFGKATLTVDKSSSTAYMELRSLTSEDS AVYYCASGPFAYWGQGLTVSA
	115	Heavy Chain CDR1	DYYMN
	144	Heavy Chain CDR2	YIFPKTGGTHYNQRFKG
5an111	117	Heavy Chain CDR3	GPFAY
	102	V _L Amino Acid Sequence	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGT NVAWYQQKPGQSPKALIYSASYRYSQVPSDF TGSGSGTDFLTISNVQSEDLAEYFCQYNSY PWTFGGGTKEIKR
	84	Light Chain CDR1	KASQNVGTNVA
	85	Light Chain CDR2	SASYRYS
	103	Light Chain CDR3	QQYNSYPWT
	128	V _H Amino Acid Sequence	EVQLQQSGPELVKPGASGKISCKASGYTFDY YYMNWVKQSHGKSLEWIGYIFPNTGGTSYN QRFKDKATLTVDKSSSTAYMELRSLTSEDSA VYYCASGPFAYWGQGLTVSA
	115	Heavy Chain CDR1	DYYMN
	129	Heavy Chain CDR2	YIFPNTGGTSYNQRFKD

Ab	SIN:	Description	Amino Acid Sequence*
5an055	117	Heavy Chain CDR3	GPFAF
	150	V _L Amino Acid Sequence	EIVLTQSPAIMSASPGEKVTLTCSASSSVSSSY LYWYQQKPGSSPKLWIYSTSNLASGVPARFS GSGSGTSYSLTISSMEAEDAASYFCHQWSSYP PTFGGGTKLEIKR
	95	Light Chain CDR1	SASSSVSSSYLY
	96	Light Chain CDR2	STSNLAS
	97	Light Chain CDR3	HQWSSYPPT
	122	V _H Amino Acid Sequence	EVQLQQSGPELVKPGASVKISCKASGYTFSY YYMNWVKKSHGKSLEWIGYIFPKTGGTNYN QRFKGKATLTVDKSSSTAYMELRSLTSEDSA VYYCASGPFAYWGQGLTVTSA
	115	Heavy Chain CDR1	DYYMN
	123	Heavy Chain CDR2	YIFPKTGGTNYNQRFKG
	117	Heavy Chain CDR3	GPFAF
5anE11	102	V _L Amino Acid Sequence	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGT NVAWYQQKPGQSPKALISASYRYSYGVDRF TGSGSGTDFTLTISNVQSEDLAEYFCQYNSY PWTFGGGTKLEIKR
	84	Light Chain CDR1	KASQNVGTNVA
	85	Light Chain CDR2	SASYRS
	103	Light Chain CDR3	QYNSYPWT
	143	V _H Amino Acid	EVQLQQSGPELVKPGASVRISCKASGYTFSY
		Sequence	YYMNWVKKSHGKSLEWIGYIFPKTGGTHYN QRFKGKATLTVDKSSSTAYMELRSLTSEDSA VYYCASGPFAYWGQGLTVTSA
	115	Heavy Chain CDR1	DYYMN
	144	Heavy Chain CDR2	YIFPKTGGTHYNQRFKG
	117	Heavy Chain CDR3	GPFAF
5an183	112	V _L Amino Acid Sequence	DIVLTQSPASLAVSLGQRATISCRASESVDSY GNSFMHWYQQKPGQPPKLLIYRASNLSEGP ARFSGSGSRDTFTLTINPVEADDVATYYCQQS NEDPLTFGAGTKLEIKR
	20	Light Chain CDR1	RASESVDSYGNSFMH
	21	Light Chain CDR2	RASNLES
	113	Light Chain CDR3	QSNEDPLT
	130	V _H Amino Acid Sequence	EVQLQQPGSVLVRPGATVKLSCKASGFTFTSS WMHWAKQRPQGLEWIGEIHTSGHTNYNEK FKGKATLTLDTSSTAYVDISLTSEDSAVYY CARGGLRRGYAMDYWGQGSVTVSS
	131	Heavy Chain CDR1	SSWMH
	132	Heavy Chain CDR2	EIHTSGHTNYNEKFKG

Ab	SIN:	Description	Amino Acid Sequence*
	133	Heavy Chain CDR3	GGLRRGYAMDY

"SIN" in the Table refers to "SEQ ID NO."

* CDR amino acid sequences are defined according to Kabat et al. (*supra*).

Example 12. Additional humanized anti-human C5a antibodies

[0388] Several additional humanized anti-C5a antibody heavy chain variable regions were generated, all of which when paired with a common light chain variable region (the light chain having the amino acid sequence depicted in SEQ ID NO:16) bound to human C5a with a K_D of less than 1 nM as determined by Biacore analysis (see above for methodology). All of these additional humanized antibodies bound specifically to human C5a, but did not bind to native, fully-folded human C5, C4a, or C3a as determined by Octet analysis (see above for methodology). The additional humanized antibodies contained: (i) a heavy chain variable region framework region 1 containing one of the following amino acid sequences: QVQLVQSGAEVKKPGASVKVSKASGYTFT (SEQ ID NO:68) or QVQLVQSGSELKKPGASVKVSKASGYTFT (SEQ ID NO:69); (ii) a heavy chain variable region framework region 2 containing one of the following amino acid sequences: WVRQAPGQGLEWMG (SEQ ID NO:70) or WVRQASGKLEWVG (SEQ ID NO:71); (iii) a heavy chain variable region framework region 3 containing one of the following amino acid sequences: RVTITRDTASTAYMELSSLRSEDTAVYYCAR (SEQ ID NO:72); RVTITADESTASTAYMELSSLRSEDTAVYYCAR (SEQ ID NO:73); or RVTITRDRSMSTAYMELSSLRSEDTAVYYCAR (SEQ ID NO:74); and a heavy chain variable region framework region 4 containing the following amino acid sequence: WGQGTTVTVSS (SEQ ID NO:75). Exemplary additional humanized heavy chain variable regions comprising one or more of the additional humanized framework sets described in this section are set forth in Fig. 5.

Example 13. Use of an anti-human C5a antibody in a mouse neutropenia model

[0389] A murine model of C5a-neutropenia was utilized to evaluate the efficacy of an anti-human free C5a antibody *in vivo*. To induce neutropenia, purified, native human C5a (hC5a) was administered by way of intravenous tail vein injection to Balb/c mice. The number of circulating neutrophils was evaluated up to five minutes after administration of hC5a.

[0390] Administration of 300 μ g/kg of hC5a was consistently found to induce neutrophil activation as measured by the myeloperoxidase (MPO) release assay (see Example 5 for use with serum as compared to cell culture supernatant, *supra*) and neutropenia (a reduction in the number of circulating neutrophils). In addition, plasma levels of hC5a and the human anti-C5a antibody BNJ383 (when administered to the mice, *infra*) were also measured to establish the pharmacodynamic response (see below).

[0391] Peripheral blood neutrophil counts were examined before challenge with hC5a or vehicle control. Compared to sham-treated control mice ($1.37 \pm 0.09 \times 10^6$ /mL), neutrophil counts in mice treated with anti-human free C5a antibody ($1.32 \pm 0.13 \times 10^6$ per mL at 24 mg/kg; $P > 0.05$) or isotype control mAb ($1.31 \pm 0.10 \times 10^6$ per mL at 24 mg/kg; $P > 0.05$) remained the same. These results indicated that antibody alone did not induce changes in circulating neutrophil counts.

[0392] To evaluate the efficacy of an anti-C5a antibody to inhibit hC5a-induced neutropenia in mice, different dosages (24 mg/kg, 12 mg/kg, 6 mg/kg, and 3 mg/kg) of the anti-human C5a antibody BNJ383 were administered to Balb/c mice 24 hours prior to hC5a injection. Administration of the anti-C5a antibody 24 hours ahead of hC5a allowed for the pharmacodynamics properties of the antibody to be studied during the β -phase of antibody elimination from the mice.

[0393] As shown in Fig. 6, neutrophil counts after treatment are expressed as a percentage of "baseline" (where the count at time 0 equals 100%). In sham-treated control mice, the neutrophil counts were $79.02 \pm 5.71\%$, $67.42 \pm 3.23\%$, and $59.54 \pm 2.11\%$ of baseline at 1, 3 and 5 minutes post hC5a administration, respectively. The isotype control antibody-treated mice demonstrated a significant reduction ($P < 0.01$) in the neutrophil count to $6.76 \pm 0.81\%$ at 1 minute, $6.68 \pm 0.81\%$ at 3 minutes, and $8.29 \pm 0.79\%$ at 5 minutes after intravenous injection of hC5a. The anti-C5a antibody exhibited a dose-dependent effect on hC5a-induced neutropenia. At the highest dose, 24 mg/kg, the anti-C5a antibody completely blocked the neutropenia. Neutrophil counts were $70.35 \pm 8.64\%$ at 1 minute, $63.35 \pm 6.08\%$ at 3 minutes, and $59.65 \pm 6.51\%$ at 5 minutes, which was comparable to the neutrophil levels in sham-treated control animals at the same time points. The lower doses of 12 mg/kg or 6 mg/kg of the anti-C5a

antibody also significantly inhibited neutrophil depletion (12 mg/kg: $42.61 \pm 5.12\%$ at 1 minute, $45.33 \pm 8.29\%$ at 3 minutes, and $41.02 \pm 7.08\%$ at 5 minutes, $P < 0.01$; 6 mg/kg: 18.00 ± 3.8 at 1 minute, $26.20 \pm 4.44\%$ at 3 minutes, and $28.03 \pm 4.51\%$ at 5 minutes, $P < 0.05$) following administration of hC5a, as compared to the isotype control antibody group ($6.76 \pm 0.81\%$ at 1 minute, $6.68 \pm 0.81\%$ at 3 minutes, and $8.29 \pm 0.79\%$ at 5 minutes). The isotype control antibody is an antibody that binds anthrax protective antigen 63 and contains a human IgG2/4 isotype Fc region. Administration of the lowest dose of the anti-C5a antibody (3 mg/kg) did not significantly reduce neutropenia ($6.28 \pm 0.88\%$ at 1 minute, $6.71 \pm 2.14\%$ at 3 minutes, and $8.75 \pm 2.98\%$ at 5 minutes, $P > 0.05$). See Fig. 6.

Anti-human C5a antibody inhibits hC5a-induced MPO release *in vivo*

[0394] As discussed above, human C5a activates neutrophils through cross-reactive binding of the mouse C5a receptor. Myeloperoxidase (MPO) release is a consequence of neutrophil activation through C5a binding to C5aR. See Darren et al. (2004) Mol Pharm 65(4):868-879. Intravenous injection of recombinant human C5a into the mouse can induce neutropenia and activate neutrophils in circulation. The ability of an anti-human free C5a antibody to inhibit MPO release due to neutrophil activation *in vivo* was evaluated using the anti-C5a antibody to bind free hC5a and prevent binding to the murine C5aR.

[0395] An *in vivo* experiment (in which human C5a was administered to mice) was performed as described above. The level of plasma MPO at time 0 was 79.25 ± 22.88 ng/mL in the sham-treated control group. Five minutes after intravenous injection of vehicle buffer, MPO levels were not significantly changed (77.46 ± 21.21 ng/mL, $P > 0.05$). Prior to intravenous injection of hC5a, MPO levels in isotype control antibody-treated (75.17 ± 14.66 ng/mL) or anti-C5a antibody-treated animals (87.57 ± 14.86 ng/mL) were comparable with the levels observed in the sham-treated control animals. After intravenous injection of hC5a, MPO levels at all doses of C5a were raised and remained at significantly higher levels at 5 minutes (Fig. 7).

[0396] When compared to isotype control antibody-treated animals (221.00 ± 51.02 ng/mL), the anti-hC5a antibody-treated animals showed dose-dependent reduction of MPO levels (114.83 ± 23.26 ng/mL, $P < 0.05$, in 24 mg/kg cohort; 104.80 ± 29.83 ng/mL, $P < 0.05$, in 12 mg/kg cohort; and 126.90 ± 36.40 ng/mL, $P = 0.08$, in 6 mg/kg cohort). The MPO levels of low dose (3 mg/kg) anti-C5a antibody-treated animals (176.55 ± 23.05 ng/mL) were not significantly different from isotype control antibody-treated animals ($P > 0.05$).

An anti-C5a antibody reduces circulating hC5a levels in mice

[0397] As noted above, C5a is a potent inflammatory peptide with several biological functions. These above studies demonstrated that human C5a cross-reacts with murine C5aR on neutrophils since intravenous injection of recombinant human C5a can induce neutropenia. While this disclosure is in no way limited by any particular theory or mechanism of action, the anti-C5a antibody maybe inhibiting human C5a-induced neutropenia by forming complexes with hC5a and preventing hC5a from binding to the murine C5aR expressed on the cell surface. hC5a levels were measured in the plasma of mice before and 1, 3, and 5 minutes after intravenous administration of hC5a to confirm that the effects of the anti-hC5a antibody *in vivo* were due to its binding-dependent inhibition of hC5a.

[0398] An experiment was performed as described above using the mouse-hC5a-induced neutropenia model. hC5a was not detected in plasma in any group of mice prior to administration of hC5a at time 0, using an enzyme-linked immunosorbent assay (ELISA). The level of hC5a in plasma, however, increased to a peak at 1 minute (7783.50 ± 327.73 ng/mL), then reduced to 4788.38 ± 260.51 ng/mL at 3 minutes, and then to 3855.75 ± 298.99 ng/mL at 5 minutes following intravenous injection of hC5a (in isotype control mAb-treated mouse). Compared to control antibody-treated mice, the level of hC5a in mice treated with 24 mg/kg of the anti-C5a antibody exhibited a 43, 30, and 23-fold decline at 1 minute (178.4 ± 14.14 ng/mL), 3 minutes (158.4 ± 10.43 ng/mL), and 5 minutes (167.2 ± 15.61 ng/mL), respectively. The level of hC5a in plasma from the 12 mg/kg and 6 mg/kg cohorts were 235.00 ± 22.33 and 609.20 ± 78.75 ng/mL at 1 minute, 210.80 ± 19.59 and 527.60 ± 52.25 ng/mL at 3 minutes, 192.20 ± 7.40 and 505.00 ± 45.96 ng/mL at 5 minutes, respectively. The anti-C5a-treated mice exhibited significantly reduced hC5a levels in a dose-dependent manner during neutropenia following intravenous injection of hC5a ($P < 0.001$). Although the mice receiving the lowest dose of anti-C5a antibody (3mg/kg) were not spared from hC5a-induced neutropenia, the mice nonetheless had a significant reduction in plasma hC5a (3130.40 ± 433.58 ng/mL at 1 minute; 1932.00 ± 268.92 ng/mL at 3 minutes; 1593.00 ± 169.68 ng/mL at 5 minutes) as compared to plasma hC5a levels found in isotype control antibody-treated mice ($P < 0.05$). See Fig. 8. These data indicated that administration of anti-C5a antibody to mice significantly decreased the concentration of free hC5a in plasma, resulting in greatly ameliorated hC5a-induced neutropenia.

[0399] Taken together, these results presented in this section indicated that an anti-human C5a antibody described herein can inhibit the biological effect of human C5a in an *in vivo* disease setting and provide strong evidence that the antibodies (and antigen-binding fragments thereof) are useful in, among other things, treating or preventing complement-associated disorders such as any of those recited herein.

Example 14. Anti-human C5a antibody crossreacts with C5a from non-human primates

[0400] Several humanized anti-hC5a antibodies were tested for their ability to crossreact with C5a from one or more non-human mammalian species. As noted above, the benefits of such an anti-C5a antibody are numerous, e.g., the ability of a research or medical practitioner to model the efficacy of a therapeutic anti-C5a antibody in a non-human disease model prior to administering the antibody to humans. Testing in non-human mammals can also allow for determination or approximation of the appropriate dosage of an anti-C5a antibody required for efficacy in humans.

[0401] Briefly, BNJ369, BNJ366, BNJ364, and BNJ383 (described above) were evaluated to determine whether they could co-immunoprecipitate C5a protein in the activated serum from several non-human primates including baboon, rhesus macaque, and cynomolgus macaque. The serum was activated by addition of zymosan. Following an overnight incubation of each antibody with activated serum, the antibodies were separated from the solution phase using protein A-conjugated agarose beads. The beads were washed thoroughly and then boiled in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer containing β -mercaptoethanol. The boiled samples were then subjected to SDS-PAGE. Non-human primate C5a was detected by western blot using the commercially-available anti-C5a neopeptide antibody #2942 (Abeam, Cambridge, MA). Each of the antibodies tested was capable of immunoprecipitating C5a (or C5a desarg) from baboon, rhesus macaque, and cynomolgus macaque indicating that the antibody is crossreactive with C5a from, these species as well as with human C5a.

[0402] The determination of binding affinity parameters to cynomolgus macaque C5a was determined as described above. Briefly, the BNJ383 antibody was screened against 3-4 concentrations of recombinant cynomolgus macaque C5a (antigen) using a capture technique as described above. The antibody was captured by an Anti-Fc (human) directly immobilized on a CM5 sensor chip with various concentrations in the range from 0.6 nM to 5.9 nM of cynomolgus C5a passed over the sensor chip surface. The surface was regenerated with 20 mM HCl, 0.02% surfactant P20 (Biacore) after each cycle to remove bound antibody and antigen. The data was evaluated using Biacore BIAevaluation software using a 1:1 Langmuir Model Fit (Rmax:Global Fit; RI:Local Fit). These experiments were for screening purposes with a minimal number of analyte concentrations (3 to 4) with 1 duplicate. The approximate K_D of the antibody for cynomolgus macaque C5a is 3.3 nM. See Table 10.

Table 10. Affinity Determination for non-Human C5a Proteins

Species	k_a (1/Ms) ($\times 10^6$)	k_d (1/s) ($\times 10^{-4}$)	K_D (M) ($\times 10^{-12}$)	χ^2
Human	0.77	8.32	108	1.23
Cynomolgus macaque	1.28	42.3	3300	1.45
Mouse	2.8	10.6	379*	2.38
*This is only an approximation of the K_D based on the quality of the curve fit.				

[0403] The BNJ383 antibody was also screened against 3-4 concentrations of recombinant mouse C5a (antigen) using a capture technique as described above to determine its affinity for mouse protein. The antibody was captured, as described above, by an anti-Fc (human) directly immobilized on a CM5 sensor chip with various concentrations in the range from 0.6 nM to 5.9 nM of mouse C5a passed over the sensor chip surface. The surface was regenerated with 20 mM HCl, 0.02% P20 after each cycle to remove bound antibody and antigen. The data were evaluated using Biacore BIAevaluation software using a 1:1 Langmuir Model Fit (Rmax:Global Fit; RI:Local Fit).

[0404] The above results indicated that several of the humanized anti-hC5a antibodies described herein are crossreactive with C5a from several non-human primate species including cynomolgus macaque, rhesus macaque, and baboon. The BNJ383 antibody; e.g., also crossreacts with mouse C5a. Furthermore, the results described in this section indicate that an anti-human C5a antibody, such as BNJ383, is useful not only in clinical applications for treating complement-associated disorders, but also in a variety of pre-clinical applications in non-human mammals, which are necessary for, or supportive of, approval of clinical use in humans.

Example 15. Competition for binding to C5a

[0405] An experiment was performed to evaluate the binding of an anti-C5a antibody described herein, BNJ383, in the presence of potentially competitive antigens. Briefly, ruthenium-labeled BNJ383 (250 pM) was incubated for two hours at room temperature with 1 nM biotinylated C5a, along with various concentrations (e.g., 400, 133, 44.4, 14.8, 4.9, 1.6, and 0.5 nM) of one of the following: (a) human C5a desarg protein in phosphate-buffered saline, (b) human plasma, (c) cynomolgus macaque plasma, (d) Balb/C (mouse) plasma, or (e) DBA/2J (mouse) plasma. With respect to the plasma components (b), (c), (d), and (e), the concentration refers to the approximate final concentration of C5 antigen in the incubation mixture.

[0406] Following the incubation period, the samples were contacted to respective individual wells of a streptavidin-coated assay plate under conditions that allowed for the binding of biotinylated C5a to the streptavidin in the wells of the plate. The wells were washed thoroughly to remove unbound material. The amount of binding of BNJ383 to C5a in the presence of competitor was determined by detecting the amount of signal produced from the detectable ruthenium label. The results are shown in Fig. 9.

[0407] Whereas human C5a desarg was an effective competitor, there was virtually no competition observed in the presence of mouse serum (17% reduction in detectable signal observed at approximately a 400:1 ratio of Balb/C mouse plasma-derived C5 to biotinylated human C5a and 25% reduction in detectable signal observed at approximately a 400:1 ratio of DBA/2J plasma-derived C5 to biotinylated human C5a). No change in the level of binding of BNJ383 to biotinylated human C5a was observed at up to approximately a 15:1 ratio of human or cynomolgus macaque plasma-derived C5 to biotinylated human C5a.

[0408] As noted above, while the disclosure is in no way limited to any particular theory or mechanism of action, the inventors hypothesize that the anti-C5a antibody may bind to a subpopulation of uncleaved, processed C5 (e.g., plasma C5) constituting less than 10% of the total population of full length C5 in a sample (e.g., a plasma sample), which subpopulation is in whole or in part denatured such that an otherwise occluded C5a neoepitope, to which the anti-C5a antibody or fragment binds, is exposed. Thus, it is believed that the antibody does not bind to a fully functional and/or fully functional species of C5 and thus does not truly bind to uncleaved, native C5. Human plasma is at least an approximately 30 to 100-fold weaker competitor for binding to biotinylated C5a than human C5a desarg.

[0409] Notwithstanding these considerations, these results further indicate that anti-human C5a antibodies described herein, such as BNJ383, preferentially bind to free human C5a even in the presence of up to approximately 20-fold excess of uncleaved, but not necessarily entirely native, plasma-derived human C5 protein.

Example 16. Effect of anti-C5a antibody on AP and CP activity *in vitro*

[0410] An experiment was performed to evaluate the effect of an anti-C5a antibody described herein (BNJ383) on alternative pathway (AP) complement activity *in vitro* using pooled normal human serum (PNHS). The experiment utilized the Wieslab® Alternative Pathway Complement Kit (Wieslab® COMPL AP330, Euro-Diagnostica, Sweden) and the associated protocol was followed with only routine optimization well within the purview of one of ordinary skill in the art. Briefly aliquots of the PNHS were incubated in wells of a lipopolysaccharide-coated plate for one hour (at 37°C) along with various concentrations (0.778, 0.389, 0.194, 0.097, 0.049, 0.024, 0.012, 0.006, 0.003, and 0.002 µM) of an anti-hC5 antibody or an anti-hC5a antibody (BNJ383). The anti-C5 antibody inhibits the cleavage of human C5 into fragments C5a and C5b; As a negative control, several wells were incubated with PNHS under the same conditions, but in the absence of anti-hC5 antibody or anti-hC5a antibody.

[0411] Following the incubation, the wells were washed thoroughly with kit-supplied 1X wash buffer. The level of alternative pathway complement activation was measured by absorbance at 405 nm, following contact of each well with a kit-supplied enzyme conjugate (an anti-C5b-9 antibody conjugated to alkaline phosphatase) and fluorogenic substrate (which is operated upon by the enzyme) and incubation for 30 minutes at room temperature. The results are shown in Fig. 10.

[0412] While the anti-C5 antibody inhibited alternative pathway complement activity completely at concentrations greater than 0.1 µM, the anti-hC5a antibody did not significantly inhibit complement activity even at the highest concentration tested.

[0413] An experiment was performed to evaluate the effect of an anti-C5a antibody described herein (BNJ383) on classical pathway (CP) complement activity *in vitro* using PNHS. The experiment utilized the Wieslab® Classical Pathway Complement Kit (Wieslab® COMPL CP310, Euro-Diagnostica, Sweden) and the associated protocol was followed with only routine optimization well within the purview of the ordinarily-skilled artisan. Briefly aliquots of the PNHS were incubated in wells of a human IgM antibody-coated plate for one hour (at 37°C) along with various concentrations (7.2, 3.6, 1.8, 0.9, 0.45, 0.2, 0.1, 0.05, 0.02, or

0.01 μ M) of an anti-hC5 antibody or an anti-hC5a antibody (BNJ383). The anti-C5 antibody inhibits the cleavage of human C5 into fragments C5a and C5b. As a control, several wells were incubated with PNHS under the same conditions, but in the absence of anti-hC5 antibody or anti-hC5a antibody.

[0414] Following the incubation, the wells were washed thoroughly with kit-supplied 1X wash buffer. The level of alternative pathway complement activation was measured by absorbance at 405 nm, following contact of each well with a kit-supplied enzyme conjugate (an anti-C5b-9 antibody conjugated to alkaline phosphatase) and fluorogenic substrate (which is operated upon by the enzyme) and incubation for 30 minutes at room temperature. The results are shown in Fig. 11.

[0415] While the anti-C5 antibody inhibited classical pathway complement activity completely at concentrations greater than 0.1 μ M, the anti-hC5a antibody did not significantly inhibit complement activity even at the highest concentration tested.

[0416] Taken together, these results indicate that, *in vitro*, the anti-hC5a antibody, BNJ383, did not significantly affect C5b-9 generation (terminal complement activation) driven by either the classical or alternative pathway of complement, thus giving further evidence that the anti-hC5a antibodies described herein specifically target the free C5a anaphylatoxin arm of complement activation.

Example 17. Anti-C5a antibody retains an unoccupied antigen-binding site available to bind to C5a even in the presence of a molar excess of hC5

[0417] The anti-C5a antibody BNJ383 (set forth above) was incubated at 4 °C for 84 hours in the presence of a 2.1-fold molar excess of human C5 (hC5) to allow for complete antibody C5 complex formation. A parallel experiment was performed using an antibody that binds to human C5 at a 2:1 stoichiometry (hereinafter the anti-C5 antibody). Antibody:C5 complexes were resolved on a TSK™ G4000 SW size exclusion column (Tosoh, Tokyo) using a Waters™ 2690/5 HPLC system with a Waters™ W2487 dual wavelength detector to determine the occupancy of binding sites. Peaks were monitored at a wavelength of 214 nm. The mobile phase for the HPLC analysis contained the following buffer composition: 3.9 mM NaH₂PO₄, 6.1 mM Na₂HPO₄, an 150 mM NaCl, at pH7.0. The flow rate was 1.0 ml per minute and the run time was 20 minutes. Data were acquired and analyzed with Waters Empower™ 2 chromatography software.

[0418] As depicted in Fig. 12, BNJ383 alone (Fig. 12A) and hC5 alone (Fig. 12B) each resolve as a single peak centered around 10.2 minutes and > 95% of the anti-C5a antibody:hC5 complexes resolve as a single peak centered around 9.2 minutes (Figure 12C). In contrast, complexes of hC5 and the anti-C5 antibody resolve in two peaks centered at 8.6 min (39%) and 9.2 min (61%) (Fig. 12D). Thus, even in a molar excess of hC5, 95.2% of the BNJ383 has a free Fab arm that may be capable of binding to human C5a.

[0419] These samples were further examined to determine if the BNJ383 antibody retained the ability to bind C5a in the presence of saturating concentrations of C5. Free antibody or antibody:C5 complexes were titrated from 500 to 0.5 ng/mL on a streptavidin coated plate to which biotin conjugated hC5a was immobilized. Captured antibody was detected with an anti-human Fc antibody conjugated to horse radish peroxidase. The results depicted in Fig. 13 demonstrate that even BNJ383 complexed with hC5 is capable of binding C5a and that the concentration of antibody available to bind C5a is not detectably diminished in the presence of saturating C5. Thus, the results described herein indicate that the antibody, even in the presence of a molar excess of uncleaved C5, retains the ability to bind to free C5a with high affinity and thereby retains, even in that molar excess, the ability to inhibit the pro-inflammatory activity of C5a.

Examples 18. BNJ383 is a potent antagonist of C5a but is an incomplete/partial antagonist of terminal complement complex formation *in vivo*

[0420] Cynomolgus macaques were administered intravenously a single dose of the BNJ383 anti-C5a antibody at 1 mg/kg, 10 mg/kg, 100 mg/kg 250 mg/kg or 400 mg/kg. Plasma samples were collected from the macaques at time points ranging from 1 day to 30 days following the administration of the antibody. Levels of C5a/C5a desarg in plasma were determined by an electrochemiluminescent (ECL) assay in which a free C5a/C5a desarg was captured on a microtiter plate coated with an antibody specific for a neopeptide on C5a/C5a desarg and detected with a non-competitive C5a antibody conjugated to a ruthenate containing ECL moiety and read on a SECTOR 2400™ plate reader (MesoScale Discovery). Circulating antibody concentrations were determined by and enzyme linked immunosorbent assay (ELISA) in which free antibody (BNJ383) was captured on a microtiter plate coated with human C5a desarg and detected with a mouse anti-human antibody conjugated to horseradish

peroxidase (HRP).

[0421] As shown in Fig. 14, like the results described in Example 13, circulating concentrations of BNJ383 as low as 10 µg/mL deplete plasma C5a/C5a desarg levels to below detectable limits in cynomolgus monkeys. These results also underscore that the antibody, even in the presence of a molar excess of uncleaved C5, retains the ability to bind to free C5a with high affinity and thereby retains, even in that molar excess, the ability to inhibit the pro-inflammatory activity of C5a.

[0422] To determine whether BNJ383 had an effect on hemolytic activity of macaque serum, the antibody was evaluated in an *in vitro* red blood cell hemolysis assay.

[0423] The red blood cell hemolysis assay is generally described in detail in, e.g., Rinder et al. (1995) J Clin Invest 96:1564-1572. Briefly, serum samples obtained from macaques administered BNJ383 (as described above) were added to multiple wells of a 96 well assay plate such that the concentration of the serum in each well was approximately 10%. The serum samples, by virtue of the time points in which they were obtained, contained various concentrations of the BNJ383 antibody. The hemolytic activity of serum from macaques not receiving BNJ383 served as a negative control and as the baseline hemolytic activity level.

[0424] Chicken erythrocytes (Lampire Biological Laboratories, Piperville, PA) were washed and resuspended in buffer at a final concentration of 5×10^7 cells/mL. The erythrocytes were sensitized to lysis by incubating the cells with an anti-chicken red blood cell polyclonal antibody composition. The sensitized erythrocytes were added to the wells of the 96 well plate and the plate was incubated at 37°C for 30 minutes. Hemoglobin release was measured by apparent absorbance at 415 nm, using a microplate reader.

[0425] As shown in Fig. 15A, even high concentrations of BNJ383 did not substantially inhibit erythrocyte hemolysis under these *ex vivo* hemolytic assay experimental conditions.

[0426] The BNJ383 antibody was also evaluated to determine if it had an effect on complement activation of macaque serum using an *ex vivo* CH50eq assay. The CH50eq assay is a method for measuring the total classical complement activity in serum. This test is an enzyme linked immunosorbent assay, which uses human gammaglobulins and mouse monoclonal antibodies as the activator of the classical complement pathway and captures the terminal complement complex (TCC) generated on a microtiter well coated with a TCC neoepitope specific antibody. Captured TCC is detected with a goat anti-TCC antibody conjugated to horse radish peroxidase. The CH50eq assay provides a direct measure of terminal complement complex (TCC) formation.

[0427] As shown in Fig. 15B, high concentrations of BNJ383 present in the macaque serum were capable of substantially inhibiting TCC formation under these *ex vivo* conditions. These results indicate that the BNJ383 antibody is not only capable of binding to and sequestering free C5a but is also capable of, as a function of concentration, partially or substantially inhibiting TCC formation.

[0428] An *ex vivo* experiment was also performed to evaluate the effect of BNJ383 on classical pathway (CP) complement activity using the macaque serum samples described above. The experiment utilized the Wieslab® Classical Pathway Complement Kit (Wieslab® COMPL CP310, Euro-Diagnostica, Sweden) and the associated protocol was followed with only routine optimization well within the purview of the ordinarily-skilled artisan. Briefly aliquots of the macaque serum samples were incubated in wells of a human IgM antibody-coated plate for one hour. As a control, several wells were incubated under the same conditions with serum from macaques not administered the BNJ383 antibody.

[0429] Following the incubation, the wells were washed thoroughly with kit-supplied 1X wash buffer. The level of alternative pathway complement activation was measured by absorbance at 405 nm, following contact of each well with a kit-supplied enzyme conjugate (an anti-C5b-9 antibody conjugated to alkaline phosphatase) and fluorogenic substrate (which is operated upon by the enzyme) and incubation for 30 minutes at room temperature. The results are shown in Fig. 15C.

[0430] The anti-hC5a antibody did significantly, though not completely, inhibit complement activity in a dose-dependent manner. Taken together, the results described herein indicate that BNJ383 is not only a potent antagonist of C5a, but is also an incomplete/partial antagonist of terminal complement complex formation *in vivo*. Thus, the antibody and antibodies sharing its properties are useful for treating a variety of complement-associated disorders in which C5a-mediated inflammation is the primary contributor to deleterious pathological effects and TCC may play a less significant or even beneficial role in the pathology.

[0431] While the present disclosure has been described with reference to the specific embodiments thereof, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted. In addition, many

modifications may be made to adapt a particular situation, material, composition of matter, process, process step or steps.

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- [US61330260A \[0001\]](#)
- [US61471465A \[0001\]](#)
- [US6355245B \[0008\]](#)
- [EP0245993A2 \[0016\]](#)
- [US20060153836A \[0169\]](#)
- [US20060160726A \[0195\]](#)
- [US6300064B \[0224\]](#)
- [WO9002809A \[0226\]](#)
- [WO9110737A \[0226\]](#)
- [WO9201047A \[0226\]](#)
- [WO9218619A \[0226\]](#)
- [WO9311236A \[0226\]](#)
- [WO9515982A \[0226\]](#)
- [WO9520401A \[0226\]](#)
- [US5698426A \[0226\]](#)
- [US5223409A \[0226\]](#)
- [US5403484A \[0226\]](#)
- [US5580717A \[0226\]](#)
- [US5427908A \[0226\] \[0226\]](#)
- [US5750753A \[0226\]](#)
- [US5821047A \[0226\]](#)
- [US5571698A \[0226\]](#)
- [US5516637A \[0226\]](#)
- [US5780225A \[0226\]](#)
- [US5658727A \[0226\]](#)
- [US5733743A \[0226\]](#)
- [US5969108A \[0226\]](#)
- [WO9222324A \[0236\]](#)
- [US4946778A \[0236\]](#)
- [US5258498A \[0236\]](#)
- [US4816567A \[0239\]](#)
- [WO93011237A \[0241\]](#)
- [US6995259B \[0242\]](#)
- [US6075181A \[0244\] \[0248\]](#)
- [US6114598A \[0244\] \[0248\]](#)
- [US6150564A \[0244\] \[0248\]](#)
- [US6162963A \[0244\] \[0248\]](#)
- [WO0243478A \[0244\]](#)
- [US6794132B \[0246\]](#)
- [US6680209B \[0246\]](#)
- [US4634666A \[0246\]](#)
- [US5939598A \[0248\]](#)
- [US6673986A \[0248\]](#)
- [US6713610A \[0248\]](#)

- [US6657103A \[0248\]](#)
- [US20030229905A1 \[0248\]](#)
- [US20040010810A1 \[0248\]](#)
- [US20040093622A1 \[0248\]](#)
- [US20060040363A1 \[0248\]](#)
- [US20050054055A1 \[0248\]](#)
- [US20050076395A1 \[0248\]](#)
- [US20050287630A1 \[0248\]](#)
- [WO9402602A \[0248\]](#)
- [WO9634096A \[0248\]](#)
- [WO9824893A \[0248\]](#)
- [EP0463151B1 \[0248\]](#)
- [US5545807A \[0249\]](#)
- [US5545806A \[0249\]](#)
- [US5625825A \[0249\]](#)
- [US5625126A \[0249\]](#)
- [US5633425A \[0249\]](#)
- [US5661016A \[0249\]](#)
- [US5770429A \[0249\]](#)
- [US5789650A \[0249\]](#)
- [US5814318A \[0249\]](#)
- [US5591669A \[0249\]](#)
- [US5612205A \[0249\]](#)
- [US5721367A \[0249\]](#)
- [US5789215A \[0249\]](#)
- [US5643763A \[0249\]](#)
- [US5569825A \[0249\]](#)
- [US5877397A \[0249\]](#)
- [US6300129B \[0249\]](#)
- [US5874299A \[0249\]](#)
- [US6255458B \[0249\]](#)
- [US7041871B \[0249\]](#)
- [EP0546073B1 \[0250\]](#)
- [WO9203918A \[0250\]](#)
- [WO9222645A \[0250\]](#)
- [WO9222647A \[0250\]](#)
- [WO9222670A \[0250\]](#)
- [WO9312227A \[0250\]](#)
- [WO9400569A \[0250\]](#)
- [WO9425585A \[0250\]](#)
- [WO9614436A \[0250\]](#)
- [WO9713852A \[0250\]](#)
- [WO9824884A \[0250\]](#)
- [WO04108158A \[0252\]](#)
- [WO0034317A \[0252\]](#)
- [WO02069232A \[0252\]](#)
- [WO9627011A \[0254\]](#)
- [US4676980A \[0254\]](#)
- [WO080241188A \[0257\]](#)
- [WO07024715A \[0257\]](#)
- [US5759808A \[0258\]](#)
- [WO0653301A \[0262\]](#)
- [US7704497B \[0262\]](#)
- [WO9428027A \[0264\]](#)
- [WO9847531A \[0264\]](#)
- [US6194551B \[0267\]](#)
- [WO9951642A \[0267\]](#)
- [WO9429351A \[0267\]](#)

- [US5648260A \[0267\]](#)
- [US5624821A \[0267\]](#)
- [WO05011735A \[0271\]](#)
- [US6001329A \[0287\]](#)
- [US6933368B \[0290\]](#)
- [US4485045A \[0295\]](#)
- [US4544545A \[0295\]](#)
- [US5013556A \[0295\]](#)
- [US20080202513A \[0297\]](#)
- [US7112341B \[0297\]](#)
- [US6019968A \[0297\]](#)
- [WO00061178A \[0297\]](#)
- [WO06122257A \[0297\]](#)
- [US20070235029A \[0297\]](#)
- [WO0069887A \[0297\]](#)
- [US5997843A \[0297\]](#)
- [US20020026176A \[0302\]](#)
- [US5443505A \[0302\]](#)
- [US5773019A \[0302\]](#)
- [US6001386A \[0302\]](#)
- [WO04073551A \[0302\]](#)
- [WO04060407A \[0303\]](#)
- [US4868116A \[0303\]](#)
- [US4980286A \[0303\]](#)
- [WO8907136A \[0303\]](#)
- [WO8902468A \[0303\]](#)
- [WO8905345A \[0303\]](#)
- [WO9207573A \[0303\]](#)
- [US20080241223A \[0315\]](#)
- [US5501856A \[0315\]](#)
- [US4863457A \[0315\]](#)
- [US3710795A \[0315\]](#)
- [EP488401A \[0315\]](#)
- [EP430539A \[0315\]](#)
- [WO04026380A \[0320\]](#)
- [WO04024156A \[0320\]](#)
- [WO0178693A \[0320\]](#)
- [US6170717B \[0320\]](#)
- [US5447150A \[0320\]](#)
- [US6095141A \[0320\]](#)
- [US20050271660A \[0321\]](#)
- [US20090110679A \[0321\]](#)
- [US6302855B \[0322\]](#)
- [US5308341A \[0323\]](#)
- [US6192691B \[0325\]](#)
- [US6277099B \[0326\]](#)
- [US6200296B \[0326\]](#)
- [US6146361A \[0326\]](#)
- [US7556615B \[0327\]](#)
- [US20070172483A \[0343\]](#)
- [US6065645A \[0356\]](#)
- [US6698622B \[0356\]](#)
- [US7393648B \[0363\]](#)

Non-patent literature cited in the description

- The Merck Manual [0003]
- HAVILAND et al. J Immunol, 1991, vol. 146, 362-368 [0008]
- MINTAMANJ Immunol, 1997, vol. 119, 1597-1602 [0011]
- WETSELKOLBJ Immunol, 1982, vol. 128, 2209-2216 [0011]
- YAMAMOTOGEWURZJ Immunol, 1978, vol. 120, 2008- [0011]
- DAMERAU et al. Molec Immunol, 1989, vol. 26, 1133-1142 [0011]
- LARRIC et al. Infection and Immunity American Society for Microbiology, USA 19870000 vol. 55, 1867-1872 [0016]
- RAWALPANGBURNJ Immunol, 2001, vol. 166, 42635-2642 [0020]
- HAENEY et al. Clin Exp Immunol, 1980, vol. 40, 16-24 [0021]
- BRODSKY Blood, 2009, vol. 113, 266522-6527 [0021]
- POLJAK Structure, 1994, vol. 2, 121121-1123 [0158]
- HUDSON et al. J Immunol Methods, 1999, vol. 23, 1-2177-189 [0158]
- SCHOONOOGHE et al. BMC Biotechnol, 2009, vol. 9, 70- [0158]
- HOLT et al. Trends Biotechnol, 2003, vol. 21, 11484-490 [0158]
- HUSTON et al. Hum Antibodies, 2001, vol. 10, 3-4127-142 [0158]
- WHEELER et al. Mol Ther, 2003, vol. 8, 3355-366 [0158]
- STOCKS Drug Discov Today, 2004, vol. 9, 22960-966 [0158]
- Epitope Mapping Pharmacia BIA technology Handbook 19940500 [0170]
- JOHNE et al. J Immunol Methods, 1993, vol. 160, 20191-8 [0170]
- KABAT et al. Sequences of Proteins of Immunological Interest NIH Publication No. 91-324219910000 [0172]
- CHOTHIA et al. Nature, 1989, vol. 342, 877-883 [0172]
- HONNEGGERPLÜCKTHUNJ Mol Biol, 2001, vol. 309, 657-670 [0172]
- THOMAS et al. Mol Immunol, 1996, vol. 33, 17/181389-1401 [0172]
- BURTON et al. Adv Immun, 1992, vol. 51, 1-18 [0184] [0263]
- CANFIELD et al. J Exp Med, 1991, vol. 173, 1483-1491 [0184]
- MUELLER et al. Mol Immunol, 1997, vol. 34, 6441-452 [0184] [0263]
- WARDZVAIFLERJ Clin Invest, 1971, vol. 50, 3606-16 [0190]
- WURZNER et al. Complement Inflamm, 1991, vol. 8, 328-340 [0190]
- Experimental Immunochimistry CC Thomas 19910000135-139 [0191]
- HILLMEN et al. N Engl J Med, 2004, vol. 350, 6552- [0191]
- MARYBOULAY Eur J Haematol, 1993, vol. 51, 5282-287 [0195]
- KANEKO et al. Immunology, 1995, vol. 86, 1149-154 [0195]
- GIANNINI et al. J Biol Chem, 1995, vol. 270, 3219166-19172 [0195]
- WARDJ Mol Med, 2009, vol. 87, 4375-378 [0196]
- CHEN et al. Nature, 2007, vol. 446, 7132203-207 [0196]
- HARLOWLANE Antibodies: A Laboratory Manual Cold Spring Harbor Laboratory Press 19880000 [0204]
- BENNY K. C. LO Antibody Engineering: Methods and Protocols Humana Press 20040000 [0204]
- BORREBAEK Antibody Engineering, A Practical Guide W. H. Freeman, and Co. 19920000 [0204]
- BORREBAEK Antibody Engineering Oxford University Press 19950000 [0204] [0241]
- JOHNE et al. Immunol Meth, 1993, vol. 160, 191-198 [0204]
- JONSSON et al. Ann Biol Clin, 1993, vol. 51, 19-26 [0204]
- JONSSON et al. Biotechniques, 1991, vol. 11, 620-627 [0204]
- LEVYLADDANat New Biol, 1971, vol. 229, 251-52 [0221]
- CROCKER et al. J Clin Pathol, 1974, vol. 27, 2122-124 [0221]
- WETSEL et al. J Biol Chem, 1990, vol. 265, 2435-2440 [0221]
- JUNGPEPYS Immunology, 1981, vol. 43, 2271-279 [0221]
- MCCARTHYHENSONJ Immunol, 1979, vol. 123, 62511-2517 [0221]
- MANDERINO et al. J Immunol Methods, 1982, vol. 53, 141-50 [0221]
- VALLOTAMÜLLER-EBERHARDJ Exp Med, 1973, vol. 137, 1109- [0221]
- TOTHE et al. Prot Sci, 1994, vol. 3, 1159-1168 [0221]
- BIEG et al. Autoimmunity, 1999, vol. 31, 115-24 [0222]
- LODMELL et al. Vaccine, 2000, vol. 18, 1059-1066 [0222]
- JOHNSON et al. J Med Chem, vol. 42, 144640-4649 [0222]
- BALDRIDGE et al. Methods, 1999, vol. 19, 103-107 [0222]
- GUPTA et al. Vaccine, 1995, vol. 13, (14)1263-1276 [0222]

- **SCHOONBROODT et al.** Nucleic Acids Res, 2005, vol. 33, 981- [0224]
- **ETZ et al.** J Bacteriol, 2001, vol. 183, 6924-6935 [0225]
- **COMELIS** Curr Opin Biotechnol, 2000, vol. 11, 450-454 [0225]
- **KLEMM et al.** Microbiology, 2000, vol. 146, 3025-3032 [0225]
- **KIEKE et al.** Protein Eng, 1997, vol. 10, 1303-1310 [0225]
- **YEUNG et al.** Biotechnol Prog, 2002, vol. 18, 212-220 [0225]
- **BODER et al.** Methods Enzymology, 2000, vol. 328, 430-444 [0225]
- **GRABHERR et al.** Comb Chem High Throughput Screen, 2001, vol. 4, 185-192 [0225]
- **MICHAEL et al.** Gene Ther, 1995, vol. 2, 660-668 [0225]
- **PEREBOEV et al.** J Virol, 2001, vol. 5, 7107-7113 [0225]
- **SCHAFFITZEL et al.** J Immunol Methods, 1999, vol. 231, 119-135 [0225]
- **HANES et al.** Nat Biotechnol, 2000, vol. 18, 1287-1292 [0225]
- **SHI et al.** JMB, 2010, vol. 397, 385-396 [0226]
- **BRINKMAN et al.** J Immunol Methods, 1995, vol. 182, 41-50 [0226]
- **AMES et al.** J Immunol Methods, 1995, vol. 184, 177-186 [0226]
- **KETTLEBOROUGH et al.** Eur J Immunol, 1994, vol. 24, 952-958 [0226]
- **PERSIC et al.** Gene, 1997, vol. 187, 9-18 [0226]
- **BURTON et al.** Advances in Immunology, 1994, vol. 57, 191-280 [0226]
- **SAMBROOK et al.** Molecular Cloning: A Laboratory Manual Cold Spring Harbor Laboratory Press 1989 0000 [0227]
- **MERZ et al.** J Neurosci Methods, 1995, vol. 62, 1-2213-9 [0227]
- **DI NIRO et al.** Biochem J, 2005, vol. 388, 889-894 [0227]
- **ENGBERGET** Methods Mol Biol, 1995, vol. 51, 355-376 [0227]
- **HOOGENBOOM** Trends in Biotechnology, 1997, vol. 15, 62-70 [0228]
- **CHASTEEN et al.** Nucleic Acids Res, 2006, vol. 34, 21145- [0228]
- **MULLETT et al.** Methods, 2000, vol. 22, 77-91 [0234]
- **DONG et al.** Reviews in Mol Biotech, 2002, vol. 82, 303-323 [0234]
- **FIVASH et al.** Curr Opin Biotechnol, 1998, vol. 9, 97-101 [0234]
- **RICH et al.** Curr Opin Biotechnol, 2000, vol. 11, 54-61 [0234]
- **MULLINAX et al.** BioTechniques, 1992, vol. 12, 6864-869 [0236]
- **SAWAI et al.** Am J Repr Immunol, 1995, vol. 34, 26-34 [0236]
- **BETTER et al.** Science, 1988, vol. 240, 1041-1043 [0236]
- **HUSTON et al.** Methods in Enzymology, 1991, vol. 203, 46-88 [0236]
- **SHU et al.** Proc Natl Acad Sci USA, 1993, vol. 90, 7995-7999 [0236]
- **SKERRA et al.** Science, 1988, vol. 240, 1038-1040 [0236]
- **GLASER et al.** J Immunol, 1992, vol. 149, 3903-3913 [0237]
- **JONES et al.** Nature, 1986, vol. 321, 522-525 [0240]
- **RIECHMANN et al.** Nature, 1988, vol. 332, 323-327 [0240] [0241]
- **VERHOEYEN et al.** Science, 1988, vol. 239, 1534-1536 [0240]
- **STAELENS et al.** Mol Immunol, 2006, vol. 43, 1243-1257 [0240]
- **JONES et al.** Nature, vol. 321, 522-525 [0241]
- **VERHOEYEN et al.** Science, 1988, vol. 239, 48471534-1536 [0241]
- **QUEEN et al.** Proc Natl Acad Sci USA, 1989, vol. 86, 10029-10033 [0241]
- **KETTLEBOROUGH et al.** Protein Engineering, Design and Selection, 1991, vol. 4, 773-783 [0241]
- **BENNY K. C. LO** Antibody Engineering: Methods and Protocols Humana Press [0241]
- **BORREBAEK** Antibody Engineering, A Practical Guide W.H. Freeman and Co. 1992 0000 [0241]
- **DAUGHERTY et al.** Nucleic Acids Res, 1991, vol. 19, 92471-2476 [0241]
- **ROGUSKA et al.** Protein Engineering, 1996, vol. 9, 10895-904 [0241]
- **YAZAKI et al.** Protein Engineering" Design & Selection, 2004, vol. 17, 5481-489 [0241]
- **SHIRAISHI et al.** Nucleic Acids Symposium Series, 2007, vol. 51, 1129-130 [0242]
- **JAKOBOVITS et al.** Proc Natl Acad Sci USA, 1993, vol. 90, 2551- [0244]
- **JAKOBOVITS et al.** Nature, 1993, vol. 362, 255-258 [0244]
- **BRUGGEMANN et al.** Year in Immunol., 1993, vol. 7, 33- [0244]
- **DUCHOSAL et al.** Nature, 1992, vol. 355, 258- [0244]
- **LONBERG et al.** Nature, 1994, vol. 368, 6474856-859 [0244]
- **TAYLOR et al.** Nucleic Acids Res, 1992, vol. 20, 6287-6295 [0244]
- **CHEN, J. et al.** International Immunology, 1993, vol. 5, 647-656 [0244]
- **TUAILLON et al.** Proc Natl Acad Sci USA, 1993, vol. 90, 3720-3724 [0244]
- **CHOI et al.** Nature Genetics, 1993, vol. 4, 1 17-123 [0244]

- **TUAILLON et al.**J Immunol, 1994, vol. 152, 2912-2920 [0244]
- **TAYLOR et al.**International Immunology, 1994, vol. 6, 579-591 [0244] [0251]
- **FISHWILD et al.**Nature Biotechnol, 1996, vol. 14, 845-851 [0244]
- **TOMIZUKA et al.**Proc Natl Acad Sci USA, 2000, vol. 97, 722-727 [0244]
- **HOOGENBOOM et al.**J Mol Biol, 1992, vol. 227, 381- [0246]
- **MARKS et al.**J Mol Biol, 1991, vol. 222, 581-597 [0246]
- **VAUGHAN et al.**Nature Biotech, 1996, vol. 14, 309- [0246]
- **OSTBERG et al.**Hybridoma, 1983, vol. 2, 361-367 [0246]
- **MENDEZ et al.**Nature Genetics, 1998, vol. 15, 146-156 [0247]
- **GREENJAKOBOVITSJ** Exp Med, 1998, vol. 188, 483-495 [0247]
- **TAYLOR et al.**Nucleic Acids Res, 1992, vol. 20, 6287- [0251]
- **CHEN et al.**Int Immunol, 1993, vol. 5, 647- [0251]
- **TUAILLON et al.**Proc Natl Acad Sci USA, 1993, vol. 90, 3720-4 [0251]
- **CHOI et al.**Nature Genetics, 1993, vol. 4, 117- [0251]
- **LONBERG et al.**Nature, 1994, vol. 368, 856-859 [0251]
- **TUAILLON et al.**J. Immunol, 1995, vol. 154, 6453-65 [0251]
- **FISHWILD et al.**Nature. Biotechnology, 1996, vol. 14, 845- [0251]
- **TUAILLON et al.**EurJImmunol., 2000, vol. 10, 2998-3005 [0251]
- **MILSTEINCUELLO**Nature, 1983, vol. 305, 537-539 [0254]
- **SURESH et al.**Methods in Enzymology, 1986, vol. 121, 210- [0254]
- **BRENNAN et al.**Science, 1985, vol. 229, 81- [0254]
- **SHALABY et al.**J Exp Med, 1992, vol. 175, 217-225 [0254]
- **KOSTELNY et al.**J Immunol, 1992, vol. 148, 51547-1553 [0254] [0255]
- **HOLLINGER et al.**Proc Natl Acad Sci USA, 1993, vol. 90, 6444-6448 [0254] [0255]
- **GRUBER et al.**J Immunol, 1994, vol. 152, 5368- [0254] [0255]
- **TUTT et al.**J Immunol, 1991, vol. 147, 60- [0254] [0256]
- **ZAPATA et al.**Protein Eng., 1995, vol. 8, 101057-1062 [0255]
- **WU et al.**Nat Biotechnol, 2007, vol. 25, 111290-1297 [0257]
- **STIJLEMANS et al.**J Biol Chem, 2004, vol. 279, 1256-1261 [0258]
- **DUMOULIN et al.**Nature, 2003, vol. 424, 783-788 [0258]
- **PLESCHBERGER et al.**Bioconjugate Chem, 2003, vol. 14, 440-448 [0258]
- **SAMBROOK et al.**Molecular Cloning: A Laboratory ManualCold Spring Harbor Laboratory Press19890000 [0262]
- **CANFIELD et al.**J Exp Med, 1991, vol. 173, 1483-1491 [0263]
- **XU et al.**Cell Immunol, 2000, vol. 200, 16-26 [0264]
- **HEZAREH METAL**J Virol, 2001, vol. 75, 12161-12168 [0264]
- **SHIELDS et al.**J Biol Chem, 2001, vol. 276, 96591-6604 [0265]
- **BAUDINO et al.**J Immunol, 2008, vol. 181, 6664-6669 [0265]
- **KLEIN et al.**Proc-Natl Acad Sci USA, 1981, vol. 78, 524-528 [0266]
- **CARON et al.**J Exp Med, 1992, vol. 176, 1191-1195 [0267]
- **SHOPES**Immunol, 1992, vol. 148, 2918-2922 [0267]
- **DUNCANWINTER**Nature, 1988, vol. 322, 738-40 [0267]
- **RAJU**BioProcess International, 2003, vol. 1, 444-53 [0268]
- **WRIGHTMORRISON**the microheterogeneity of human IgG oligosaccharides can affect biological functions such as CDC and ADCC, binding to various Fc receptors, and binding to Clq proteinTIBTECH, 1997, vol. 15, 26-32 [0268]
- **ISRAEL et al.**Immunology, 1996, vol. 89, 4573-578 [0268]
- **NEWKIRK et al.**Clin Exp Immunol, 1996, vol. 106, 2259-264 [0268]
- **SHIELDS et al.**have shown that IgG, with alterations in amino acid sequence that have improved binding to FcγR, can exhibit up to 100% enhanced ADCC using human effector cellsJ Biol Chem, 2001, vol. 276, 96591-6604 [0268]
- **SHIELDS et al.**J Biol Chem, 2002, vol. 277, 3026733-26740 [0268]
- **SHINKAWA et al.**J Biol Chem, 2003, vol. 278, 53466-73 [0269]
- **UMANA et al.**who changed the glycosylation pattern of chCE7, a chimeric IgG1 anti-neuroblastoma antibodyNat Biotechnol, 1999, vol. 17, 2176-180 [0270]
- **WRIGHTMORRISON**produced antibodies in a CHO cell line deficient in glycosylation and showed that antibodies produced in this cell line were incapable of complement-mediated cytolysisJ Exp Med, 1994, vol. 180, 1087-1096 [0270]
- **MULLIGANBERG**Proc Natl Acad Sci USA, 1981, vol. 78, 2072- [0273]
- **SOUTHERNBERG**Mol. Appl Genet, 1982, vol. 1, 327- [0273]
- **WIGLER et al.**Cell, 1979, vol. 16, 77- [0273]

- **SARVER et al.**Proc. Natl Acad Sci USA, 1982, vol. 79, 7147- [0273]
- **DEANS et al.**Proc Natl Acad Sci USA, 1984, vol. 81, 1292- [0273]
- **LUSKYBOTCHAN**Nature, 1982, vol. 293, 79- [0273]
- **HOUEBINE**Curr Opin Biotechnol, 2002, vol. 13, 6625-629 [0276]
- **VAN KUIK-ROMEIJN et al.**Transgenic Res, 2000, vol. 9, 2155-159 [0276]
- **POLLOCK et al.**J Immunol Methods, 1999, vol. 231, 1-2147-157 [0276]
- **HOU et al.**Cytokine, 1998, vol. 10, 319-30 [0277]
- **Current Protocols in Molecular Biology**Wiley & Sons [0277]
- **Molecular Cloning A Laboratory Manual**Cold Spring Harbor Laboratory Press20010000 [0277]
- **KASZUBSKA et al.**Protein Expression and Purification, 2000, vol. 18, 213-220 [0277]
- **ROGERS et al.**J Nucl Med, 1997, vol. 38, 1221-1229 [0287]
- **WELCHREDVANLY**Handbook of Radiopharmaceuticals: Radiochemistry and ApplicationsJohn Wiley and Sons20030000 [0288]
- **LEE et al.**Bioconj Chem, 1999, vol. 10, 6973-8 [0289]
- **KINSTLER et al.**Advanced Drug Deliveries Reviews, 2002, vol. 54, 477-485 [0289]
- **ROBERTS et al.**Advanced Drug Delivery Reviews, 2002, vol. 54, 459-476 [0289]
- **PAVISIĆ et al.**Int J Pharm, 2010, vol. 387, 1-2110-119 [0289]
- **WRIGHT et al.**EMBO J, 1991, vol. 10, 102717-2723 [0290]
- **CO et al.**Mol Immunol, 1993, vol. 30, 1361- [0290]
- **BERGE et al.**J Pharm Sci, 1977, vol. 66, 1-19 [0291]
- **GENNAM**Remington: The Science and Practice of PharmacyLippincott, Williams & Wilkins20000000 [0292]
- **ANSEL et al.**Pharmaceutical Dosage Forms and Drug Delivery SystemsLippincott Williams & Wilkins Publishers19990000 [0292]
- **KIBBE**Handbook of Pharmaceutical ExcipientsAmerican Pharmaceutical Association20000000 [0292]
- **EPSTEIN et al.**Proc Natl Acad Sci USA, 1985, vol. 82, 3688- [0295]
- **HWANG et al.**Proc Natl Acad Sci USA, 1980, vol. 77, 4030- [0295]
- **J.R. ROBINSON**Sustained and Controlled Release Drug Delivery SystemsMarcel Dekker, Inc.19780000 [0295]
- **AMBATIADAMIS**Prog Retin Eye Res, 2002, vol. 21, 2145-151 [0302]
- **RANTAURTTI**Adv Drug Delivery Rev, 2006, vol. 58, 111164-1181 [0302]
- **BAROCASBALACHANDRAN**Expert Opin Drug Delivery, 2008, vol. 5, 11-10 [0302]
- **GULSENCHAUHAN**Invest Ophthalmol Vis Sci, 2004, vol. 45, 2342-2347 [0302]
- **KIM et al.**Ophthalmic Res, 2007, vol. 39, 244-254 [0302]
- **EGLITIS et al.**Science, 1985, vol. 230, 1395-1398 [0303]
- **DANOSMULLIGAN**Proc Natl Acad Sci USA, 1988, vol. 85, 6460-6464 [0303]
- **WILSON et al.**Proc Natl Acad Sci USA, 1988, vol. 85, 3014-3018 [0303]
- **ARMENTANO et al.**Proc. Natl. Acad. Sci. USA, 1990, vol. 87, 6141-6145 [0303]
- **HUBER et al.**Proc Natl Acad Sci USA, 1991, vol. 88, 8039-8043 [0303]
- **FERRY et al.**Proc Natl Acad Sci USA, 1991, vol. 88, 8377-8381 [0303]
- **CHOWDHURY et al.**Science, 1991, vol. 254, 1802-1805 [0303]
- **VAN BEUSECHEM et al.**Proc Natl Acad Sci USA, 1992, vol. 89, 7640-7644 [0303]
- **KAY et al.**Human Gene Therapy, 1992, vol. 3, 641-647 [0303]
- **DAI et al.**Proc Natl Acad Sci USA, 1992, vol. 89, 10892-10895 [0303]
- **HWU et al.**J Immunol., 1993, vol. 150, 4104-4115 [0303]
- **BERKNER et al.**BioTechniques, 1988, vol. 6, 616- [0303]
- **ROSENFELD et al.**Science, 1991, vol. 252, 431-434 [0303]
- **ROSENFELD et al.**Cell, 1992, vol. 68, 143-155 [0303]
- **FLOTTE et al.**Am J Respir Cell Mol Biol, 1992, vol. 7, 349-356 [0303]
- **SAMULSKI et al.**J Virol, 1989, vol. 63, 3822-3828 [0303]
- **MCLAUGHLIN et al.**J Virol, 1989, vol. 62, 1963-1973 [0303]
- **MIHU et al.**J Gasrointestin LiverDis, 2007, vol. 16, 4419-424 [0304]
- **VAN GURP et al.**Am J Transplantation, 2008, vol. 8, 81711-1718 [0335]
- **HANOUSKA et al.**Clin Cancer Res, 2007, vol. 13, 523-531 [0335]
- **HETHERINGTON et al.**Antimicrobial Agents and Chemotherapy, 2006, vol. 50, 103499-3500 [0335]
- **APPEL et al.**J Am Soc Nephrol, 2005, vol. 16, 1392-1404 [0339]
- **HOLERS**Immunological Reviews, 2008, vol. 223, 300-316 [0343]
- **HOLERSTHURMAN**Molecular Immunology, 2004, vol. 41, 147-152 [0343]
- **KAPLAN**Curr Opin Investig Drugs, 2002, vol. 3, 71017-23 [0347]
- **HILL**Clin Adv Hematol Oncol, 2005, vol. 3, 11849-50 [0347]

- **ROTHER et al.** Nature Biotechnology, 2007, vol. 25, 111256-1488 [0347]
- **PARK et al.** Anesth Analg, 1999, vol. 99, 142-48 [0347]
- **TOFUKUJI et al.** J Thorac Cardiovasc Surg, 1998, vol. 116, 61060-1068 [0347]
- **SCHMID et al.** Shock, 1997, vol. 8, 2119-124 [0347]
- **BLESS et al.** Am J Physiol, 1999, vol. 276, 1L57-L63 [0347]
- **KARLSSONLARSSON** Methods Mol Biol, 2004, vol. 248, 389-415 [0365]
- **WANG et al.** J Immunol, 2000, vol. 164, 4340-4347 [0380]
- **DARREN et al.** Mol Pharm, 2004, vol. 65, 4868-879 [0394]
- **RINDER et al.** J Clin Invest, 1995, vol. 96, 1564-1572 [0423]

Patentkrav

1. Isoleret antistof eller antigenbindende fragment deraf, der binder til et frit C5a-polypeptid, hvor det frie C5a er et humant polypeptid (hC5a) med aminosyresekvensen, der er vist i SEQ ID NO: 1, og hvor antistoffet eller det antigenbindende fragment deraf binder til det frie hC5a-polypeptid *in vitro* med en K_D , der er mindre end $1,25 \times 10^{-9}$ M målt ved hjælp af overfladeplasmonresonans (SPR) i nærvær af et molært overskud af uspaltet, nativt humant C5, og hvor antistoffet eller det antigenbindende fragment deraf omfatter:

I.

(a) et letkædepolypeptid, der omfatter:

(i) et letkæde-CDR1, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 20; et letkæde-CDR2, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 21; og et letkæde-CDR3, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 22; eller

(ii) et letkæde-CDR1, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 20; et letkæde-CDR2, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 38; og et letkæde-CDR3, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 22; og

(b) et tungkædepolypeptid, der omfatter:

(i) et tungkæde-CDR1, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 28; et tungkæde-CDR2, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 29; og et tungkæde-CDR3, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 30; eller

(ii) et tungkæde-CDR1, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 28; et tungkæde-CDR2, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 46; og et tungkæde-CDR3, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 47;

II.

(a) et letkædepolypeptid, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 37, og et tungkædepolypeptid, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 27;

(b) et letkædepolyeptid, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 36, og et tungkædepolyeptid, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 33;

5 (c) et letkædepolyeptid, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 19, og et tungkædepolyeptid, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 27;

(d) et letkædepolyeptid, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 17, og et tungkædepolyeptid, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 25;

10 (e) et letkædepolyeptid, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 42, og et tungkædepolyeptid, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 27;

(f) et letkædepolyeptid, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 40, og et tungkædepolyeptid, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 33;

15 (g) et letkædepolyeptid, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 17, og et tungkædepolyeptid, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 33;

(h) et letkædepolyeptid, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 19, og et tungkædepolyeptid, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 45;

(i) et letkædepolyeptid, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 17, og et tungkædepolyeptid, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 44;

25 (j) et letkædepolyeptid, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 17, og et tungkædepolyeptid, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 49;

(k) et letkædepolyeptid, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 37, og et tungkædepolyeptid, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 45; eller

30 (l) et letkædepolyeptid, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 36, og et tungkædepolyeptid, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 49; eller

35 III.

(a) et letkædepolyeptid, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 42, og et tungkædepolyeptid, der

omfatter aminosyresekvensen, der er vist i SEQ ID NO: 45;

(b) et letkædepolypeptid, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 40, og et tungkædepolypeptid, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 49.

5

2. Isoleret antistof eller antigenbindende fragment deraf ifølge krav 1, hvor antistoffet eller det antigenbindende fragment deraf omfatter: (a) et letkædepolypeptid, der

10 omfatter: (i) et letkæde-CDR1, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 20; et letkæde-CDR2, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 21; og et letkæde-CDR3, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 22; og et tungkædepolypeptid, der omfatter: (i) et tungkæde-CDR1, der omfatter

15 aminosyresekvensen, der er vist i SEQ ID NO: 28; et tungkæde-CDR2, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 29; og et tungkæde-CDR3, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 30.

20 3. Isoleret antistof eller antigenbindende fragment deraf ifølge krav 1, hvor antistoffet eller det antigenbindende fragment deraf omfatter: (a) et letkædepolypeptid, der omfatter: (i) et letkæde-CDR1, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 20; et letkæde-

25 CDR2, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 21; og et letkæde-CDR3, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 22; og et tungkædepolypeptid, der omfatter: et tungkæde-CDR1, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 28; et tungkæde-CDR2, der omfatter

30 aminosyresekvensen, der er vist i SEQ ID NO: 46; og et tungkæde-CDR3, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 47.

4. Isoleret antistof eller antigenbindende fragment deraf

35 ifølge krav 1, hvor antistoffet eller det antigenbindende fragment deraf omfatter: (a) et letkædepolypeptid, der omfatter: (i) et letkæde-CDR1, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 20; et letkæde-

CDR2, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 38; og et letkæde-CDR3, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 22; og et tungkædepolypeptid, der omfatter: (i) et tungkæde-CDR1, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 28; et tungkæde-CDR2, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 29; og et tungkæde-CDR3, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 30.

10 5. Isoleret antistof eller antigenbindende fragment deraf ifølge krav 1, hvor antistoffet eller det antigenbindende fragment deraf omfatter: (a) et letkædepolypeptid, der omfatter: (i) et letkæde-CDR1, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 20; et letkæde-CDR2, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 38; og et letkæde-CDR3, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 22; og et tungkædepolypeptid, der omfatter: et tungkæde-CDR1, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 28; et tungkæde-CDR2, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 46; og et tungkæde-CDR3, der omfatter aminosyresekvensen, der er vist i SEQ ID NO: 47.

DRAWINGS




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8




Fig. 9




Fig. 10




Fig. 11




Fig. 12A




Fig. 12B




Fig. 12C




Fig. 12D

Binding of BNJ383 to hC5a desArg in the presence of C5




Fig. 13





Fig. 14






Fig. 15B




Fig. 15C